U.S. patent application number 12/651984 was filed with the patent office on 2010-04-29 for triazolopyrazine derivatives.
This patent application is currently assigned to PFIZER INC.. Invention is credited to Hengmiao Cheng, Jingrong Jean Cui, Jacqui Elizabeth Hoffman, Lei Jia, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Bich Tran-Dube.
Application Number | 20100105656 12/651984 |
Document ID | / |
Family ID | 38441445 |
Filed Date | 2010-04-29 |
United States Patent
Application |
20100105656 |
Kind Code |
A1 |
Cheng; Hengmiao ; et
al. |
April 29, 2010 |
TRIAZOLOPYRAZINE DERIVATIVES
Abstract
The invention relates to compounds of the formula I ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 are as defined herein. The invention
also relates to pharmaceutical compositions containing the
compounds of formula I and to methods of treating
hyperproliferative disorders in a mammal by administering the
compounds of formula I.
Inventors: |
Cheng; Hengmiao; (San Diego,
CA) ; Cui; Jingrong Jean; (San Diego, CA) ;
Hoffman; Jacqui Elizabeth; (San Diego, CA) ; Jia;
Lei; (San Diego, CA) ; Johnson; Mary Catherine;
(San Diego, CA) ; Kania; Robert Steven; (San
Diego, CA) ; Le; Phuong Thi Quy; (San Diego, CA)
; Nambu; Mitchell David; (San Diego, CA) ;
Pairish; Mason Alan; (San Diego, CA) ; Shen;
Hong; (San Diego, CA) ; Tran-Dube; Michelle Bich;
(San Diego, CA) |
Correspondence
Address: |
PFIZER INC
10555 SCIENCE CENTER DRIVE
SAN DIEGO
CA
92121
US
|
Assignee: |
PFIZER INC.
|
Family ID: |
38441445 |
Appl. No.: |
12/651984 |
Filed: |
January 4, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11745921 |
May 8, 2007 |
|
|
|
12651984 |
|
|
|
|
60799966 |
May 11, 2006 |
|
|
|
60893231 |
Mar 6, 2007 |
|
|
|
Current U.S.
Class: |
514/210.21 ;
514/218; 514/234.2; 514/249 |
Current CPC
Class: |
A61P 35/00 20180101;
C07D 487/04 20130101; A61P 35/02 20180101 |
Class at
Publication: |
514/210.21 ;
514/218; 514/234.2; 514/249 |
International
Class: |
A61K 31/397 20060101
A61K031/397; A61K 31/551 20060101 A61K031/551; A61K 31/5377
20060101 A61K031/5377; A61K 31/4985 20060101 A61K031/4985; A61P
35/02 20060101 A61P035/02; A61P 35/00 20060101 A61P035/00 |
Claims
1. A method of treating a mammal having a c-Met related disorder,
comprising administering to the mammal a therapeutically effective
amount of a compound of the formula I: ##STR00313## wherein:
R.sup.1 is selected from hydrogen, Br, Cl, F,
--O(CH.sub.2).sub.nCH.sub.3, --NR.sup.10C(O)OR.sup.12,
--(CR.sup.12R.sup.13).sub.nNR.sup.10R.sup.11,
--O(CH.sub.2).sub.nOR.sup.10, --(CH.sub.2).sub.nOR.sup.10,
--C(O)R.sup.10, --C(O)OR.sup.10, --C(O)NR.sup.10R.sup.11,
--NR.sup.10R.sup.11, --S(O).sub.2R.sup.10, --S(O)R.sup.10,
--S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3, --CF.sub.2H,
--NR.sup.10C(O)NR.sup.10R.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10S(O).sub.2R.sup.11, --N(CH.sub.2).sub.n(C.sub.3-C.sub.8
cycloalkyl), --CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl,
C.sub.3-C.sub.8 cycloalkyl, 3-8 membered heteroalicyclic, 3-8
membered heteroalicyclic-(3-8 membered heteroalicyclic), 8-10
membered heterobicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10
aryl, C.sub.2-C.sub.6 alkenyl, and C.sub.2-C.sub.6 alkynyl wherein
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, 3-8 membered
heteroalicyclic, 8-10 membered heterobicyclic, 5-7 membered
heteroaryl, C.sub.6-C.sub.10 aryl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl are optionally substituted by one or more
moieties selected from the group consisting of Br, Cl, F,
--(CH.sub.2).sub.nCH(OR.sup.10)CH.sub.3,
--(CH.sub.2).sub.nOR.sup.10,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.10, --C(O)R.sup.10,
--C(O)OR.sup.10, --(CR.sup.10R.sup.11).sub.nC(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11,
--(CR.sup.10R.sup.11).sub.nC(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3,
--CF.sub.2H, --(CH.sub.2).sub.nNR.sup.10C(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10C(O)OR.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10C(O)OR.sup.11, --NR.sup.10S(O).sub.2R.sup.11, --CN,
--NO.sub.2, oxo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic),
--(CH.sub.2).sub.n(5-7 membered heteroaryl),
--(CH.sub.2).sub.n(C.sub.6-C.sub.10 aryl), C.sub.2-C.sub.6 alkenyl,
and C.sub.2-C.sub.6 alkynyl; R.sup.2 is H; R.sup.3 is selected from
##STR00314## R.sup.10 and R.sup.11 are independently selected from
H, --(CH.sub.2).sub.nOR.sup.12,
(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.12,
--CHR.sup.12(CH.sub.2).sub.nOR.sup.13, --C(O)OR.sup.12,
--(CH.sub.2).sub.nCHR.sup.12OR.sup.13,
--C(CH.sub.3).sub.2(CH.sub.2).sub.nOR.sup.12, --CH.sub.2CF.sub.2H,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2NR.sup.12R.sup.13,
--(CH.sub.2).sub.nNR.sup.12R.sup.13,
--(CH.sub.2).sub.nCHOR.sup.12(CH.sub.2).sub.nOR.sup.13,
--(CH.sub.2).sub.n(NR.sup.12R.sup.13)C(O)NR.sup.12R.sup.13,
--(CH.sub.2).sub.nS(O).sub.2R.sup.12,
--(CH.sub.2).sub.nC(O)NR.sup.12R.sup.13,
--NR.sup.12(CH.sub.2).sub.n(5-7 membered heteroaryl),
--NR.sup.12(CH.sub.2).sub.n(3-8 membered heterocycle),
--(CH.sub.2).sub.n(8-10 membered heterobicyclic),
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic), C.sub.1-C.sub.6
alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl,
C.sub.2-C.sub.6 alkenyl, 3-8 membered heteroalicyclic and
C.sub.2-C.sub.6 alkynyl, wherein said 5-7 membered heteroaryl, 3-8
membered heterocycle and 8-10 membered heterobicyclic are
optionally substituted by one or more moieties selected from the
group consisting of --(CH.sub.2).sub.nOR.sup.12, C.sub.1-C.sub.6
alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl,
C.sub.2-C.sub.6 alkenyl, 3-8 membered heteroalicyclic and
C.sub.2-C.sub.6 alkynyl; or when R.sup.10 and R.sup.11 are attached
to the same atom, R.sup.10 and R.sup.11 optionally combine to form
a 3-8 membered heteroalicyclic ring; R.sup.12 and R.sup.13 are
independently selected from H, C.sub.1-C.sub.6 alkyl,
--C(O)CH.sub.3, C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl,
C.sub.2-C.sub.6 alkenyl, 5-7 membered heteroaryl and
C.sub.2-C.sub.6 alkynyl, wherein said 5-7 membered heteroaryl is
optionally substituted by one or more moieties selected from the
group consisting of C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8
cycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl; or when R.sup.12 and R.sup.13 are attached
to the same atom, R.sup.12 and R.sup.13 optionally combine to form
a 3-8 membered heteroalicyclic ring; R.sup.4 is selected from the
group consisting of hydrogen, and C.sub.1-C.sub.6 alkyl; and each n
is independently 0, 1, 2, 3 or 4; wherein 3-8 membered
heteroalicyclic and 3-8 membered heterocycle are independently
selected from the group consisting of aziridinyl, oxetanyl,
thiapanyl, azepanyl, tetrahydrofuranyl, tetrahydrothiophenyl,
pyrrolidinyl, tetrahydropyranyl, tetrahydrothiopyranyl,
piperidinyl, 1,4-dioxanyl, 1,4-oxathianyl, morpholinyl,
1,4-dithianyl, piperazinyl, 1,4-azathianyl, azepanyl,
1,4-oxaazepanyl, 1,4-dithiepanyl, 1,4-thieazapanyl, 1,4-diazepanyl,
3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl,
1,2,3,4-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl,
1,2-dihydropyridyl, and imidazolidinyl; wherein 8-10 membered
heterobicyclic is selected from the group consisting of
benzofuranyl, benzothiophenyl, indolyl, benzimidazolyl, indazolyl,
benzotriazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl,
pyrrolo[3,2-b]pyridinyl, pyrrolo[3,2-c]pyridinyl,
imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl,
pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3-c]pyridinyl,
pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, isoindolyl,
quinolinyl, isoquinoliinyl, quinazolinyl, quinaxolinyl, indazolyl,
purinyl, indolininyl, imidazo[1,2-a]pyridinyl,
pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl,
imidazo[1,2-c]pyrimidinyl, 3H-indolyl, indolyl, isoindolinyl,
2,3-dihydrobenzofuranyl, 1,3-dihydrobenzofuranyl, 1H-isoindolyl,
1,2,3,4-tetrahydroquinoxalinyl, 1,2-dihydroquinoxalinyl,
1,2-dihydroquinazolinyl, 3,4-dihydroquinazolinyl,
3,3a-dihydropyrazolo[1,5-a]pyrimidinyl,
5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl,
octahydropyrrolo[1,2-a]pyrazine,
4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl, and
4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine; wherein 5-7 membered
heteroaryl is selected from the group consisting of pyrrolyl,
furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl,
thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl,
1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl,
tetrazolyl, pyridinyl, pyridazinyl, and pyrimidinyl; or a
pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the c-Met related disorder is
cancer.
3. The method of claim 2, wherein the cancer is selected from
breast cancer, lung cancer, colorectal cancer, prostate cancer,
pancreatic cancer, glioma, liver cancer, gastric cancer, head
cancer, neck cancer, melanoma, renal cancer, leukemia, myeloma, and
sarcoma.
Description
[0001] This application is a Divisional of U.S. application Ser.
No. 11/745,921, filed on May 8, 2007, which claims the benefit of
U.S. Provisional Application No. 60/799,966, filed May 11, 2006,
and U.S. Provisional Application No. 60/893,231, filed Mar. 6,
2007, the contents of which are hereby incorporated by reference in
their entireties.
[0002] This invention relates to novel triazolopyrazine derivatives
that are useful in the treatment of hyperproliferative diseases,
such as cancers, in mammals. This invention also relates to a
method of using such compounds in the treatment of
hyperproliferative diseases in mammals, especially humans, and to
pharmaceutical compositions containing such compounds.
BACKGROUND OF THE INVENTION
[0003] The hepatocyte growth factor (HGF) receptor (c-Met or HGFR)
receptor tyrosine kinase (RTK) has been shown in many human cancers
to be involved in oncogenesis, tumor progression with enhanced cell
motility and invasion, as well as metastasis (see, e.g., Ma, P. C.,
Maulik, G., Christensen, J. & Salgia, R. (2003b). Cancer
Metastasis Rev, 22, 309-25; Maulik, G., Shrikhande, A., Kijima, T.,
Ma, P. C., Morrison, P. T. & Salgia, R. (2002b). Cytokine
Growth Factor Rev, 13, 41-59). c-Met (HGFR) can be activated
through overexpression or mutations in various human cancers
including small cell lung cancer (SCLC) (Ma, P. C., Kijima, T.,
Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E.
& Salgia, R. (2003a). Cancer Res, 63, 6272-6281).
[0004] c-Met is a receptor tyrosine kinase that is encoded by the
Met proto-oncogene and transduces the biological effects of
hepatocyte growth factor (HGF), which is also referred to as
scatter factor (SF). Jiang et al., Crit. Rev. Oncol. Hematol. 29:
209-248 (1999). c-Met and HGF are expressed in numerous tissues,
although their expression is normally confined predominantly to
cells of epithelial and mesenchymal origin, respectively. c-Met and
HGF are required for normal mammalian development and have been
shown to be important in cell migration, cell proliferation and
survival, morphogenic differentiation, and organization of
3-dimensional tubular structures (e.g., renal tubular cells, gland
formation, etc.). In addition to its effects on epithelial cells,
HGF/SF has been reported to be an angiogenic factor, and c-Met
signaling in endothelial cells can induce many of the cellular
responses necessary for angiogenesis (proliferation, motility,
invasion).
[0005] The c-Met receptor has been shown to be expressed in a
number of human cancers. c-Met and its ligand, HGF, have also been
shown to be co-expressed at elevated levels in a variety of human
cancers (particularly sarcomas). However, because the receptor and
ligand are usually expressed by different cell types, c-Met
signaling is most commonly regulated by tumor-stroma (tumor-host)
interactions. Furthermore, c-Met gene amplification, mutation, and
rearrangement have been observed in a subset of human cancers.
Families with germline mutations that activate c-Met kinase are
prone to multiple kidney tumors as well as tumors in other tissues.
Numerous studies have correlated the expression of c-Met and/or
HGF/SF with the state of disease progression of different types of
cancer (including lung, colon, breast, prostate, liver, pancreas,
brain, kidney, ovaries, stomach, skin, and bone cancers).
Furthermore, the overexpression of c-Met or HGF have been shown to
correlate with poor prognosis and disease outcome in a number of
major human cancers including lung, liver, gastric, and breast.
c-Met has also been directly implicated in cancers without a
successful treatment regimen such as pancreatic cancer, glioma, and
hepatocellular carcinoma.
[0006] A family of novel compounds have been discovered which
exhibit c-Met modulating ability and have an ameliorating effect
against disorders related to abnormal c-Met activity. c-Met is an
attractive target from a clinical perspective because: 1) c-Met has
been implicated in the growth and metastases of most types of
cancer; 2) growth at the secondary site appears to be the
rate-limiting step in metastasis; and 3) by the time of diagnosis,
R is likely that the disease has already spread.
[0007] These observations suggest that c-Met kinase inhibitors
would be an effective treatment for primary tumors that are driven
by c-Met, but more importantly, would prevent disseminated
micrometastases from growing into life-threatening metastases.
Therefore, the utility of a c-Met inhibitor extends to preventative
and adjuvant therapy settings. In addition, certain cancers (e.g.,
papillary renal cell carcinoma, some gastric and lung cancers) can
be treated which are believed to be driven by c-Met
mutation/genetic alteration and dependent on c-Met for growth and
survival. These cancers are expected to be sensitive to treatment.
Furthermore, various human cancers are the primary target
indication for c-Met antagonists. These cancers include major
cancers such as breast, lung, colorectal, prostate; as well as
pancreatic cancer, glioma, liver cancer, gastric cancer, head and
neck cancers, melanoma, renal cancer, leukemias, myeloma, and
sarcomas. c-Met has been directly implicated in cancers such as
pancreatic cancer, glioma, and hepatocellular carcinoma.
[0008] Accordingly, c-Met (HGFR) inhibitors and methods of using
such inhibitors for the treatment of abnormal cell growth, such as
cancer represent a substantial unmet medical need in the treatment
of these and possibly other cancers.
SUMMARY OF THE INVENTION
[0009] In one embodiment, the present invention relates to a
compound of the formula I:
##STR00002##
[0010] wherein:
[0011] R.sup.1 and R.sup.2 are independently selected from
hydrogen, Br, Cl, F, --O(CH.sub.2).sub.nCH.sub.3,
--NR.sup.10C(O)OR.sup.12,
--(CR.sup.12R.sup.13).sub.nNR.sup.10R.sup.11,
--O(CH.sub.2).sub.nOR.sup.10, --(CH.sub.2).sub.nOR.sup.10,
--C(O)R.sup.10, --C(O)OR.sup.10, --C(O)NR.sup.10R.sup.11,
--NR.sup.10R.sup.11, --S(O).sub.2R.sup.10, --S(O)R.sup.10,
--S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3, --CF.sub.2H,
--NR.sup.10C(O)NR.sup.10R.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10S(O).sub.2R.sup.11, --N(CH.sub.2).sub.n(C.sub.3-C.sub.8
cycloalkyl), --CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl,
C.sub.3-C.sub.8 cycloalkyl, 3-8 membered heteroalicyclic, 3-8
membered heteroalicyclic-(3-8 membered heteroalicyclic), 8-10
membered heterobicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10
aryl, C.sub.2-C.sub.6 alkenyl, and C.sub.2-C.sub.6 alkynyl wherein
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, 3-8 membered
heteroalicyclic, 8-10 membered heterobicyclic, 5-7 membered
heteroaryl, C.sub.6-C.sub.10 aryl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl are optionally substituted by one or more
moieties selected from the group consisting of Br, Cl, F,
--(CH.sub.2).sub.nCH(OR.sup.10)CH.sub.3,
--(CH.sub.2).sub.nOR.sup.10,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.10, --C(O)R.sup.10,
--C(O)OR.sup.10, --(CR.sup.10R.sup.11).sub.nC(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11,
--(CR.sup.10R.sup.11).sub.nC(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, CF.sub.3,
--CF.sub.2H, --(CH.sub.2).sub.nNR.sup.10C(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10C(O)OR.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10C(O)OR.sup.11, --NR.sup.10S(O).sub.2R.sup.11, --CN,
--NO.sub.2, oxo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic),
--(CH.sub.2).sub.n(5-7 membered heteroaryl),
--(CH.sub.2).sub.n(C.sub.6-C.sub.10 aryl), C.sub.2-C.sub.6 alkenyl,
and C.sub.2-C.sub.6 alkynyl;
[0012] R.sup.3 is a moiety of the formula:
##STR00003##
[0013] wherein R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are
independently selected from hydrogen, Br, Cl, F,
--(CH.sub.2).sub.nOR.sup.10, --C(O)R.sup.10, --C(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11, --NR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3,
--CF.sub.2H, --NR.sup.10C(O)NR.sup.10R.sup.11,
--NR.sup.10C(O)R.sup.11, --NR.sup.10SO.sub.2R.sup.11, --CN,
--NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, 3-8
membered heteroalicyclic, 8-10 membered heterobicyclic, 5-7
membered heteroaryl, C.sub.6-C.sub.10 aryl, C.sub.2-C.sub.6
alkenyl, and C.sub.2-C.sub.6 alkynyl wherein C.sub.1-C.sub.6 alkyl,
C.sub.3-C.sub.8 cycloalkyl, 3-8 membered heteroalicyclic, 8-10
membered heterobicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10
aryl, C.sub.2-C.sub.6 alkenyl, and C.sub.2-C.sub.6 alkynyl are
optionally substituted by one or more moieties selected from the
group consisting of Br, Cl, F, --(CH.sub.2).sub.nOR.sup.10,
--C(O)R.sup.10, --C(O)OR.sup.10, --C(O)NR.sup.10R.sup.11,
--NR.sup.10R.sup.11, --S(O).sub.2R.sup.10, --S(O)R.sup.10,
--S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3, --CF.sub.2H,
--NR.sup.10C(O)NR.sup.10R.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10S(O).sub.2R.sup.11, --CN, --NO.sub.2, oxo,
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8
heteroalicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10 aryl,
C.sub.2-C.sub.6 alkenyl, and C.sub.2-C.sub.6 alkynyl;
[0014] with the proviso that one of R.sup.7 and R.sup.8, or R.sup.8
and R.sup.9 combine to form a ring selected from saturated
C.sub.4-C.sub.8 cycloalkyl, unsaturated C.sub.5-C.sub.8 cycloalkyl,
3-8 membered heteroalicyclic, 5-7 membered heteroaryl and
C.sub.6-C.sub.10 aryl, wherein said ring is optionally substituted
by one or more moieties selected from the group consisting of Br,
Cl, F, --(CH.sub.2).sub.nOR.sup.10, --C(O)R.sup.10,
--C(O)OR.sup.10, --C(O)NR.sup.10R.sup.11, --NR.sup.10R.sup.11,
--S(O).sub.2R.sup.10, --S(O)R.sup.10,
--S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3, --CF.sub.2H,
--NR.sup.10C(O)NR.sup.10R.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10S(O).sub.2R.sup.11, --CN, --NO.sub.2, oxo,
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8
heteroalicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10 aryl,
C.sub.2-C.sub.6 alkenyl, and C.sub.2-C.sub.6 alkynyl;
[0015] R.sup.10 and R.sup.11 are independently selected from H,
--(CH.sub.2).sub.nOR.sup.12,
(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.12,
--CHR.sup.12(CH.sub.2).sub.nOR.sup.13, --C(O)OR.sup.12,
--(CH.sub.2).sub.nCHR.sup.12OR.sup.13,
--C(CH.sub.3).sub.2(CH.sub.2).sub.nOR.sup.12, --CH.sub.2CF.sub.2H,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2NR.sup.12R.sup.13,
--(CH.sub.2).sub.nNR.sup.12R.sup.13,
--(CH.sub.2).sub.nCHOR.sup.12(CH.sub.2).sub.nOR.sup.13,
--(CH.sub.2).sub.n(NR.sup.12R.sup.13)C(O)NR.sup.12R.sup.13,
--(CH.sub.2).sub.nS(O).sub.2R.sup.12,
--(CH.sub.2).sub.nC(O)NR.sup.12R.sup.13,
--NR.sup.12(CH.sub.2).sub.n(5-7 membered heteroaryl),
--NR.sup.12(CH.sub.2).sub.n(3-8 membered heterocycle),
--(CH.sub.2).sub.n(8-10 membered heterobicyclic),
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic), C.sub.1-C.sub.6
alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl,
C.sub.2-C.sub.6 alkenyl and C.sub.2-C.sub.6 alkynyl, wherein said
5-7 membered heteroaryl, 3-8 membered heterocycle and 8-10 membered
heterobicyclic are optionally substituted by one or more moieties
selected from the group consisting of --(CH.sub.2).sub.nOR.sup.12,
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10
aryl, C.sub.2-C.sub.6 alkenyl, 3-8 membered heteroalicyclic and
C.sub.2-C.sub.6 alkynyl; or when R.sup.10 and R.sup.11 are attached
to the same atom, R.sup.10 and R.sup.11 optionally combine to form
a 3-8 membered heteroalicyclic ring;
[0016] R.sup.12 and R.sup.13 are independently selected from H,
C.sub.1-C.sub.6 alkyl, --C(O)CH.sub.3, C.sub.3-C.sub.8 cycloalkyl,
C.sub.6-C.sub.10 aryl, C.sub.2-C.sub.6 alkenyl, 5-7 membered
heteroaryl and C.sub.2-C.sub.6 alkynyl, wherein said 5-7 membered
heteroaryl is optionally substituted by one or more moieties
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.3-C.sub.8 cycloalkyl, C.sub.6-C.sub.10 aryl, C.sub.2-C.sub.6
alkenyl, and C.sub.2-C.sub.6 alkynyl; or when R.sup.12 and R.sup.13
are attached to the same atom, R.sup.12 and R.sup.13 optionally
combine to form a 3-8 membered heteroalicyclic ring;
[0017] R.sup.4 is selected from the group consisting of hydrogen,
F, C.sub.1-C.sub.6 alkyl and aryl; and each n is independently 0,
1, 2, 3 or 4;
[0018] or a pharmaceutically acceptable salt thereof.
[0019] The present invention contemplates each of the following
embodiments separately or in connection with any other embodiment
described herein except where an inconsistency in describing the
present invention might occur. Based on the present disclosure the
person having ordinary skill in the art will readily appreciate
what such inconsistencies might be.
[0020] In another embodiment, R.sup.1 and R.sup.2 are independently
selected from hydrogen, Br, --OR.sup.10,
--O(CH.sub.2).sub.nCH.sub.3, --OCH.sub.2(CH.sub.2).sub.nOR.sup.10,
--C(O)NR.sup.10R.sup.11, --NR.sup.10R.sup.11, C.sub.1-C.sub.6
alkyl, 3-8 membered heteroalicyclic, 3-8 membered
heteroalicyclic-(3-8 membered heteroalicyclic), 8-10 membered
heterobicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10 aryl and
C.sub.2-C.sub.6 alkenyl, wherein C.sub.1-C.sub.6 alkyl, 3-8
membered heteroalicyclic, 3-8 membered heteroalicyclic-(3-8
membered heteroalicyclic), 8-10 membered heterobicyclic, 5-7
membered heteroaryl, C.sub.6-C.sub.10 aryl and C.sub.2-C.sub.6
alkenyl are optionally substituted by one or more moieties selected
from the group consisting of Br, Cl, F,
--(CH.sub.2).sub.nCH(OR.sup.10)CH.sub.3,
--(CH.sub.2).sub.nOR.sup.10,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.10,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic), --C(O)R.sup.10,
--C(O)OR.sup.10, --(CR.sup.10R.sup.11).sub.nC(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11,
--(CR.sup.10R.sup.11).sub.nC(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3,
--CF.sub.2H, --(CH.sub.2).sub.nNR.sup.10C(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10C(O)OR.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10C(O)OR.sup.11, --NR.sup.10S(O).sub.2R.sup.11, --CN,
--NO.sub.2, oxo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic),
--(CH.sub.2).sub.n(5-7 membered heteroaryl),
--(CH.sub.2).sub.n(C.sub.6-C.sub.10 aryl), C.sub.2-C.sub.6 alkenyl,
and C.sub.2-C.sub.6 alkynyl.
[0021] In another embodiment, R.sup.1 and R.sup.2 are independently
selected from --OR.sup.10, --O(CH.sub.2).sub.nCH.sub.3,
--NR.sup.10C(O)OR.sup.12,
--(CR.sup.12R.sup.13).sub.nNR.sup.10R.sup.11,
--OCH.sub.2(CH.sub.2).sub.nOR.sup.10, --C(O)NR.sup.10R.sup.11,
--NR.sup.10R.sup.11, C.sub.1-C.sub.6 alkyl, 3-8 membered
heteroalicyclic, 3-8 membered heteroalicyclic-(3-8 membered
heteroalicyclic), 8-10 membered heterobicyclic, 5-7 membered
heteroaryl, C.sub.6-C.sub.10 aryl and C.sub.2-C.sub.6 alkenyl,
wherein C.sub.1-C.sub.6 alkyl, 3-8 membered heteroalicyclic, 3-8
membered heteroalicyclic-(3-8 membered heteroalicyclic), 8-10
membered heterobicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10
aryl and C.sub.2-C.sub.6 alkenyl are optionally substituted by one
or more moieties selected from the group consisting of Br, Cl, F,
--(CH.sub.2).sub.nCH(OR.sup.10)CH.sub.3,
--(CH.sub.2).sub.nOR.sup.10,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.10,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic), --C(O)R.sup.10,
--C(O)OR.sup.10, --(CR.sup.10R.sup.11).sub.nC(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11,
--(CR.sup.10R.sup.11).sub.nC(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3,
--CF.sub.2H, --(CH.sub.2).sub.nNR.sup.10C(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10C(O)OR.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10C(O)OR.sup.11, --NR.sup.10S(O).sub.2R.sup.11, --CN,
--NO.sub.2, oxo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic),
--(CH.sub.2).sub.n(5-7 membered heteroaryl),
--(CH.sub.2).sub.n(C.sub.6-C.sub.10 aryl), C.sub.2-C.sub.6 alkenyl,
and C.sub.2-C.sub.6 alkynyl.
[0022] In another embodiment, R.sup.1 is selected from Br,
--OR.sup.10, --O(CH.sub.2).sub.nCH.sub.3, --NR.sup.10C(O)OR.sup.12,
--(CR.sup.12R.sup.13).sub.nNR.sup.10R.sup.11,
--OCH.sub.2(CH.sub.2).sub.nOR.sup.10, --C(O)NR.sup.10R.sup.11,
--NR.sup.10R.sup.11, C.sub.1-C.sub.6 alkyl, 3-8 membered
heteroalicyclic, 3-8 membered heteroalicyclic-(3-8 membered
heteroalicyclic), 8-10 membered heterobicyclic, 5-7 membered
heteroaryl, C.sub.6-C.sub.10 aryl and C.sub.2-C.sub.6 alkenyl,
wherein C.sub.1-C.sub.6 alkyl, 3-8 membered heteroalicyclic, 3-8
membered heteroalicyclic-(3-8 membered heteroalicyclic), 8-10
membered heterobicyclic, 5-7 membered heteroaryl, C.sub.6-C.sub.10
aryl and C.sub.2-C.sub.6 alkenyl are optionally substituted by one
or more moieties selected from the group consisting of Br, Cl, F,
--(CH.sub.2).sub.nCH(OR.sup.10)CH.sub.3,
--(CH.sub.2).sub.nOR.sup.10,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.10,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic), --C(O)R.sup.10,
--C(O)OR.sup.10, --(CR.sup.10R.sup.11).sub.nC(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11,
--(CR.sup.10R.sup.11).sub.nC(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3,
--CF.sub.2H, --(CH.sub.2).sub.nNR.sup.10C(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10C(O)OR.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10C(O)OR.sup.11, --NR.sup.10S(O).sub.2R.sup.11, --CN,
--NO.sub.2, oxo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic),
--(CH.sub.2).sub.n(5-7 membered heteroaryl),
--(CH.sub.2).sub.n(C.sub.6-C.sub.10 aryl), C.sub.2-C.sub.6 alkenyl,
and C.sub.2-C.sub.6 alkynyl.
[0023] In another embodiment, R.sup.1 is a 5-7 membered heteroaryl
optionally substituted by one or more moieties selected from the
group consisting of Br, Cl, F,
--(CH.sub.2).sub.nCH(OR.sup.10)CH.sub.3,
--(CH.sub.2).sub.nOR.sup.10,
--(CH.sub.2).sub.nC(CH.sub.3).sub.2OR.sup.10,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic), --C(O)R.sup.10,
--C(O)OR.sup.10, --(CR.sup.10R.sup.11).sub.nC(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11,
--(CR.sup.10R.sup.11).sub.nC(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3,
--CF.sub.2H, --(CH.sub.2).sub.nNR.sup.10C(O)NR.sup.10R.sup.11,
--(CH.sub.2).sub.nNR.sup.10C(O)OR.sup.11, --NR.sup.10C(O)R.sup.11,
--NR.sup.10C(O)OR.sup.11, --NR.sup.10S(O).sub.2R.sup.11, --CN,
--NO.sub.2, oxo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl,
--(CH.sub.2).sub.n(3-8 membered heteroalicyclic),
--(CH.sub.2).sub.n(5-7 membered heteroaryl),
--(CH.sub.2).sub.n(C.sub.6-C.sub.10 aryl), C.sub.2-C.sub.6 alkenyl,
and C.sub.2-C.sub.6 alkynyl.
[0024] In another embodiment, R.sup.7 and R.sup.8 combine to form a
ring selected from saturated C.sub.4-C.sub.8 cycloalkyl,
unsaturated C.sub.5-C.sub.8 cycloalkyl, 3-8 membered
heteroalicyclic, 5-7 membered heteroaryl and C.sub.6-C.sub.10 aryl,
wherein said ring is optionally substituted by one or more moieties
selected from the group consisting of Br, Cl, F,
--(CH.sub.2).sub.nOR.sup.10, --C(O)R.sup.10, --C(O)OR.sup.10,
--C(O)NR.sup.10R.sup.11, --NR.sup.10R.sup.11, --S(O).sub.2R.sup.10,
--S(O)R.sup.10, --S(O).sub.2NR.sup.10R.sup.11, --CF.sub.3,
--CF.sub.2H, --NR.sup.10C(O)NR.sup.10R.sup.11,
--NR.sup.10C(O)R.sup.11, --NR.sup.10S(O).sub.2R.sup.11, --CN,
--NO.sub.2, oxo, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl,
C.sub.3-C.sub.8 heteroalicyclic, 5-7 membered heteroaryl,
C.sub.6-C.sub.10 aryl, C.sub.2-C.sub.6 alkenyl, and C.sub.2-C.sub.6
alkynyl.
[0025] In a further embodiment, R.sup.9 is H. In a further
embodiment, at least one of R.sup.1 and R.sup.2 is not hydrogen. In
another embodiment, R.sup.2 is H. In another embodiment, R.sup.4 is
H. In another embodiment, R.sup.4 is C.sub.1-C.sub.6 alkyl. In
another embodiment, R.sup.4 is methyl. In another embodiment,
R.sup.5 and R.sup.6 are H.
[0026] In another embodiment, R.sup.3 is selected from
##STR00004##
[0027] In another embodiment, R.sup.3 is selected from
##STR00005##
[0028] In another embodiment, R.sup.3 is
##STR00006##
[0029] In another embodiment, R.sup.3 is
##STR00007##
[0030] In another embodiment, R.sup.3 is
##STR00008##
[0031] In another embodiment, the present invention relates to a
compound selected from
6-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)me-
thyl)quinoline,N-(piperidin-4-yl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]tri-
azolo[4,5-b]pyrazin-5-yl)benzamide,
N-(2-aminoethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyra-
zin-5-yl)benzamide,
N-(2-(dimethylamino)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[-
4,5-b]pyrazin-5-yl)benzamide,
6-((6-(4-methyl-1H-imidazol-1-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)m-
ethyl)quinoline,
N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl-
)benzamide,
6-((6-(3-methoxyphenyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quin-
oline,
6-((6-(4-methoxyphenyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methy-
l)quinoline,
6-((6-(1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quin-
oline,
(R)-1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-y-
l)pyrrolidin-3-amine,
(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)phenyl)-
methanol,
(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-y-
l)phenyl)methanamine,
6-[6-(1-ethoxy-vinyl)-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl]-quinoline-
,
2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyraz-
ol-1-yl]-ethanol,
6-[6-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-[1,2,3]triazolo[4,5-b]p-
yrazin-1-ylmethyl]-quinoline, and
6-[6-(2H-Pyrazol-3-yl)-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl]-quinolin-
e, or a pharmaceutically acceptable salt thereof.
[0032] In another embodiment, the present invention relates to a
compound selected from
[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol--
1-yl]-acetic acid,
6-[(S)-1-(6-Bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)-ethyl]-quinoline,
6-[(R)-1-(6-Bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)-ethyl]-quinoline,
6-{1-[6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[4,5-b]pyrazin-1-yl]-et-
hyl}-quinoline,
6-{(S)-1-[6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[4,5-b]pyrazin-1-yl-
]-ethyl}-quinoline,
6-{(R)-1-[6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[4,5-b]pyrazin-1-yl-
]-ethyl}-quinoline,
2-{4-[3-(1-Quinolin-6-yl-ethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl]-py-
razol-1-yl}-ethanol,
2-{4-[3-((S)-1-Quinolin-6-yl-ethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl-
)-pyrazol-1-yl}-ethanol,
2-{4-[3-((R)-1-Quinolin-6-yl-ethyl)-3H-[1,2,3]-triazolo[4,5-b]pyrazin-5-y-
l)-pyrazol-1-yl}-ethanol,
2-[4-(3-Quinazolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyra-
zol-1-yl]-ethanol, and
6-[6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl]-
-quinazoline.
[0033] In a further embodiment, the present invention relates to a
compound selected from any 10 compounds exemplified in Tables 3, 4
and 5.
[0034] In a further embodiment, the present invention relates to
any one compound exemplified in Tables 3, 4 and 5.
[0035] In another embodiment, the present invention provides a
crystalline form of the free base of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol. In a particular embodiment, the crystalline form
of the free base of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol is anhydrous. In another embodiment, the
crystalline form of the free base of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol is a hydrate.
[0036] In a further aspect the crystalline form is a polymorph form
1 of the free base of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol. In a further aspect, the crystalline form of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising a
peak at diffraction angle (2.theta.) of 5.8.+-.0.1. In a further
aspect, the crystalline form of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 5.8.+-.0.1 and
15.5.+-.0.1. In a further aspect, the crystalline form of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 5.8.+-.0.1, 15.5.+-.0.1,
and 16.2.+-.0.1. In a further aspect, the crystalline form of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 5.8.+-.0.1, 13.6.+-.0.1,
15.5.+-.0.1, and 16.2.+-.0.1. In a further aspect the crystalline
form of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 5.8.+-.0.1, 11.6.+-.0.1,
13.6.+-.0.1, 15.5.+-.0.1, and 16.2.+-.0.1. In a further aspect the
crystalline form of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 5.8.+-.0.1, 11.6.+-.0.1,
13.6.+-.0.1, 15.5.+-.0.1, 16.2.+-.0.1, and 23.4.+-.0.1. In a
further aspect the crystalline form of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 5.8.+-.0.1, 11.6.+-.0.1,
13.6.+-.0.1, 15.5.+-.0.1, 16.2.+-.0.1, 23.4.+-.0.1, and
27.6.+-.0.1.
[0037] In another embodiment, the present invention provides a
crystalline form of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol. In a particular embodiment, the crystalline form
of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl]-pyrazo-
l-1-yl]-ethanol is anhydrous. In another embodiment, the
crystalline form of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol is a hydrate.
[0038] In a further aspect the crystalline form is a polymorph form
1 of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol. In a further aspect, the crystalline form of the
mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl-
)-pyrazol-1-yl]-ethanol has a powder X-ray diffraction pattern
comprising a peak at diffraction angle (2.theta.) of 18.3.+-.0.1.
In a further aspect, the crystalline form of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 18.3.+-.0.1 and
19.3.+-.0.1. In a further aspect, the crystalline form of the
mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 12.3.+-.0.1, 18.3.+-.0.1
and 19.3.+-.0.1. In a further aspect, the crystalline form of the
mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl-
)-pyrazol-1-yl]-ethanol has a powder X-ray diffraction pattern
comprising peaks at diffraction angles (2.theta.) of 12.3.+-.0.1,
14.8.+-.0.1, 18.3.+-.0.1 and 19.3.+-.0.1. In a further aspect the
crystalline form of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 12.3.+-.0.1, 14.8.+-.0.1,
18.3.+-.0.1, 19.3.+-.0.1 and 23.1.+-.0.1. In a further aspect the
crystalline form of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 12.3.+-.0.1, 14.8.+-.0.1,
18.3.+-.0.1, 19.3.+-.0.1, 23.1.+-.0.1, and 24.9.+-.0.1. In a
further aspect the crystalline form of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has a powder X-ray diffraction pattern comprising
peaks at diffraction angles (2.theta.) of 12.3.+-.0.1, 14.8.+-.0.1,
17.7.+-.0.1, 18.3.+-.0.1, 19.3.+-.0.1, 23.1.+-.0.1, and
24.9.+-.0.1.
[0039] In a further aspect, the invention relates to pharmaceutical
composition comprising a compound of the formula (I) or a
pharmaceutically acceptable salt thereof, and a pharmaceutically
acceptable excipient.
[0040] In a further aspect, the invention relates to the use of a
compound of the formula (I) or a pharmaceutically acceptable salt
thereof, for the manufacture of a medicament to treat a c-Met
related disorder in a mammal.
[0041] In a further aspect, the invention relates to the use of a
compound of the formula (I) or a pharmaceutically acceptable salt
thereof, for the manufacture of medicament for the treatment of
cancer in a mammal.
[0042] In a further aspect, the invention relates to the use,
wherein the cancer is selected from breast cancer, lung cancer,
colorectal cancer, prostate cancer, pancreatic cancer, glioma,
liver cancer, gastric cancer, head cancer, neck cancer, melanoma,
renal cancer, leukemia, myeloma, and sarcoma.
[0043] In a further aspect, the invention relates to a method of
treating a mammal having a c-Met related disorder, comprising
administering to the mammal a therapeutically effective amount of a
compound of the formula (I) or with a pharmaceutically acceptable
salt thereof.
[0044] In a further aspect, the invention relates to a method of
treating a mammal having cancer, comprising administering to the
mammal a therapeutically effective amount of a compound of the
formula (I) or with a pharmaceutically acceptable salt thereof.
[0045] In a further aspect, the invention relates to a method of
treating cancer where the cancer is selected from breast cancer,
lung cancer, colorectal cancer, prostate cancer, pancreatic cancer,
glioma, liver cancer, gastric cancer, head cancer, neck cancer,
melanoma, renal cancer, leukemia, myeloma, and sarcoma. In a
further embodiment the mammal is a human. In a further embodiment
the mammal is a canine.
DEFINITIONS
[0046] "Pharmaceutically acceptable salt" refers to those salts,
which retain the biological effectiveness and properties of the
parent compound. Such salts include:
[0047] acid addition salt which is obtained by reaction of the free
base of the parent compound with inorganic acids such as
hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid,
phosphoric acid, sulfuric acid, and perchloric acid and the like,
or with organic acids such as acetic acid, oxalic acid, (D) or (L)
malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid,
p-toluenesulfonic acid, salicylic acid, tartaric acid,
benzenesulfonic acid (besylate), benzoic acid, camphorsulfonic
acid, citric acid, fumaric acid, gluconic acid, glutamic acid,
isethionic acid, lactic acid, maleic acid, malic acid, mandelic
acid, mucic acid, pamoic acid, pantothenic acid, succinic acid,
tartaric acid, or malonic acid and the like, preferably
hydrochloric acid or (L)-malic acid; or
[0048] salts formed when an acidic proton present in the parent
compound either is replaced by a metal ion, e.g., an alkali metal
ion, an alkaline earth ion, or an aluminum ion; or coordinates with
an organic base such as ethanolamine, diethanolamine,
triethanolamine, tromethamine, N-methylglucamine, and the like.
[0049] "Pharmaceutically acceptable excipient" or "excipient"
refers to an inert substance added to a pharmaceutical composition
to further facilitate administration of a compound. Examples,
without limitation, of excipients include calcium carbonate,
calcium phosphate, various sugars and types of starch, cellulose
derivatives, gelatin, vegetable oils, polyethylene glycols,
diluents, granulating agents, lubricants, binders, disintegrating
agents, and the like.
[0050] A "pharmaceutical composition" refers to a mixture of one or
more of the compounds described herein, or physiologically
acceptable salts thereof, with other chemical components, such as
physiologically acceptable carriers and excipients. The purpose of
a pharmaceutical composition is to facilitate administration of a
compound to an organism.
[0051] As used herein, a "physiologically acceptable carrier"
refers to a carrier or diluent that does not cause significant
irritation to an organism and does not abrogate the biological
activity and properties of the administered compound.
[0052] The term "method" refers to manners, means, techniques and
procedures for accomplishing a given task including, but not
limited to, those manners, means, techniques and procedures either
known to, or readily developed from known manners, means,
techniques and procedures by, practitioners of the chemical,
pharmaceutical, biological, biochemical and medical arts.
[0053] As used herein, the term "modulation" or "modulating" refers
to the ateration of the catalytic activity of c-Met. In particular,
modulating refers to the activation of the catalytic activity of
c-Met, preferably the activation or inhibition of the catalytic
activity of c-Met, depending on the concentration of the compound
or salt to which c-Met is exposed or, more preferably, the
inhibition of the catalytic activity of c-Met.
[0054] The term "contacting" as used herein refers to bringing a
compound of this invention and c-Met together in such a manner that
the compound can affect the catalytic activity of c-Met, either
directly, i.e., by interacting with c-Met itself, or indirectly,
i.e., by interacting with another molecule on which the catalytic
activity of c-Met is dependent. Such "contacting" can be
accomplished in vitro, i.e., in a test tube, a petri dish or the
like. In a test tube, contacting may involve only a compound and
c-Met or it may involve whole cells. Cells may also be maintained
or grown in cell culture dishes and contacted with a compound in
that environment. In this context, the ability of a particular
compound to affect a c-Met related disorder, i.e., the IC.sub.50 of
the compound, defined below, can be determined before use of the
compounds in vivo with more complex living organisms is attempted.
For cells outside the organism, multiple methods exist, and are
well-known to those skilled in the art, to get c-Met in contact
with the compounds including, but not limited to, direct cell
microinjection and numerous transmembrane carrier techniques.
[0055] "In vitro" refers to procedures performed in an artificial
environment such as, e.g., without limitation, in a test tube or
culture medium. The skilled artisan will understand that, for
example, isolated c-Met may be contacted with a modulator in an in
vitro environment. Alternatively, an isolated cell may be contacted
with a modulator in an in vitro environment.
[0056] As used herein, "in vivo" refers to procedures performed
within a living organism such as, without limitation, a mouse, rat,
rabbit, ungulate, bovine, equine, porcine, canine, feline, primate,
or human.
[0057] As used herein, "c-Met related disorder," refers to a
condition characterized by inappropriate, i.e., under-activity or,
more commonly, over-activity of the c-Met catalytic activity. A
"c-Met related disorder" also refers to a condition where there may
be a mutation in the gene that produces c-Met, which, in turn,
produces a c-Met that has an increased or decreased c-Met catalytic
activity.
[0058] Inappropriate catalytic activity can arise as the result of
either: (1) c-Met expression in cells which normally do not express
c-Met, (2) increased c-Met expression leading to unwanted cell
proliferation, differentiation and/or growth, or, (3) decreased
c-Met expression leading to unwanted reductions in cell
proliferation, differentiation and/or growth. Over-activity of a
c-Met refers to either amplification of the gene encoding a c-Met
or production of a level of c-Met activity which can correlate with
a cell proliferation, differentiation and/or growth disorder (that
is, as the level of the c-Met increases, the severity of one or
more of the symptoms of the cellular disorder increases).
Under-activity is, of course, the converse, wherein the severity of
one or more symptoms of a cellular disorder increase as the level
of the c-Met activity decreases.
[0059] As used herein, the terms "treat", "treating" and
"treatment" refer to a method of alleviating or abrogating a c-Met
mediated cellular disorder and/or its attendant symptoms. With
regard particularly to cancer, these terms simply mean that the
life expectancy of an individual affected with a cancer will be
increased or that one or more of the symptoms of the disease will
be reduced.
[0060] The term "organism" refers to any living entity comprised of
at least one cell. A living organism can be as simple as, for
example, a single eukaryotic cell or as complex as a mammal. In a
preferred aspect, the organism is a mammal. In a particularly
preferred aspect, the mammal is a human being.
[0061] The term "therapeutically effective amount" as used herein
refers to that amount of the compound being administered which will
relieve to some extent one or more of the symptoms of the disorder
being treated. In reference to the treatment of cancer, a
therapeutically effective amount refers to that amount which has
the effect of (1) reducing the size of the tumor, (2) inhibiting
(that is, slowing to some extent, preferably stopping) tumor
metastasis, (3) inhibiting to some extent (that is, slowing to some
extent, preferably stopping) tumor growth, and/or, (4) relieving to
some extent (or, preferably, eliminating) one or more symptoms
associated with the cancer.
[0062] By "monitoring" is meant observing or detecting the effect
of contacting a compound with a cell expressing a c-Met. The
observed or detected effect can be a change in cell phenotype, in
the catalytic activity of c-Met or a change in the interaction of
c-Met with a natural binding partner. Techniques for observing or
detecting such effects are well-known in the art. For example, the
catalytic activity of c-Met may be observed by determining the rate
or amount of phosphorylation of a target molecule.
[0063] "Cell phenotype" refers to the outward appearance of a cell
or tissue or the biological function of the cell or tissue.
Examples, without limitation, of a cell phenotype are cell size,
cell growth, cell proliferation, cell differentiation, cell
survival, apoptosis, and nutrient uptake and use. Such phenotypic
characteristics are measurable by techniques well-known in the
art.
[0064] A "natural binding partner" refers to a polypeptide that
binds to a c-Met in a cell.
[0065] Natural binding partners can play a role in propagating a
signal in a c-Met-mediated signal transduction process. A change in
the interaction of the natural binding partner with c-Met can
manifest itself as an increased or decreased concentration of the
c-Met/natural binding partner complex and, as a result, in an
observable change in the ability of c-Met to mediate signal
transduction.
[0066] As used herein, "administer" or "administration" refers to
the delivery of a compound or salt of the present invention or of a
pharmaceutical composition containing a compound or salt of this
invention to an organism for the purpose of prevention or treatment
of a c-Met-related disorder.
[0067] The terms "abnormal cell growth" and "hyperproliferative
disorder" are used interchangeably in this application.
[0068] "Abnormal cell growth", as used herein, refers to cell
growth that is independent of normal regulatory mechanisms (e.g.,
loss of contact inhibition), including the abnormal growth of
normal cells and the growth of abnormal cells. This includes, but
is not limited to, the abnormal growth of: (1) tumor cells
(tumors), both benign and malignant, expressing an activated Ras
oncogene; (2) tumor cells, both benign and malignant, in which the
Ras protein is activated as a result of oncogenic mutation in
another gene; (3) benign and malignant cells of other proliferative
diseases in which aberrant Ras activation occurs. Examples of such
benign proliferative diseases are psoriasis, benign prostatic
hypertrophy, human papilloma virus (HPV), and restinosis. "Abnormal
cell growth" also refers to and includes the abnormal growth of
cells, both benign and malignant, resulting from activity of the
enzyme farnesyl protein transferase.
[0069] "Alkyl" refers to a saturated aliphatic hydrocarbon
including straight chain or branched chain. Preferably, the alkyl
group has 1 to 20 carbon atoms (whenever a numerical range; e.g.,
"1-20", is stated herein, it means that the group, in this case the
alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon
atoms, etc. up to and including 20 carbon atoms). More preferably,
it is a medium size alkyl having 1 to 10 carbon atoms. Most
preferably, it is a lower alkyl having 1 to 6 carbon atoms. The
alkyl group may be substituted or unsubstituted. When substituted,
each substituent group is preferably one or more individually
selected from halogen, -hydroxy, --COR', --COOR', --OCOR',
--CONRR', --RNCOR', --NRR', --CN, --NO.sub.2, --CF.sub.3--SR',
--SOR', --SO.sub.2R', --SO.sub.2OR', --SO.sub.2NRR', thiocarbonyl,
--RNSO.sub.2R', perfluoroalkyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower
alkenyl, lower alkynyl, cycloalkyl, heteroalicycle, heteroaryl and
aryl. R and R' can be independently H, alkyl, or aryl, wherein
alkyl or aryl may be further substituted with halogen,
(CH.sub.2).sub.nN(R'').sub.2, (CH.sub.2).sub.nCO.sub.2R'',
(CH.sub.2).sub.nOR'', (CH.sub.2).sub.nOC(O)R'', alkoxycarbonyl,
aryloxycarbonyl, aminocarbonyl, a heteroalicyclic ring, aryl,
alkoxy, --OCF.sub.3, aryloxy, C(O)NH.sub.2 or heteroaryl. R'' can
be H, alkyl or aryl. n is 0-3.
[0070] "Alkenyl" refers to an aliphatic hydrocarbon having at least
one carbon-carbon double bond, including straight chain, branched
chain or cyclic groups having at least one carbon-carbon double
bond. Preferably, the alkenyl group has 2 to 20 carbon atoms
(whenever a numerical range; e.g., "2-20", is stated herein, it
means that the group, in this case the alkenyl group, may contain 2
carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon
atoms). More preferably, it is a medium size alkenyl having 2 to 10
carbon atoms. Most preferably, it is a lower alkenyl having 2 to 6
carbon atoms. Examples, without limitation, of alkenyl groups
include 1-propenyl, 1- and 2-butenyl, etc. The alkenyl group may be
substituted or unsubstituted. When substituted, each substituent
group is preferably one or more individually selected from halogen,
-hydroxy, --COR', --COOR', --OCOR', --CONRR', --RNCOR', --NRR',
--CN, --NO.sub.2, --CF.sub.3, --SR', --SOR', --SO.sub.2R',
--SO.sub.2OR', --SO.sub.2NRR', thiocarbonyl, --RNSO.sub.2R',
perfluoroalkyl, O-carbamyl, N-carbamyl, O-thiocarbamyl,
N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower
alkynyl, cycloalkyl, heteroalicycle, heteroaryl and aryl. Wherein R
and R' are defined herein.
[0071] "Alkynyl" refers to an aliphatic hydrocarbon having at least
one carbon-carbon triple bond, including straight chain, branched
chain or cyclic groups having at least one carbon-carbon triple
bond. Preferably, the alkenyl group has 2 to 20 carbon atoms
(whenever a numerical range; e.g., "2-20", is stated herein, it
means that the group, in this case the alkynyl group, may contain 2
carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon
atoms). More preferably, it is a medium size alkynyl having 2 to 10
carbon atoms. Most preferably, it is a lower alkynyl having 2 to 6
carbon atoms. Examples, without limitation, of alkynyl groups
include 1-propynyl, 1- and 2-butynyl, etc. The alkynyl group may be
substituted or unsubstituted. When substituted, each substituent
group is preferably one or more individually selected from halogen,
-hydroxy, --COR', --COOR', --OCOR', --CONRR', --RNCOR', --NRR',
--CN, --NO.sub.2, --CF.sub.3, --SR', --SOR', --SO.sub.2R',
--SO.sub.2OR', --SO.sub.2NRR', thiocarbonyl, --RNSO.sub.2R',
perfluoroalkyl, O-carbamyl, N-carbamyl, O-thiocarbamyl,
N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower
alkynyl, cycloalkyl, heteroalicycle, heteroaryl and aryl. Wherein R
and R' are defined herein.
[0072] A "cycloalkyl" or an "alicyclic" group refers to an
all-carbon monocyclic or fused ring (i.e., rings which share an
adjacent pair of carbon atoms) group wherein one of more of the
rings does not have a completely conjugated pi-electron system.
Preferably, the cycloalkyl group has from 3-8 carbon atoms in the
ring(s). Examples, without limitation, of cycloalkyl groups are
cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane,
adamantane, cyclohexadiene, cycloheptane and, cycloheptatriene. A
cycloalkyl group may be substituted or unsubstituted. When
substituted, each substituent group is preferably one or more
individually selected from halogen, -hydroxy, --COR', --COOR',
--OCOR', --CONRR', --RNCOR', --NRR', --CN, --NO.sub.2, --CF.sub.3,
--SR', --SOR', --SO.sub.2R', --SO.sub.2OR', --SO.sub.2NRR',
thiocarbonyl, --RNSO.sub.2R', perfluoroalkyl, O-carbamyl,
N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower
alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heteroalicycle,
heteroaryl and aryl. Wherein R and R' are defined herein.
[0073] An "aryl" group refers to an all-carbon monocyclic or
fused-ring polycyclic (i.e., rings which share adjacent pairs of
carbon atoms) groups having a completely conjugated pi-electron
system. Preferably, the aryl group has from 6 to 12 carbon atoms in
the ring(s). Examples, without limitation, of aryl groups are
phenyl, naphthalenyl and anthracenyl. The aryl group may be
substituted or unsubstituted. When substituted, each substituted
group is preferably one or more selected halogen, hydroxy, alkoxy,
aryloxy, --COR', --COOR', --OCOR', --CONRR', --RNCOR', --NRR',
--CN, --NO.sub.2, --CF.sub.3, --SR', --SOR', --SO.sub.2R',
--SO.sub.2OR', --SO.sub.2NRR', thiocarbonyl, --RNSO.sub.2R',
perfluoroalkyl, O-carbamyl, N-carbamyl, O-thiocarbamyl,
N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower
alkynyl, cycloalkyl, heteroalicycle, heteroaryl and aryl. Wherein R
and R' are defined herein.
[0074] As used herein, a "heteroaryl" group refers to a monocyclic
group having in the ring one or more atoms selected from the group
consisting of nitrogen, oxygen and sulfur with the proviso that
heteroaryl groups containing highly unstable heteroatom
arrangements, such as O--O, O--O--O and the like, are not
contemplated by the present invention. One of ordinary skill in the
art will recognize unstable groups that are not contemplated by the
invention. In addition, the heteroaryl group has a completely
conjugated pi-electron system. Preferably, the heteroaryl group has
from 5 to 7 ring atoms. Examples of typical monocyclic heteroaryl
groups include, but are not limited to:
##STR00009##
[0075] When substituted, each substituted group is preferably one
or more selected from halogen, hydroxy, --COR', --COOR', --OCOR',
--CONRR', --RNCOR', --NRR', --CN, --NO.sub.2, --CF.sub.3, --SR',
--SOR', --SO.sub.2R', --SO.sub.2OR', --SO.sub.2NRR', thiocarbonyl,
--RNSO.sub.2R', perfluoroalkyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower
alkenyl, lower alkynyl, cycloalkyl, heteroalicycle, heteroaryl and
aryl. Wherein R and R' are defined herein.
[0076] A "heteroalicyclic ring" or "heteroalicycle" or
"heterocyclic" or "heterocycle" group refers to a monocyclic group
having in the ring one or more atoms selected from the group
consisting of nitrogen, oxygen and sulfur. The rings may be
saturated and also have one or more double bonds (i.e. partially
unsaturated). However, the rings may not have a completely
conjugated pi-electron system. Preferably, the heteroalicyclic ring
contains from 3 to 8 ring atoms. Examples of suitable saturated
heteroalicyclic groups include, but are not limited to:
##STR00010##
[0077] Examples of suitable partially unsaturated heteroalicyclic
groups include, but are not limited to:
##STR00011##
[0078] The foregoing groups, as derived from the compounds listed
above, may be C-attached or N-attached where such is possible. For
instance, a group derived from pyrrole may be pyrrol-1-yl
(N-attached) or pyrrol-3-yl (C-attached). The heteroalicyclic ring
may be substituted or unsubstituted. The heteroalicydic ring may
contain one or more oxo groups. When substituted, the substituted
group(s) is preferably one or more selected halogen, hydroxy,
--COR', --COOR', OCOR', --CONRR', --RNCOR', --NRR', --CN,
--NO.sub.2, --CZ.sub.3, --SR', --SOR', --SO.sub.2R', --SO.sub.2OR',
--SO.sub.2NRR', thiocarbonyl, --RNSO.sub.2R', perfluoroalkyl,
O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, silyl,
ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl,
heteroalicycle, heteroaryl and aryl. Wherein R and R' are defined
herein.
[0079] A "3-8 Membered heteroalicyclic-(3-8 membered
heteroalicyclic)" group refers to a group having two 3-8 membered
heteroalicyclic groups covalently bonded to each other through a
single ring atom of each. The 3-8 membered heteroalicyclic rings
may be any heteroalicyclic ring as defined above. Furthermore, the
heteroalicyclic rings may be substituted or unsubstituted as
defined above.
[0080] "Heterobicyclic" or "heterobicycle" refers to a fused ring
(i.e., rings which share an adjacent pair of atoms) group having in
the ring(s) one or more atoms selected from the group consisting of
nitrogen, oxygen and sulfur and, in addition, having a completely
conjugated pi-electron system (i.e.--aromatic heterobicyclic) or
one or more double bonds that does not create a completely
conjugated pi-electron system, with the proviso that heterobicyclic
groups containing highly unstable heteroatom arrangements, such as
O--O, O--O--O and the like, are not contemplated by the present
invention. One of ordinary skill in the art will recognize unstable
groups that are not contemplated by the invention. Preferably, the
heterobicyclic group contains from 8-10 ring atoms. The
heterobicyclic ring may be substituted or unsubstituted. The
heterobicyclic ring may contain one or more oxo groups. Examples of
suitable fused ring aromatic heterobicyclic groups include, but are
not limited to:
##STR00012## ##STR00013##
Examples of suitable fused ring heterobicyclic groups include, but
are not limited to:
##STR00014##
[0081] When substituted, the substituted group(s) is preferably one
or more selected halogen, hydroxy, --COR', --COOR', OCOR',
--CONRR', --RNCOR', --NRR', --CN, --NO.sub.2, --CZ.sub.3, --SR',
--SOR', --SO.sub.2R', --SO.sub.2OR', --SO.sub.2NRR', thiocarbonyl,
--RNSO.sub.2R', perfluoroalkyl, O-carbamyl, N-carbamyl,
O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower
alkenyl, lower alkynyl, cycloalkyl, heteroalicycle, heteroaryl and
aryl. Wherein R and R' are defined herein.
[0082] When used herein, the R groups on substitutents having two
or more R groups on different atoms, such as
--(CH.sub.2).sub.n(NR.sup.12R.sup.13)C(O)NR.sup.12R.sup.13 or
--NR.sup.10C(O)NR.sup.10R.sup.11, may be the same or different.
Specifically, in the exemplary substituent
--NR.sup.10C(O)NR.sup.10R.sup.11, the two R.sup.10 groups may be
the same or different with respect to each other, likewise, the two
R.sup.10 groups may be the same or different with respect to the
R.sup.11 group. In, for example,
--(CH.sub.2).sub.n(NR.sup.12R.sup.13)C(O)NR.sup.12R.sup.13, the two
R.sup.12 groups may be the same or different with respect to each
other, and the two R.sup.13 groups may be the same or different
with respect to each other. Likewise, the two R.sup.12 groups may
be the same or different with respect to the two R.sup.13 group. In
addition, where a single atom is substituted by more than one
group, the groups on that atom may be the same or different. So, in
--NR.sup.10C(O)NR.sup.10R.sup.11, the R.sup.10 and R.sup.11 on the
same nitrogen may be the same or different from one another.
[0083] An "oxo" group refers to a carbonyl moiety such that alkyl
substituted by oxo refers to a ketone group.
[0084] A "hydroxy" group refers to an --OH group.
[0085] An "alkoxy" group refers to both an --Oalkyl and an
--Ocycloalkyl group, as defined herein.
[0086] An "alkoxycarbonyl" refers to a --C(O)OR.
[0087] An "aminocarbonyl" refers to a --C(O)NRR'.
[0088] An "aryloxycarbonyl" refers to --C(O)Oaryl.
[0089] An "aryloxy" group refers to both an --Oaryl and an
--Oheteroaryl group, as defined herein.
[0090] An "arylalkyl" group refers to -alkylaryl, where alkyl and
aryl are defined herein.
[0091] An "arylsulfonyl" group refers to a --SO.sub.2aryl.
[0092] An "alkylsulfonyl" group refer to a --SO.sub.2alkyl.
[0093] A "heteroaryloxyl" group refers to a heteroaryl group with
heteroaryl as defined herein.
[0094] A "heteroalicycloxy" group refers to a heteroalicyclic-O
group with heteroalicyclic as defined herein.
[0095] A "carbonyl" group refers to a --C(.dbd.O)R.
[0096] An "aldehyde" group refers to a carbonyl group where R is
hydrogen.
[0097] A "thiocarbonyl" group refers to a --C(.dbd.S)--R group.
[0098] A "trihalomethanecarbonyl" group refers to a Z.sub.3CC(O)
group, where Z is halogen.
[0099] A "C-carboxyl" group refers to a --C(O)OR groups.
[0100] An "O-carboxyl" group refers to a RC(O)O group.
[0101] A "carboxylic acid" group refers to a C-carboxyl group in
which R is hydrogen.
[0102] A "halo" or "halogen" group refers to fluorine, chlorine,
bromine or iodine.
[0103] A "trihalomethyl" group refers to a --CZ.sub.3 group.
[0104] A "trihalomethanesulfonyl" group refers to a
Z.sub.3CS(O).sub.2 group.
[0105] A "trihalomethanesulfonamido" group refers to a
Z.sub.3CS(O).sub.2NR-group.
[0106] A "sulfinyl" group refers to a --S(O)R group.
[0107] A "sulfonyl" group refers to a --S(O).sub.2R group.
[0108] An "S-sulfonamido" group refers to a
--S(O).sub.2NR-group.
[0109] An "N-Sulfonamido" group refers to a --NR--S(O).sub.2R
group.
[0110] An "O-carbamyl" group refers to a --OC(O)NRR' group.
[0111] An "N-carbamyl" group refers to a ROC(O)NR-group.
[0112] An "O-thiocarbamyl" group refers to a --OC(S)NRR' group.
[0113] An "N-thiocarbamyl" group refers to a ROC(S)NR' group.
[0114] An "amino" group refers to an --NH.sub.2 or an
--NRR'group.
[0115] A "C-amido" group refers to a --C(O)NRR' group.
[0116] An "N-amido" group refers to a R'C(O)NR group.
[0117] A "nitro" group refers to a --NO.sub.2 group.
[0118] A "cyano" group refers to a --CN group.
[0119] A "silyl" group refers to a --Si(R).sub.3 group.
[0120] A "phosphonyl" group refers to a --P(.dbd.O)(OR).sub.2
group.
[0121] An "aminoalkyl" group refers to an -alkylNRR' group.
[0122] An "alkylaminoalkyl" group refers to an -alkyl-NR-alkyl
group.
[0123] A "dialkylamionalkyl" group refers to an
-alkylN-(alkyl).sub.2 group.
[0124] A "perfluoroalkyl group" refers to an alkyl group where all
of the hydrogen atoms have been replaced with fluorine atoms.
[0125] Compounds that have the same molecular formula but differ in
the nature or sequence of bonding of their atoms or arrangements of
their atoms in space are termed "isomers." Isomers that differ in
the arrangement of their atoms in space are termed "stereoisomers".
Stereoisomers that are not mirror images of one another are termed
"diastereomers" and those that are non-superimposable mirror images
of each other are termed "enantiomers". When a compound has an
asymmetric center, for example, it is bonded to four different
groups, a pair of enantiomers is possible. An enantiomer can be
characterized by the absolute configuration of its asymmetric
center and is described by the R- and S-sequencing rules of Cahn
and Prelog, or by the manner in which the molecule rotates the
plane of polarized light and designated as dextrorotatory or
levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral
compound can exist as either individual enantiomer or as a mixture
thereof. A mixture containing equal proportions of the enantiomers
is called a "racemic mixture". The chemical formulae referred to
herein may exhibit the phenomena of tautomerism and structural
isomerism. This invention encompasses any tautomeric or structural
isomeric form and mixtures thereof which possess the ability to
modulate c-Met activity and is not limited to any one tautomeric or
structural isomeric form. This invention encompasses any tautomeric
or structural isomeric form and mixtures thereof which possess the
ability to modulate c-Met activity and is not limited to any one
tautomeric or structural isomeric form.
[0126] The compounds of this invention may possess one or more
asymmetric centers; such compounds can therefore be produced as
individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless
indicated otherwise, the description or naming of a particular
compound in the specification and claims is intended to include
both individual enantiomers and mixtures, racemic or otherwise,
thereof. The methods for the determination of stereochemistry and
the separation of stereoisomers are well-known in the art (see
discussion in Chapter 4 of "Advanced Organic Chemistry", 4th
edition J. March, John Wiley and Sons, New York, 1992). Thus, this
invention also encompasses any stereoisomeric form, their
corresponding enantiomers (d- and l- or (+) and (-) isomers) and
diastereomers thereof, and mixtures thereof, which possess the
ability to modulate c-Met activity and is not limited to any one
stereoisomeric form.
[0127] The compounds of the Formula (I) may exhibit the phenomena
of tautomerism and structural isomerism. For example, the compounds
described herein may adopt an E or a Z configuration about a double
bond or they may be a mixture of E and Z. This invention
encompasses any tautomeric or structural isomeric form and mixtures
thereof which possess the ability to modulate c-Met activity and is
not limited to any one tautomeric or structural isomeric form.
[0128] It is contemplated that compounds of the Formula (I) would
be metabolized by enzymes in the body of the organism such as human
being to generate a metabolite that can modulate the activity of
c-Met. Such metabolites are within the scope of the present
invention.
[0129] Those compounds of the formula I that are acidic in nature
are capable of forming base salts with various pharmacologically
acceptable cations. Examples of such salts include the alkali metal
or alkaline earth metal salts and particularly, the sodium and
potassium salts.
[0130] The compounds of the present invention have asymmetric
centers and therefore exist in different enantiomeric and
diastereomeric forms. This invention relates to the use of all
optical isomers and stereoisomers of the compounds of the present
invention, and mixtures thereof, and to all pharmaceutical
compositions and methods of treatment that may employ or contain
them. The compounds of formula I may also exist as tautomers. This
invention relates to the use of all such tautomers and mixtures
thereof.
[0131] This invention also encompasses pharmaceutical compositions
containing and methods of treating proliferative disorders or
abnormal cell growth through administering prodrugs of compounds of
the formula I. Compounds of formula I having free amino, amido,
hydroxy or carboxylic groups can be converted into prodrugs.
Prodrugs include compounds wherein an amino acid residue, or a
polypeptide chain of two or more (e.g., two, three or four) amino
acid residues is covalently joined through an amide or ester bond
to a free amino, hydroxy or carboxylic acid group of compounds of
formula I. The amino acid residues include but are not limited to
the 20 naturally occurring amino acids commonly designated by three
letter symbols and also includes 4-hydroxyproline, hydroxylysine,
demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine,
gamma-aminobutyric acid, citrulline homocysteine, homoserine,
ornithine and methionine sulfone. Additional types of prodrugs are
also encompassed. For instance, free carboxyl groups can be
derivatized as amides or alkyl esters. Free hydroxy groups may be
derivatized using groups including but not limited to
hemisuccinates, phosphate esters, dimethylaminoacetates, and
phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug
Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and
amino groups are also included, as are carbonate prodrugs,
sulfonate esters and sulfate esters of hydroxy groups.
Derivatization of hydroxy groups as (acyloxy)methyl and
(acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester,
optionally substituted with groups including but not limited to
ether, amine and carboxylic acid functionalities, or where the acyl
group is an amino acid ester as described above, are also
encompassed. Prodrugs of this type are described in J. Med. Chem.
1996, 39, 10. Free amines can also be derivatized as amides,
sulfonamides or phosphonamides. All of these prodrug moieties may
incorporate groups including but not limited to ether, amine and
carboxylic acid functionalities.
DETAILED DESCRIPTION OF THE INVENTION
[0132] The compounds presented herein are exemplary and are not to
be construed as limiting the scope of the invention.
[0133] A general synthetic route to the compounds of the present
invention is shown in Scheme 1. One of skill in the art will
recognize that this general scheme may be modified and yet still
produce the compounds of the present invention. The groups R.sup.a,
R.sup.b, R.sup.c, R.sup.d and R.sup.e shown in Scheme 1 include but
are not limited to those substituents described herein in
connection with the present invention. Further exemplary methods
for making the compounds of the invention are outlined in the
non-limiting examples below.
##STR00015##
[0134] In one aspect, this invention is directed to a
pharmaceutical composition comprising one or more compounds of
Formula (I) or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable excipient.
[0135] A unique physical form of the free base
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has been made. Tabulated data of the powder X-ray
diffraction (PXRD) pattern of free base polymorph form 1 is shown
in Table 1 below. See Method 42 below.
TABLE-US-00001 TABLE 1 PXRD data tabulation for Form 1 of the free
base 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-
b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol. Peak Intensity Peak
Intensity 2.theta. (.degree.) D-Value (Counts) (%) 5.8 15.1648 2244
100 11.6 7.6345 641 28.5 13.6 6.4963 1153 51.4 15.5 5.7308 2058
91.7 16.2 5.4736 1600 71.3 23.4 3.7947 527 23.5 27.6 3.235 519
23.1
[0136] A unique physical form of the mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol has been made. Tabulated data of the powder X-ray
diffraction (PXRD) pattern of mesylate salt polymorph form 1 is
shown in Table 2 below. See Method 42 below.
TABLE-US-00002 TABLE 2 PXRD data tabulation for Form 1 of the
mesylate salt of
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-
b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol. Peak Intensity Peak
Intensity 2.theta. (.degree.) D-Value (Counts) (%) 12.3 7.1688 579
60.1 14.8 5.9761 577 59.9 17.7 4.9997 498 51.6 18.3 4.8401 964 100
19.3 4.5913 715 74.1 23.1 3.851 570 59.1 24.9 3.5698 503 52.2
[0137] It is also an aspect of this invention that a compound
described herein, or its salt, might be combined with other
chemotherapeutic agents for the treatment of the diseases and
disorders discussed above. For instance, a compound or salt of this
invention might be combined with alkylating agents such as
fluorouracil (5-FU) alone or in further combination with
leukovorin; or other alkylating agents such as, without limitation,
other pyrimidine analogs such as UFT, capecitabine, gemcitabine and
cytarabine, the alkyl sulfonates, e.g., busulfan (used in the
treatment of chronic granulocytic leukemia), improsulfan and
piposulfan; aziridines, e.g., benzodepa, carboquone, meturedepa and
uredepa; ethyleneimines and methylmelamines, e.g., altretamine,
triethylenemelamine, triethylenephosphoramide,
triethylenethiophosphorami- de and trimethylolmelamine; and the
nitrogen mustards, e.g., chlorambucil (used in the treatment of
chronic lymphocytic leukemia, primary macroglobulinemia and
non-Hodgkin's lymphoma), cyciophosphamide (used in the treatment of
Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer,
ovarian cancer, lung cancer, Wilm's tumor and rhabdomyosarcoma),
estramustine, ifosfamide, novembrichin, prednimustine and uracil
mustard (used in the treatment of primary thrombocytosis,
non-Hodgkin's lymphoma, Hodgkin's disease and ovarian cancer); and
triazines, e.g., dacarbazine (used in the treatment of soft tissue
sarcoma).
[0138] Likewise a compound or salt of this invention might be
expected to have a beneficial effect in combination with other
antimetabolite chemotherapeutic agents such as, without limitation,
folic acid analogs, e.g. methotrexate (used in the treatment of
acute lymphocytic leukemia, choriocarcinoma, mycosis fungiodes
breast cancer, head and neck cancer and osteogenic sarcoma) and
pteropterin; and the purine analogs such as mercaptopurine and
thioguanine which find use in the treatment of acute granulocytic,
acute lymphocytic and chronic granulocytic leukemias.
[0139] A compound or salt of this invention might also be expected
to prove efficacious in combination with natural product based
chemotherapeutic agents such as, without limitation, the vinca
alkaloids, e.g., vinblastin (used in the treatment of breast and
testicular cancer), vincristine and vindesine; the
epipodophylotoxins, e.g., etoposide and teniposide, both of which
are useful in the treatment of testicular cancer and Kaposi's
sarcoma; the antibiotic chemotherapeutic agents, e.g.,
daunorubicin, doxorubicin, epirubicin, mitomycin (used to treat
stomach, cervix, colon, breast, bladder and pancreatic cancer),
dactinomycin, temozolomide, plicamycin, bleomycin (used in the
treatment of skin, esophagus and genitourinary tract cancer); and
the enzymatic chemotherapeutic agents such as L-asparaginase.
[0140] In addition to the above, a compound or salt of this
invention might be expected to have a beneficial effect used in
combination with the platinum coordination complexes (cisplatin,
etc.); substituted ureas such as hydroxyurea; methylhydrazine
derivatives, e.g., procarbazine; adrenocortical suppressants, e.g.,
mitotane, aminoglutethimide; and hormone and hormone antagonists
such as the adrenocorticosteriods (e.g., prednisone), progestins
(e.g., hydroxyprogesterone caproate); estrogens (e.g.,
diethylstilbesterol); antiestrogens such as tamoxifen; androgens,
e.g., testosterone propionate; and aromatase inhibitors (such as
anastrozole).
[0141] Finally, the combination of a compound of this invention
might be expected to be particularly effective in combination with
mitoxantrone or paclitaxel for the treatment of solid tumor cancers
or leukemias such as, without limitation, acute myelogenous
(non-lymphocytic) leukemia.
[0142] The above method can be carried out in combination with a
chemotherapeutic agent selected from the group consisting of
mitotic inhibitors, alkylating agents, antimetabolites, cell cycle
inhibitors, enzymes, topoisomerase inhibitors, biological response
modifiers, anti-hormones, antiangiogenic agents such as MMP-2,
MMP-9 and COX-2 inhibitors, and anti-androgens.
[0143] Examples of useful COX-II inhibitors include Vioxx..TM.,
CELEBREX..TM.. (alecoxib), valdecoxib, paracoxib, rofecoxib, and
Cox 189. Examples of useful matrix metalloproteinase inhibitors are
described in WO 96/33172 (published Oct. 24, 1996), WO 96/27583
(published Mar. 7, 1996), European Patent Application No.
97304971.1 (filed Jul. 8, 1997), European Patent Application No.
99308617.2 (filed Oct. 29, 1999), WO 98/07697 (published Feb. 26,
1998), WO 98/03516 (published Jan. 29, 1998), WO 98/34918
(published Aug. 13, 1998), WO 98/34915 (published Aug. 13, 1998),
WO 98/33768 (published Aug. 6, 1998), WO 98/30566 (published Jul.
16, 1998), European Patent Publication 606,046 (published Jul. 13,
1994), European Patent Publication 931,788 (published Jul. 28,
1999), WO 90/05719 (published May 31, 1990), WO 99/52910 (published
Oct. 21, 1999), WO 99/52889 (published Oct. 21, 1999), WO 99/29667
(published Jun. 17, 1999), PCT International Application No.
PCT/IB98/01113 (filed Jul. 21, 1998), European Patent Application
No. 99302232.1 (filed Mar. 25, 1999), Great Britain patent
application number 9912961.1 (filed Jun. 3, 1999), U.S. Provisional
Application No. 60/148,464 (filed Aug. 12, 1999), U.S. Pat. No.
5,863,949 (issued Jan. 26, 1999), U.S. Pat. No. 5,861,510 (issued
Jan. 19, 1999), and European Patent Publication 780,386 (published
Jun. 25, 1997), all of which are incorporated herein in their
entireties by reference.
[0144] Preferred MMP-2 and MMP-9 inhibitors are those that have
little or no activity inhibiting MMP-1. More preferred, are those
that selectively inhibit MMP-2 and/or MMP-9 relative to the other
matrix-metalloproteinase-s (i.e. MMP-1, MMP-3, MMP-4, MMP-5, MMP-6,
MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). Some specific
examples of MMP inhibitors useful in the present invention are
AG-3340, RO 32-3555, RS 13-0830, and the compounds recited in the
following list:
[0145]
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-cyclo-
-pentyl)-amino]propionic acid;
3-exo-3-[4-(4-fluoro-phenoxy)-benzenesulfon-ylamino]-8-oxa-bicyclo[3.2.1]-
octane-3-carboxylic acid hydroxyamide; (2R,3R)
1-[4-(2-chloro-4-fluoro-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-pi-
peridine-2-carboxylic acid hydroxyamide;
4-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]tetrahydro-pyran-4-carboxyli-
c acid hydroxyamide;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxy-carbamoylcyclobutyl)-
-amino]-propionic acid;
4-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxyl-
ic acid hydroxyamide; (R)
3-[4-(4-chloro-phenoxy)-benzenesulfonyl-amino]-tetrahydro-pyran-3-carboxy-
lic acid hydroxyamide; (2R,3R)
1-[4-(4-fluoro-2-methylbenzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-pip-
eridine-2-carboxylic acid hydroxyamide;
3-[[(4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-1-methylet-
hyl)-amino]propionic acid;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(4-hydroxycarbamoyl-tetrahydrop-
yran-4-yl)-amino]-propionic acid;
3-exo-3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]o-
ctane-3-carboxylic acid hydroxy-amide;
3-endo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicylo[3.2.1]o-
ctane-3-carboxylic acid hydroxyamide; and (R)
3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-furan-3-carboxyl-
ic acid hydroxyamide; and pharmaceutically acceptable salts and
solvates of said compounds.
[0146] Other anti-angiogenesis agents, including other COX-II
inhibitors and other MMP inhibitors, can also be used in the
present invention.
[0147] Compounds of the Formula (I) can also be used with signal
transduction inhibitors, such as agents that can inhibit EGFR
(epidermal growth factor receptor) responses, such as EGFR
antibodies, EGF antibodies, and molecules that are EGFR inhibitors;
VEGF (vascular endothelial growth factor) inhibitors; and erbB2
receptor inhibitors, such as organic molecules or antibodies that
bind to the erbB2 receptor, for example, HERCEPTIN.TM.. (Genentech,
Inc. of South San Francisco, Calif., USA). EGFR inhibitors are
described in, for example in WO 95/19970 (published Jul. 27, 1995),
WO 98/14451 (published Apr. 9, 1998), WO 98/02434 (published Jan.
22, 1998), and U.S. Pat. No. 5,747,498 (issued May 5, 1998), and
such substances can be used in the present invention as described
herein.
[0148] EGFR-inhibiting agents include, but are not limited to, the
monoclonal antibodies C225 and anti-EGFR 22Mab (ImClone Systems
Incorporated of New York, N.Y., USA), the compounds ZD-1839
(AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex
Inc. of Annandale, N.J., USA), and OLX-103 (Merck & Co. of
Whitehouse Station, N.J., USA), VRCTC-310 (Ventech Research) and
EGF fusion toxin (Seragen Inc. of Hopkinton, Mass.).
[0149] These and other EGFR-inhibiting agents can be used in the
present invention.
[0150] VEGF inhibitors can also be combined with a compounds of the
Formulae (I). VEGF inhibitors are described in, for example in WO
99/24440 (published May 20, 1999), PCT International Application
PCT/IB99/00797 (filed May 3, 1999), in WO 95/21613 (published Aug.
17, 1995), WO 99/61422 (published Dec. 2, 1999), U.S. Pat. No.
5,834,504 (issued Nov. 10, 1998), WO 01/60814, WO 98/50356
(published Nov. 12, 1998), U.S. Pat. No. 5,883,113 (issued Mar. 16,
1999), U.S. Pat. No. 5,886,020 (issued Mar. 23, 1999), U.S. Pat.
No. 5,792,783 (issued Aug. 11, 1998), WO 99/10349 (published Mar.
4, 1999), WO 97/32856 (published Sep. 12, 1997), WO 97/22596
(published Jun. 26, 1997), WO 98/54093 (published Dec. 3, 1998), WO
98/02438 (published Jan. 22, 1998), WO 99/16755 (published Apr. 8,
1999), and WO 98/02437 (published Jan. 22, 1998), all of which are
incorporated herein in their entireties by reference. Other
examples of some specific VEGF inhibitors useful in the present
invention are IM862 (Cytran Inc. of Kirkland, Wash., USA);
anti-VEGF monoclonal antibody of Genentech, Inc. of South San
Francisco, Calif.; and angiozyme, a synthetic ribozyme from
Ribozyme (Boulder, Colo.) and Chiron (Emeryville, Calif.). These
and other VEGF inhibitors can be used in the present invention as
described herein.
[0151] ErbB2 receptor inhibitors, such as GW-282974 (Glaxo Wellcome
pic), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals
Inc. of TheWoodlands, Tex., USA) and 2B-1 (Chiron), can furthermore
be combined with a compound of the Formula (I) for example those
indicated in WO 98/02434 (published Jan. 22, 1998), WO 99/35146
(published Jul. 15, 1999), WO 99/35132 (published Jul. 15, 1999),
WO 98/02437 (published Jan. 22, 1998), WO 97/13760 (published Apr.
17, 1997), WO 95/19970 (published Jul. 27, 1995), U.S. Pat. No.
5,587,458 (issued Dec. 24, 1996), and U.S. Pat. No. 5,877,305
(issued Mar. 2, 1999), which are all hereby incorporated herein in
their entireties by reference. ErbB2 receptor inhibitors useful in
the present invention are also described in U.S. Provisional
Application No. 60/117,341, filed Jan. 27, 1999, and in U.S.
Provisional Application No. 60/117,346, filed Jan. 27, 1999, both
of which are incorporated in their entireties herein by reference.
The erbB2 receptor inhibitor compounds and substance described in
the aforementioned PCT applications, U.S. patents, and U.S.
provisional applications, as well as other compounds and substances
that inhibit the erbB2 receptor, can be used with compounds of the
Formula (I), in accordance with the present invention.
[0152] Compounds of the Formula (I) can also be used with other
agents useful in treating cancer, including, but not limited to,
agents capable of enhancing antitumor immune responses, such as
CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents
capable of blocking CTLA4; and anti-proliferative agents such as
other farnesyl protein transferase inhibitors, for example the
farnesyl protein transferase inhibitors described in the references
cited in the "Background" section, of U.S. Pat. No. 6,258,824 B1.
Specific CTLA4 antibodies that can be used in the present invention
include those described in U.S. Provisional Application No.
60/113,647 (filed Dec. 23, 1998) which is incorporated by reference
in its entirety, however other CTLA4 antibodies can be used in the
present invention.
[0153] The above method can be also be carried out in combination
with radiation therapy, wherein the amount of a compound of the
Formula (I) in combination with the radiation therapy, is effective
in treating the above diseases. The level of radiation therapy
administered may be reduced to a sub-efficacy dose when
administered in combination with the compounds of the preferred
embodiments of the present invention.
[0154] Techniques for administering radiation therapy are known in
the art, and these techniques can be used in the combination
therapy described herein. The administration of the compound of the
invention in this combination therapy can be determined as
described herein.
[0155] Another aspect of the invention is directed of the use of
compounds of the Formulae (I) in the preparation of a medicament,
which is useful in the treatment of a disease mediated by abnormal
Met kinase activity.
[0156] Indications
[0157] A precise understanding of the mechanism by which the
compounds of the invention, in particular, the compounds generated
in vivo from the compounds of the invention, inhibit c-Met is not
required in order to practice the present invention. However, while
not hereby being bound to any particular mechanism or theory, it is
believed that the compounds interact with the amino acids in the
catalytic region of c-Met. The compounds disclosed herein may thus
have utility as in vitro assays for c-Met as well as exhibiting in
vivo therapeutic effects through interaction with c-Met.
[0158] In another aspect, this invention relates to a method for
treating or preventing a c-Met related disorder by administering a
therapeutically effective amount of a compound of this invention,
or a salt thereof, to an organism.
[0159] It is also an aspect of this invention that a pharmaceutical
composition containing a compound of this invention, or a salt
thereof, is administered to an organism for the purpose of
preventing or treating a c-Met related disorder.
[0160] This invention is therefore directed to compounds that
modulate PK signal transduction by affecting the enzymatic activity
of c-Met, thereby interfering with the signal transduced by c-Met.
More particularly, the present invention is directed to compounds
which modulate c-Met mediated signal transduction pathways as a
therapeutic approach to treat the many cancers described
herein.
[0161] A method for identifying a chemical compound that modulates
the catalytic activity of c-Met is another aspect of this
invention. The method involves contacting cells expressing c-Met
with a compound of this invention (or its salt) and monitoring the
cells for any effect that the compound has on them. Alternatively,
the method can involve contacting the c-Met protein itself (i.e.,
not in a cell) with a chemical compound of the preferred
embodiments of the present invention and monitoring the protein for
any effect that the compound has on it. The effect may be
observable, either to the naked eye or through the use of
instrumentation. The effect may be, for example, a change or
absence in a cell phenotype. The change or absence of change in the
cell phenotype monitored, for example, may be, without limitation,
a change or absence of change in the catalytic activity of c-Met in
the cells or a change or absence of change in the interaction of
c-Met with a natural binding partner.
[0162] Pharmaceutical Compositions and Use
[0163] A compound of the present invention or a physiologically
acceptable salt thereof, can be administered as such to a human
patient or can be administered in pharmaceutical compositions in
which the foregoing materials are mixed with suitable carriers or
excipient(s). Techniques for formulation and administration of
drugs may be found in "Remington's Pharmacological Sciences," Mack
Publishing Co., Easton, Pa., latest edition.
[0164] Routes of Administration
[0165] Suitable routes of administration may include, without
limitation, oral, intraoral, rectal, transmucosal or intestinal
administration or intramuscular, epicutaneous, parenteral,
subcutaneous, transdermal, intramedullary, intrathecal, direct
intraventricular, intravenous, intravitreal, intraperitoneal,
intranasal, intramuscular, intradural, intrarespiratory, nasal
inhalation or intraocular injections. The preferred routes of
administration are oral and parenteral.
[0166] Alternatively, one may administer the compound in a local
rather than systemic manner, for example, via injection of the
compound directly into a solid tumor, often in a depot or sustained
release formulation.
[0167] Furthermore, one may administer the drug in a targeted drug
delivery system, for example, in a liposome coated with
tumor-specific antibody. The liposomes will be targeted to and
taken up selectively by the tumor.
[0168] Composition/Formulation
[0169] Pharmaceutical compositions of the present invention may be
manufactured by processes well known in the art, e.g., by means of
conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping, lyophilizing
processes or spray drying.
[0170] Pharmaceutical compositions for use in the methods of the
present invention may be prepared by any methods of pharmacy, but
all methods include the step of bringing in association the active
ingredient with the carrier which constitutes one or more necessary
ingredients. In particular, pharmaceutical compositions for use in
accordance with the present invention may be formulated in
conventional manner using one or more physiologically acceptable
carriers comprising excipients and auxiliaries which facilitate
processing of the active compounds into preparations which can be
used pharmaceutically. Proper formulation is dependent upon the
route of administration chosen.
[0171] Dosage forms include tablets, troches, dispersions,
suspensions, solutions, capsules, patches, syrups, elixirs, gels,
powders, magmas, lozenges, ointments, creams, pastes, plasters,
lotions, discs, suppositories, nasal or oral sprays, aerosols and
the like.
[0172] For injection, the compounds of the invention may be
formulated in aqueous solutions, preferably in physiologically
compatible buffers such buffers with or without a low concentration
of surfactant or cosolvent, or physiological saline buffer. For
transmucosal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants are
generally known in the art.
[0173] For oral administration, the compounds can be formulated by
combining the active compounds with pharmaceutically acceptable
carriers well known in the art. Such carriers enable the compounds
of the invention to be formulated as tablets, pills, lozenges,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient. Pharmaceutical
preparations for oral use can be made using a solid excipient,
optionally grinding the resulting mixture, and processing the
mixture of granules, after adding other suitable auxiliaries if
desired, to obtain tablets or dragee cores. Useful excipients are,
in particular, fillers such as sugars, including lactose, sucrose,
mannitol, or sorbitol, cellulose preparations such as, for example,
maize starch, wheat starch, rice starch and potato starch and other
materials such as gelatin, gum tragacanth, methyl cellulose,
hydroxypropyl methyl-cellulose, sodium carboxymethylcellulose,
and/or polyvinyl-pyrrolidone (PVP). If desired, disintegrating
agents may be added, such as cross-linked polyvinyl pyrrolidone,
agar, or alginic acid. A salt such as sodium alginate may also be
used.
[0174] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0175] Pharmaceutical compositions which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with a filler such as lactose, a binder such as starch,
and/or a lubricant such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, liquid polyethylene glycols, cremophor, capmul,
medium or long chain mono-di- or triglycerides. Stabilizers may be
added in these formulations, also.
[0176] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray using a pressurized pack or a
nebulizer and a suitable propellant, e.g., without limitation,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetra-fluoroethane or carbon dioxide. In the case of a
pressurized aerosol, the dosage unit may be controlled by providing
a valve to deliver a metered amount. Capsules and cartridges of,
for example, gelatin for use in an inhaler or insufflator may be
formulated containing a powder mix of the compound and a suitable
powder base such as lactose or starch.
[0177] The compounds may also be formulated for parenteral
administration, e.g., by bolus injection or continuous infusion.
Formulations for injection may be presented in unit dosage form,
e.g., in ampoules or in multi-dose containers, with an added
preservative. The compositions may take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and may contain
formulating materials such as suspending, stabilizing and/or
dispersing agents.
[0178] Pharmaceutical compositions for parenteral administration
include aqueous solutions of a water soluble form, such as, without
limitation, a salt, of the active compound. Additionally,
suspensions of the active compounds may be prepared in a lipophilic
vehicle. Suitable lipophilic vehicles include fatty oils such as
sesame oil, synthetic fatty acid esters such as ethyl oleate and
triglycerides, or materials such as liposomes. Aqueous injection
suspensions may contain substances which increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol,
or dextran. Optionally, the suspension may also contain suitable
stabilizers and/or agents that increase the solubility of the
compounds to allow for the preparation of highly concentrated
solutions.
[0179] Alternatively, the active ingredient may be in powder form
for constitution with a suitable vehicle, e.g., sterile,
pyrogen-free water, before use.
[0180] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, using, e.g.,
conventional suppository bases such as cocoa butter or other
glycerides.
[0181] In addition to the formulations described previously, the
compounds may also be formulated as depot preparations. Such long
acting formulations may be administered by implantation (for
example, subcutaneously or intramuscularly) or by intramuscular
injection. A compound of this invention may be formulated for this
route of administration with suitable polymeric or hydrophobic
materials (for instance, in an emulsion with a pharmacologically
acceptable oil), with ion exchange resins, or as a sparingly
soluble derivative such as, without limitation, a sparingly soluble
salt.
[0182] A non-limiting example of a pharmaceutical carrier for the
hydrophobic compounds of the invention is a cosolvent system
comprising benzyl alcohol, a nonpolar surfactant, a water-miscible
organic polymer and an aqueous phase such as the VPD co-solvent
system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the
nonpolar surfactant Polysorbate 80, and 65% w/v polyethylene glycol
300, made up to volume in absolute ethanol. The VPD co-solvent
system (VPD:D5W) consists of VPD diluted 1:1 with a 5% dextrose in
water solution. This co-solvent system dissolves hydrophobic
compounds well, and itself produces low toxicity upon systemic
administration. Naturally, the proportions of such a co-solvent
system may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other
low-toxicity nonpolar surfactants may be used instead of
Polysorbate 80, the fraction size of polyethylene glycol may be
varied, other biocompatible polymers may replace polyethylene
glycol, e.g., polyvinyl pyrrolidone, and other sugars or
polysaccharides may substitute for dextrose.
[0183] Alternatively, other delivery systems for hydrophobic
pharmaceutical compounds may be employed. Liposomes and emulsions
are well known examples of delivery vehicles or carriers for
hydrophobic drugs. In addition, certain organic solvents such as
dimethylsulfoxide also may be employed, although often at the cost
of greater toxicity.
[0184] Additionally, the compounds may be delivered using a
sustained-release system, such as semipermeable matrices of solid
hydrophobic polymers containing the therapeutic agent. Various
sustained-release materials have been established and are well
known by those skilled in the art. Sustained-release capsules may,
depending on their chemical nature, release the compounds for a few
weeks up to over 100 days. Depending on the chemical nature and the
biological stability of the therapeutic reagent, additional
strategies for protein stabilization may be employed.
[0185] The pharmaceutical compositions herein also may comprise
suitable solid or gel phase carriers or excipients. Examples of
such carriers or excipients include, but are not limited to,
calcium carbonate, calcium phosphate, various sugars, starches,
cellulose derivatives, gelatin, and polymers such as polyethylene
glycols.
[0186] Many of the PK modulating compounds of the invention may be
provided as physiologically acceptable salts wherein the claimed
compound may form the negatively or the positively charged species.
Examples of salts in which the compound forms the positively
charged moiety include, without limitation, quaternary ammonium
(defined elsewhere herein), salts such as the hydrochloride,
sulfate, carbonate, lactate, tartrate, maleate, sucinate, malate,
acetate and methylsulfonate (CH.sub.3SO.sub.3), wherein the
nitrogen atom of the quaternary ammonium group is a nitrogen of the
selected compound of this invention which has reacted with the
appropriate acid. Salts in which a compound of this invention forms
the negatively charged species include, without limitation, the
sodium, potassium, calcium and magnesium salts formed by the
reaction of a carboxylic acid group in the compound with an
appropriate base (e.g. sodium hydroxide (NaOH), potassium hydroxide
(KOH), Calcium hydroxide (Ca(OH).sub.2), etc.).
[0187] Dosage
[0188] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an amount sufficient to achieve the intended purpose,
i.e., the modulation of PK activity or the treatment or prevention
of a PK-related disorder.
[0189] More specifically, a therapeutically effective amount means
an amount of compound effective to prevent, alleviate or ameliorate
symptoms of disease or prolong the survival of the subject being
treated.
[0190] Determination of a therapeutically effective amount is well
within the capability of those skilled in the art, especially in
light of the detailed disclosure provided herein.
[0191] For any compound used in the methods of the invention, the
therapeutically effective amount or dose can be estimated initially
from cell culture assays. Then, the dosage can be formulated for
use in animal models so as to achieve a circulating concentration
range that includes the IC.sub.50 as determined in cell culture
(i.e., the concentration of the test compound which achieves a
half-maximal inhibition of c-Met activity). Such information can
then be used to more accurately determine useful doses in
humans.
[0192] Toxicity and therapeutic efficacy of the compounds described
herein can be determined by standard pharmaceutical procedures in
cell cultures or experimental animals, e.g., by determining the
IC.sub.50 and the LD.sub.50 (both of which are discussed elsewhere
herein) for a subject compound. The data obtained from these cell
culture assays and animal studies can be used in formulating a
range of dosage for use in humans. The dosage may vary depending
upon the dosage form employed and the route of administration
utilized. The exact formulation, route of administration and dosage
can be chosen by the individual physician in view of the patient's
condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological
Basis of Therapeutics", Ch. 1 p. 1).
[0193] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active species which are sufficient to
maintain the kinase modulating effects. These plasma levels are
referred to as minimal effective concentrations (MECs). The MEC
will vary for each compound but can be estimated from in vitro
data, e.g., the concentration necessary to achieve 50-90%
inhibition of a kinase may be ascertained using the assays
described herein. Dosages necessary to achieve the MEC will depend
on individual characteristics and route of administration. HPLC
assays or bioassays can be used to determine plasma
concentrations.
[0194] Dosage intervals can also be determined using MEC value.
Compounds should be administered using a regimen that maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90%. At present, the
therapeutically effective amounts of compounds of the formula I may
range from approximately 10 mg/m.sup.2 to 1000 mg/m.sup.2 perday.
Even more preferably 25 mg/m.sup.2 to 500 mg/m.sup.2.
[0195] In cases of local administration or selective uptake, the
effective local concentration of the drug may not be related to
plasma concentration and other procedures known in the art may be
employed to determine the correct dosage amount and interval.
[0196] The amount of a composition administered will, of course, be
dependent on the subject being treated, the severity of the
affliction, the manner of administration, the judgment of the
prescribing physician, etc.
[0197] Packaging
[0198] The compositions may, if desired, be presented in a pack or
dispenser device, such as an FDA approved kit, which may contain
one or more unit dosage forms containing the active ingredient. The
pack may for example comprise metal or plastic foil, such as a
blister pack. The pack or dispenser device may be accompanied by
instructions for administration. The pack or dispenser may also be
accompanied by a notice associated with the container in a form
prescribed by a governmental agency regulating the manufacture, use
or sale of pharmaceuticals, which notice is reflective of approval
by the agency of the form of the compositions or of human or
veterinary administration. Such notice, for example, may be of the
labeling approved by the U.S. Food and Drug Administration for
prescription drugs or of an approved product insert. Compositions
comprising a compound of the invention formulated in a compatible
pharmaceutical carrier may also be prepared, placed in an
appropriate container, and labeled for treatment of an indicated
condition. Suitable conditions indicated on the label may include
treatment of a tumor, inhibition of angiogenesis, treatment of
fibrosis, diabetes, and the like.
EXAMPLES
[0199] Compounds of the present invention can be made according to
general Methods 1-39 described below. It will be understood by
those skilled in the art that the following general methods are not
limiting to the invention. It may be possible to alter exact
solvents, conditions and reagents and quantities without
deleterious effects. Specific embodiments of the present invention
are summarized in Tables 1 and 2 below. Examples 174 and 175 as
well as examples 176 and 177 are single enantiomers. However, the
exact stereochemistry was not determined.
[0200] Powder X-ray Diffraction (PXRD): PXRD data shown in Tables 1
and 2 was collected according to the following protocol. A sample
(2 mg) was placed on a microscopic glass slide. The sample was then
placed in a Discover D8 (Bruker AXS Instruments) equipped with a
GADDS detector. The system used a copper X-ray source maintained at
40 kV and 40 mA to provide CU.alpha.1 emission at 1.5406 angstroms.
Data were collected from 4 to 40.degree. 2.theta. using two-frame
acquisition with 60.1 second/frame. Diffraction peaks are typically
measured with an error of .+-.0.1 degrees (2.theta.).
[0201] Abbreviations:
[0202] DCM: Dichloromethane (also known as Methylene chloride)
[0203] DMF: N,N-dimethylformamide
[0204] HPLC: High-performance liquid chromatography (also known as
high-pressure liquid chromatography)
[0205] AcOH: Acetic acid
[0206] HATU:
2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate
[0207] DME: Dimethyl ether
[0208] EtOAc: Ethyl acetate
[0209] n-BuOH: n-Butanol
[0210] ACN: Acetonitrile
[0211] MeOH: Methanol
[0212] DMSO: Dimethylsulfoxide
[0213] TEA: Triethylamine
[0214] NMP: N-Methyl-2-Pyrrolidone
[0215] THF: Tetrahydrofuran
[0216] DMAC: Dimethyl Acetamide
[0217] CDMT: 2-Chloro-4,6-dimethoxy-1,3,5-triazine
[0218] TFA: Trifluoroacetic acid
[0219] DIPEA: Diisopropylethylamine
Method 1:
##STR00016##
[0221] To a stirred solution of
6-((6-(1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)-
quinoline (0.05 g, 0.15 mmol) in DMF (2 ml) was added NaH (95%,
0.007 g, 0.26 mmol) under nitrogen, the solution was stirred for 30
min, then tert-butyl 3-(methylsulfonyloxy)azetidine-1-carboxylate
(0.047 g, 0.18 mmol) was added, the mixture was stirred for 24
hours, purified by prep-HPLC after lyophilizing gave a solid, this
solid was dissolved in DCM (2 ml), 4N HCl (2 ml) was added at rt,
stirred for 6 hours, remove solvent, the residue was purified by
prep-HPLC to give a solid
6-((6-(1-(azetidin-3-yl)-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazi-
n-1-yl)methyl)quinoline (25 mg) yield 34%.
Method 2:
##STR00017##
[0223]
6-((6-(1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)m-
ethyl)quinoline (0.05 g, 0.15 mmol) and tert-butyl
4-(bromomethyl)piperidine-1-carboxylate (0.052 g, 0.18 mmol) in DMF
(2 ml) were stirred, Cs.sub.2CO.sub.3 (0.101 g, 0.3 mmol) was
added, the mixture was stirred at rt for 24 hours, LCMS checked
that reaction was completed, remove solvent, the residue was
purified by prep-HPLC, after lyophilizing gave a solid, this solid
was dissolved in DCM (2 ml), 4N HCl (1 ml) was added at rt, stirred
for 6 hours, remove solvent, the residue was purified by prep-HPLC
to give a solid
6-((6-(1-(piperidin-4-ylmethyl)-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b-
]pyrazin-1-yl)methyl)quinoline (45 mg), yield 56.2%
Method 3:
##STR00018##
[0225] 6-bromo-N.sup.2-(quinolin-6-ylmethyl)pyrazine-2,3-diamine: A
mixture of quinolin-6-ylmethanamine (13 g, 82 mmol),
3,5-dibromopyrazin-2-amine (21 g, 82 mmol) and
di-isopropylethylamine (16 mL, 89 mmol) was heated to 130.degree.
C. for five hours. The reaction was diluted with
dichloromethane:ethanol (9:1) and the resulting suspension was
filtered. The precipitate was washed sequentially with water and
ether and air dried to afford
6-bromo-N.sup.2-(quinolin-6-ylmethyl)pyrazine-2,3-diamine (13 g,
49%).
Method 4:
##STR00019##
[0227]
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline:
To a 6.degree. C. mixture of
6-bromo-N.sup.2-(quinolin-6-ylmethyl)pyrazine-2,3-diamine (16 g, 48
mmol), AcOH (97 mL) and H.sub.2O (97 mL) was added NaNO.sub.2 (4.0
g, 58 mmol) in H.sub.2O (12 mL) dropwise over 15 min. After 1.5
hours, a 1:1 mixture of concentrated sulfuric acid and water (6 mL)
was added dropwise. After 1.5 hours, NaNO.sub.2 (0.5 g, 7 mmol) in
H.sub.2O (2 mL) and a 1:1 mixture of concentrated sulfuric acid and
water (5 mL) were added. The reaction was allowed to warm to room
temperature overnight. The reaction was re-cooled in an ice bath
and over a period of 1.5 hours, a 1:1 mixture of concentrated
sulfuric acid and water (30 mL) and NaNO.sub.2 (1.5 g, 22 mmol) in
H.sub.2O (5 mL) was added. Aqueous 3.75 M NaOH (210 mL) was added
dropwise and the resulting suspension was filtered. The precipitate
was washed sequentially with water and ether, then suspended in
dichloromethane:ethanol (1:1) and filtered. The filtrate was washed
sequentially with 1M aqueous Na.sub.2CO.sub.3 and brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated by rotary evaporation
to afford
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(9.6 g, 58%).
Method 5:
##STR00020##
[0229]
N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[-
1,2,3]triazolo[4,5-b]pyrazin-5-yl)benzamide: HATU (82 mg, 0.22
mmol) was added to a mixture of
4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)benzoic
acid (75 mg, 0.20 mmol),
N.sup.1,N.sup.1,N.sup.2-trimethylethane-1,2-diamine (22 mg, 0.22
mmol) and triethylamine (0.060 mL, 0.43 mmol) in DMF (2.0 mL).
After stirring for 18 hours, the reaction was partitioned between
dichloromethane:ethanol (9:1) and water. The organic layer was
separated, dried over Na.sub.2SO.sub.4, filtered and concentrated
by rotary evaporation to afford 108 mg of crude material. The
material was purified by pre-HPLC to give
N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]-
triazolo[4,5-b]pyrazin-5-yl)benzamide (54 mg, yield 48%).
Method 6:
##STR00021##
[0231]
6-((6-(2-fluorophenyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl-
)quinoline: A mixture of DME (3.0 mL) and 1 M aqueous
Na.sub.2CO.sub.3 (0.88 mL) was degassed by bubbling in Argon for 10
minutes. The mixture was transferred via syringe to a vial
containing
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(100 mg, 0.29 mmol), 2-fluorophenylboronic acid (45 mg, 0.32 mmol)
and Pd(dppf).sub.2Cl.sub.2.CH.sub.2Cl.sub.2 (6.2 mg, 0.01 mmol).
The vial was capped and heated to 80.degree. C. for 3.5 hours. The
crude reaction mixture was diluted with dichloromethane then washed
with water. The dichloromethane was dried over Na.sub.2SO.sub.4,
filtered and concentrated by rotary evaporation. The residue was
purified by column chromatography using gradient elution with ethyl
acetate and dichloromethane to afford
6-((6-(2-fluorophenyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quino-
line (77 mg, 74%).
Method 7:
##STR00022##
[0233]
6-((6-(1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methy-
l)quinoline: A mixture of DME (3.0 mL) and 1 M aqueous CsF (0.88
mL) was degassed by bubbling in Argon for 10 minutes. The mixture
was transferred via syringe to a vial containing
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(100 mg, 0.29 mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate
(95 mg, 0.32 mmol) and Pd(dppf).sub.2Cl.sub.2.CH.sub.2Cl.sub.2 (6.1
mg, 0.01 mmol). The vial was capped and heated to 80.degree. C. for
16 hours. Water (5 mL) was added to the crude reaction mixture and
the resulting suspension was filtered. The precipitate was washed
with water and air dried. The precipitate was purified by column
chromatography using gradient elution with methanol and
dichloromethane to afford
6-((6-(1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quin-
oline (60 mg, 62%).
Method 8:
##STR00023##
[0235]
N-(piperidin-4-yl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,-
5-b]pyrazin-5-yl)benzamide: Trifluoroacetic acid (0.33 mL, 4.2
mmol) was added to a solution of tert-butyl
4-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)benza-
mido)piperidine-1-carboxylate (72 mg, 0.13 mmol) in DCM (1.0 mL).
After 96 hours, the reaction was concentrated by rotary
evaporation. The residue was purified by prep-HPLC to give
N-(piperidin-4-yl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]py-
razin-5-yl)benzamide (7 mg, yield 25%).
Method 9:
##STR00024##
[0237]
6-((6-(4-methyl-1H-imidazol-1-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin--
1-yl)methyl)quinoline: A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(50 mg, 0.15 mmol), 4-methyl-1H-imidazole (36 mg, 0.44 mmol) and
CsF (25 mg, 0.16 mmol) in acetonitrile (1.45 mL) was heated in a
microwave to 160.degree. C. for 20 minutes. The reaction was
diluted with water (5 mL) and the resulting suspension was
filtered. The precipitate was washed with water and then purified
by column chromatography using gradient elution with methanol and
dichloromethane to afford
6-((6-(4-methyl-1H-imidazol-1-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)m-
ethyl)quinoline (28 mg, yield 56%).
Method 10:
##STR00025##
[0239] Step 1:
[0240] A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline,
(200 mg, 0.5862 mmol), potassium carbonate (243 mg, 1.76 mmol), and
(R)-tert-butyl pyrrolidin-3-ylcarbamate, (218 mg, 1.17 mmol) in
2-propanol (6 mL) was heated in the microwave at 80.degree. C. for
20 min. The mixture was allowed to cool and the solids were
collected by filtration then purified by flash chromatography
eluting with chloroform/ethyl acetate (25-75%) to afford the
desired product, A (239 mg, 91%).
[0241] Step 2:
[0242] To a solution of tert-butyl
(1R)-3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)cyc-
lopentylcarbamate, A (100 mg, 0.224 mmol) in dichloromethane (2.2
mL) was added hydrochloric acid (4 N in dioxane 560 .mu.L, 2.24
mmol). After stirring at room temperature for 6 hours, the reaction
was diluted with dichloromethane and quenched with saturated sodium
bicarbonate (.about.5 mL). The organic layer was separated and
concentrated to afford the desired product, B (65 mg, 84%).
Method 11:
##STR00026##
[0244] A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(50 mg, 0.15 mmol), potassium carbonate (81 mg, 0.59 mmol), and
(R)--N,N-dimethylpyrrolidin-3-amine (50 mg, 0.44 mmol) in
2-propanol (1.5 mL) was heated in the microwave at 60.degree. C.
for 10 min. The mixture was filtered and the filtrate was
concentrated. The residue was purified by flash chromatography
eluting with chloroform/7N ammonia in methanol (0.1-3.5%) followed
by a second column eluting with chloroform/methanol (1-7%) to
afford the desired product (21 mg, 36%).
Method 12:
##STR00027##
[0246] A solution of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(50 mg, 0.15 mmol), (4-aminomethylphenyl) boronic acid
hydrochloride (30 mg, 0.16 mmol), 1M sodium carbonate (601 uL) in
dimethoxymethane (1.5 mL) was degassed by alternating between
vacuum and nitrogen (3.times.), then Pd(PPh.sub.3).sub.2Cl.sub.2
was added and the mixture was heated to 80.degree. C. for 1.5 hr.
The reaction was cooled to room temperature and water was added and
stirred. The solids were filtered then dissolved in dichloromethane
(20 mL) containing .about.5 drops TFA. The solution was
concentrated and the residue was purified by flash chromatography
eluting with chloroform/7N ammonia in methanol (0.5-7%) to afford
the desired product (26 mg, 48%).
Method 13:
##STR00028##
[0248] To a microwave vessel was added
3,5-dibromo-pyrazin-2-ylamine (2.0 g, 7.9 mmol),
C-(2,3-Dihydro-benzofuran-5-yl)-methylamine, HCl salt (2.36 g, 12.7
mmol), triethylamine (2.22 mL, 15.8 mmol), and n-BuOH (6 mL). The
reaction suspension was irradiated at 170.degree. C. for 3 hours.
The nBuOH was removed in vacuo. EtOAc (20 mL) was added to the
crude mixture and washed with water (20 mL). The aqueous layer was
extracted again (3.times.20 mL). The organics were dried over
Na.sub.2SO.sub.4, concentrated and purified by silica gel
chromatography with EtOAc:Hexanes (1:1) to give
6-bromo-N.sup.2-(2,3-dihydro-benzofuran-5-ylmethyl)-pyrazine-2,3-diamine
(2.11 gram, 84% yield).
Method 14:
##STR00029##
[0250] To a solution of
6-bromo-N.sup.2-(2,3-dihydro-benzofuran-5-ylmethyl)-pyrazine-2,3-diamine
(1.0 g, 3.12 mmol) in AcOH:H2O (8 mL: 8 mL) was added the solution
of NaNO.sub.2 (2.12 g, 31.2 mmol) in water (5 mL). The mixture was
stirred at room temperature for 1 hour, and then heated at
65.degree. C. for 16 hours. The solvents were removed, and then
EtOAc (20 mL) and water (20 mL) were added. The aqueous layer was
extracted with EtOAc (3.times.20 mL). The combined extracts were
dried over Na.sub.2SO.sub.4, concentrated and purified by silica
gel chromatography with EtOAc: Hexanes to provide
6-bromo-1-(2,3-dihydro-benzofuran-5-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]py-
razine (543 mg, 52% yield).
Method 15:
##STR00030##
[0252] To a solution of (R)-pyrrolidin-3-yl-carbamic acid
tert-butyl ester (37 mg, 0.165 mmoL) in anhydrous DMF (2 mL) was
added NaH (60% in oil, 7 mg, 0.18 mmol). The solution was stirred
at 23.degree. C. for 15 minutes.
6-Bromo-1-(2,3-dihydro-benzofuran-5-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]py-
razine (50 mg, 0.15 mmol) was added and the reaction solution was
microwaved at 100.degree. C. for 30 min. Water (10 mL) was added
and the aqueous layer was extracted with EtOAc (3.times.10 mL). The
combined extracts were dried with Na.sub.2SO.sub.4, and
concentrated to provide
{(R)-1-[3-(2,3-Dihydro-benzofuran-5-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]py-
razin-5-yl]-pyrrolidin-3-yl}-carbamic acid tert-butyl ester (67 mg,
99% yield).
Method 16:
##STR00031##
[0254] To a solution of
{(R)-1-[3-(2,3-Dihydro-benzofuran-5-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]py-
razin-5-yl]-pyrrolidin-3-yl}-carbamic acid tert-butyl ester (67 mg,
0.15 mmol) in CH.sub.2Cl.sub.2 (10 mL) was added 4M HCl/Dioxane
dropwise (2 mL). The reaction was stirred at room temperature for 2
hours. The organic layer was decanted and the crude solid was
purified with a reverse-phased preparative HPLC eluting with
acetonitrile-water having 0.1% acetic acid to provide 61 mg of
(R)-1-[3-(2,3-Dihydro-benzofuran-5-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyr-
azin-5-yl]-pyrrolidin-3-ylamine as the acetate salt (99%
yield).
Method 17:
##STR00032##
[0256] To a solution of
6-bromo-1-(2,3-dihydro-benzofuran-5-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]py-
razine (50 mg, 0.15 mmol),
1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole
(34 mg, 0.165 mmol), and sodium carbonate (48 mg, 0.45 mmol) in
DME/water (4 mL/1 mL) degassed with N.sub.2 was added
Pd(PPh.sub.3).sub.2Cl.sub.2 (5 mg, 0.008 mmol). The reaction
solution was degassed with N.sub.2 again and stirred for 16 hours
at 80.degree. C. The reaction mixture was filtered through celite,
concentrated, and purified with a reverse-phased preparative HPLC
eluting with acetonitrile-water having 0.1% acetic acid to give
1-(2,3-dihydro-benzofuran-5-ylmethyl)-6-(1-methyl-1H-pyrazol-4-yl-
)-1H-[1,2,3]triazolo[4,5-b]pyrazine (12 mg, 24% yield).
Method 18:
##STR00033##
[0258] To a suspension of
6-[6-(1H-pyrazol-4-yl)-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl]-quinolin-
e (50 mg, 0.15 mmol) and Cs.sub.2CO.sub.3 (50 mg, 0.15 mmol) in DMF
(2 mL) was added 2,2-dimethyl-oxirane. The reaction was stirred at
80.degree. C. for 16 hours. The reaction was then purified with a
reverse-phased preparative HPLC eluting with acetonitrile-water
having 0.1% acetic acid to yield
2-methyl-1-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]py-
razin-5-yl)-pyrazol-1-yl]-propan-2-ol (13 mg, 22% yield).
Method 19:
##STR00034##
[0260] A solution of
6-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl)-quinoline (200
mg, 0.586 mmol) in MeOH (10 mL):AcOH (1 mL):EtOAc (1 mL) was
degassed 3 times with nitrogen. To this solution was added Pd/C (20
mg). A balloon containing hydrogen was added via syringe and the
reaction was allowed to stir for 18 hours at room temperature. The
reaction did not complete and more Pd/C was added (20 mg) and
stirred for 18 hours at room temperature. The reaction was stopped
when LCMS showed a ratio of 1:1 (product:starting material). The
reaction was filtered over celite and washed with EtOAc (50 mL).
The filtered solution was concentrated and purified by
[0261] Biotage silica gel column chromatography with EtOAc: Hexanes
to give 30 mg of the product
6-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl-quinoline (20%
yield).
Method 20:
##STR00035##
[0263] To a solution of
6-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl)-quinoline (2
g, 5.86 mmol) in ACN (47 mL) (degassed 3 times with nitrogen) was
added Pd(PPh.sub.3).sub.2Cl.sub.2 (205 mg, 0.293 mmol), CuI (167
mg, 0.879 mmol), and butyl-(1-ethoxy-vinyl)-stannane (5.9 mL, 17.59
mmol). The reaction was refluxed for 4 hours until the LC-MS showed
complete product. The reaction was filtered over a celite pad and
washed with ether (100 mL). The solution was washed with water
(1.times.50 mL), dried over Na.sub.2SO.sub.4, and concentrated. The
crude product was purified by silica gel column chromatography with
EtOAc: Hexanes to give 1.05 g of the product
6-[6-(1-ethoxy-vinyl)[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl]-quinoline
(55% yield).
Method 21:
##STR00036##
[0265] To a solution of the
6-[6-(1-ethoxy-vinyl)-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl]-quinoline
(1.0 g, 3.00 mmol) in ACN (50 mL), was added 2 N HCl dropwise. The
reaction was refluxed for 1 hour, and then neutralized with
NaHCO.sub.3. The solution was extracted with EtOAc (3.times.100 mL)
to give the product
1-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-e-
thanone (950 mg, 99% yield).
Method 22:
##STR00037##
[0267] To a solution of
1-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-ethanone
(100 mg, 0.33 mmol) in THF was added MeMgBr (0.260 mL, 0.362 mmol,
1.4M in toluene/THF) at 0.degree. C. The reaction was allowed to
stir for 16 hours at room temperature. The LC-MS showed a 1:1 ratio
(ketone:alcohol), so another equivalent of the MeMgBr was added and
the reaction was stirred for an additional 16 hours. The crude
reaction was concentrated and purified by a reverse-phase C-18
preparative eluting of ACN--H.sub.2O with 0.1% acetic acid HPLC to
give
2-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-propan-2--
ol (4 mgs, 4% yield).
Method 23:
##STR00038##
[0269] To a solution of
1-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-ethanone
(150 mg, 0.493 mmol) in MeOH (5 mL) was added ammonium acetate (76
mg, 0.987 mmol). The reaction was stirred for 2 hours at room
temperature. Sodium cyano borohydride (62 mg, 0.987) was added and
the reaction was heated to 70.degree. C. for 16 hours. LC-MS showed
.about.1:1 ratio of alcohol and amine. The reaction was
concentrated and purified by a reverse-phase C-18 preparative HPLC
eluting with ACN--H.sub.2O having 0.1% acetic acid to give
1-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-ethanol
(70 mg) and
1-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-ethylamin-
e (20 mg).
Method 24:
##STR00039##
[0271] A suspension of
2-Methyl-2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-y-
l)-pyrazol-1-yl]-propionic acid methyl ester (50 mg, 0.116 mmol) in
ammonium hydroxide (2 mL) was irradiated at 100.degree. C. in a
microwave for 30 min to give the primary amide and carboxylic acid
(1:1 ratio). The reaction was concentrated and purified by Dioxnex
HPLC to give
2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-isobutyramide (20 mg) and
2-methyl-2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-y-
l)-pyrazol-1-yl]-propionic acid (25 mg).
Method 25:
##STR00040##
[0273] The racemic
1-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-6-(1-methyl-1H-pyrazol-4--
yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine was purified by a chiral
column (Chiralpak IA 4.6.times.250 mm 5u column) eluting with 50%
MeOH and a flow rate of 2.5 uL/min to give
1-[(S)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-6-(1-methyl-1H-pyrazo-
l-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine with an optical rotation
of 0.146.degree. in dichloromethane (5.6 mg/mL) and
1-[(R)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-6-(1-methyl-1H-pyrazo-
l-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine with an optical rotation
of 0.26.degree. in dichloromethane (9.32 mg/mL).
Method 26:
##STR00041##
[0275] In a glove box, the following was added to a 2.0 mL Personal
Chemistry Microwave reaction tube: one triangular stir bar, the
appropriate heterohalide solution in NMP (320 .mu.L, 80 .mu.mol,
1.0 eq., 0.25 M), the appropriate amine in NMP (640 .mu.L, 160
.mu.mol, 2.0 eq., 0.25 M), and a solution of TEA in NMP (240 .mu.L,
120 .mu.mol, 1.5 eq., 0.5 M). The microwave tube was sealed with a
septum cap, and outside the glove box, the reaction mixtures were
heated in a Personal Chemistry Microwave Synthesizer for 15 minutes
at 80.degree. C. for secondary amines and 45 minutes at 80.degree.
C. for primary amines. The reaction mixtures were transferred into
a 10.times.75 mm test tube. The microwave tubes were washed with
DMF (0.5 mL) and the wash DMF was combined with the originally
transferred material. The solvents were removed, and the residues
were reconstituted in DMSO.
Method 27:
Synthesis of
N-2-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]glycin-
amide
##STR00042##
[0277] A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline,
(100, 0.293), triethylamine (123 .mu.L, 0.879 mmol), aminoacetamide
hydrochloride (49 mg, 0.44 mmol) in 2-propanol (3.0 mL) was heated
in the microwave at 100.degree. C. for 10 minutes, then 120.degree.
C. for 10 minutes. The reaction mixture was diluted with
dichloromethane and filtered. The precipitate was purified by flash
chromatography using a Horizon purification system on a 12M column
eluting with chloroform/7 N ammonia in methanol (0.1-10%) to afford
the title compound (20 mg, 20%).
Synthesis of
(3R)--N-methyl-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazi-
n-6-yl]pyrrolidin-3-amine
##STR00043##
[0279] Step 1:
##STR00044##
[0280] A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(200 mg, 0.586 mmol), potassium carbonate (243 mg, 1.76 mmol), and
(R)-tert-butyl pyrrolidin-3-ylcarbamate (218 mg, 1.17 mmol) in
2-propanol (6.0 mL) was heated in the microwave at 80.degree. C.
for 20 minutes. The mixture was allowed to cool and the solids were
collected by filtration then purified by flash chromatography using
a Horizon purification system eluting with chloroform/ethyl acetate
(25-75%) to afford (R)-tert-butyl
1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)pyrrolid-
in-3-ylcarbamate, (239 mg, 91%).
[0281] .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.38 (s, 9H)
1.88-1.99 (m, 1H) 2.10-2.22 (m, 1H) 3.44 (dd, J=11.49, 4.42 Hz, 1H)
3.61-3.73 (m, 3H) 4.12-4.23 (m, 1H) 5.91 (s, 2H) 7.27 (d, J=5.56
Hz, 1H) 7.53 (dd, J=8.34, 4.29 Hz, 1H) 7.76 (dd, J=8.72, 1.89 Hz,
1H) 7.93 (d, J=1.26 Hz, 1H) 8.00 (d, J=8.84 Hz, 1H) 8.21 (s, 1H)
8.33-8.38 (m, 1H) 8.89 (dd, J=4.29, 1.77 Hz, 1H).
[0282] Step 2:
##STR00045##
[0283] To a cooled (0.degree. C.) solution of (R)-tert-butyl
1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)pyrrolid-
in-3-ylcarbamate (111 mg, 0.249 mmol) in tetrahydrofuran (2.0 mL)
was added sodium hydride (60% dispersion in mineral oil, 15 mg,
0.37 mmol). After 30 minutes at 0.degree. C., a solution of methyl
iodide (23 uL, 0.37 mmol) in tetrahydrofuran (0.5 mL) was added
dropwise over 15 minutes. The reaction mixture was allowed to warm
to room temperature as the ice bath melted, stirred overnight, then
quenched by adding water (1.0 mL). The tetrahydrofuran was removed
in vacuo and the remaining aqueous solution was diluted with ethyl
acetate (100 mL). The organic solution was washed with water (20
mL), brine (20 mL), dried (MgSO.sub.4), filtered and concentrated.
The crude product was purified by flash chromatography using a
Horizon purification system on a 25S column eluting with
chloroform/acetone (2-20%) to afford tert-butyl
methyl{(3R)-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-
-yl]pyrrolidin-3-yl}carbamate (104 mg, 91%).
[0284] .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.50 (s, 9H)
2.14-2.23 (m, 1H) 2.23-2.32 (m, 1H) 2.85 (s, 3H) 3.49 (m, 1H)
3.54-3.64 (m, 1H) 3.80-3.90 (m, 2H) 4.95 (brm, 1H) 5.89 (s, 2H)
7.44 (dd, J=8.08, 4.29 Hz, 1H) 7.82 (d, J=1.77 Hz, 1H) 7.85 (s, 1H)
8.06 (s, 1H) 8.13 (d, J=8.84 Hz, 1H) 8.17 (d, J=8.59 Hz, 1H) 8.92
(dd, J=4.17, 1.39 Hz, 1H).
[0285] Step 3:
##STR00046##
[0286] To a cooled (0.degree. C.) solution of tert-butyl
methyl{(3R)-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-
-yl]pyrrolidin-3-yl}carbamate (101 mg, 0.219 mmol) in
dichloromethane (2.2 mL) was added hydrochloric acid (4 N in
dioxane, 1.10 mL, 4.39 mmol). The reaction mixture was allowed to
warm to room temperature as the ice bath melted, stirred for 3 hrs,
then diluted with dichloromethane (20 mL). The organic solution was
washed with saturated sodium bicarbonate (5 mL) and separated. The
aqueous solution was extracted with dichloromethane (3.times.20 mL)
and the organics were combined and concentrated. The crude product
was purified by flash chromatography using a Horizon purification
system on a 12M column eluting with chloroform/7 N ammonia in
methanol (0.1-3.5%) to afford the title compound as the free base
which was converted to the dihydrochloric acid salt (56 mg,
63%).
Method 28:
Synthesis of
N,N-dimethyl-2-{[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-
-6-yl]oxy}ethanamine
##STR00047##
[0288] A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline,
(100, 0.293), triethylamine (123 .mu.L, 0.879 mmol),
N,N-dimethylethanolamine (959 .mu.L, 0.586 mmol) in n-butanol (3.0
mL) was heated in the microwave at 120.degree. C. for 20 minutes,
then concentrated. The crude product was purified by flash
chromatography using a Horizon purification system on a 25S column
eluting with chloroform/7 N ammonia in methanol (0.1-5%) to afford
the title compound (75 mg, 74%).
Method 29:
Synthesis of
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
ine-3-carboxamide
##STR00048##
[0290] Step 1:
##STR00049##
[0291] A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline,
(350 mg, 1.03 mmol), potassium carbonate (436 mg, 3.16 mmol), and
3-pyrrolidine carboxylic acid (236 mg, 2.05 mmol) in n-butanol
(10.0 mL) was heated in the microwave at 120.degree. C. for 60
minutes. The reaction mixture was cooled to room temperature,
filtered, rinsed with ethyl acetate, and the filtrate was
concentrated. The crude product was purified by flash
chromatography using a Horizon purification system on a 25S column
eluting with chloroform containing 0.1% acetic acid/methanol
(0.5-7%) to afford
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
ine-3-carboxylic acid (152 mg, 39%).
[0292] .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 2.72-2.81
(m, 1H) 2.81-2.91 (m, 1H) 3.77-3.87 (m, 1H) 4.12-4.31 (m, 2H)
4.32-4.44 (m, 2H) 6.51 (s, 2H) 8.12 (dd, J=8.34, 4.29 Hz, 1H) 8.35
(dd, J=8.84, 2.02 Hz, 1H) 8.53 (d, J=1.52 Hz, 1H) 8.59 (d, J=8.59
Hz, 1H) 8.83 (s, 1H) 8.95 (dd, J=8.34, 1.01 Hz, 1H) 9.48 (dd,
J=4.17, 1.64 Hz, 1H) 12.97 (s, 1H).
[0293] Step 2:
##STR00050##
[0294] To a solution of
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
ine-3-carboxylic acid (143 mg, 0.328 mmol) and
1-hydroxybenzotriazole hydrate (93 mg, 0.69 mmol) in DMF (4.0 mL)
was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (132 mg, 0.690 mmol) followed by N-methyl morpholine
(159 .mu.L, 1.31 mmol). The resulting solution was stirred for 4
hours at room temperature then ammonia (7 N in methanol, 234 .mu.L,
1.64 mmol) was added and the reaction was stirred overnight. To the
reaction was added more 1-hydroxybenzotriazole hydrate,
N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, and
N-methyl morpholine and the solution was stirred for 1 hour at room
temperature then ammonia (0.5 N in dioxane) was added. After 6
hours, the solution was diluted with methyl tert-butyl ether (100
mL) and the organic solution was washed with saturated sodium
bicarbonate (2.times.20 mL) and brine (20 mL). The combined aqueous
layers were combined and lyophilized. The resulting solids were
slurried in 1:1 methanol:chloroform, filtered and the filtrate was
concentrated. The crude product was purified by flash
chromatography using a Horizon purification system on a 40S column
eluting with chloroform/7 N methanolic ammonia (0.1-6%) to afford
the title compound as the racemic mixture (86 mg, 70%). The mixture
was separated by SCF chromatography to afford pure the enantiomers
in 100% ee (peak 1, 37%; peak 2, 42%).
Method 30:
Synthesis of
4,4-dimethyl-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin--
6-yl]imidazolidin-2-one
##STR00051##
[0296] To cooled (0.degree. C.) solution of
2-methyl-N-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6--
yl]propane-1,2-diamine (80 mg, 0.19 mmol) in THF (2.0 mL) and
dimethylacetamide (1.0 mL) was added phosgene (20% in toluene, 110
.mu.L, 0.21 mmol). After 1 hour the reaction mixture was
concentrated and the crude product was purified by flash
chromatography using a Horizon purification system on a 25S column
eluting with chloroform/ethyl acetate (35-95%) to afford the title
compound (37 mg, 52%).
Method 31:
Synthesis of
6-{[6-(3,3-difluoro-1,3'-bipyrrolidin-1'-yl)-1H-[1,2,3]triazolo[4,5-b]pyr-
azin-1-yl]methyl}quinoline
##STR00052##
[0298] Step 1:
##STR00053##
[0299] A mixture of
6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline
(5.00 g, 14.7 mmol), pyrrolidin-3-ol (2.55 g, 29.3 mmol), and
triethylamine (4.09 mL, 29.3 mmol) in 2-propanol (32 mL) was heated
in the microwave for 30 minutes at 70.degree. C. in two vials. The
reaction mixtures were combined and concentrated. The crude product
was purified by flash chromatography using a Horizon purification
system in three batches (2.times.40M and 1.times.40S columns)
eluting with chloroform/methanol (0.1-8%). The resulting solid was
dissolved in chloroform containing 0.1% methanol (810 mL) and
washed with water and 1:1 water:brine, dried (MgSO.sub.4), filtered
and concentrated to afford
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
in-3-ol (5.08 g, 99%).
[0300] .sup.1H NMR (400 MHz, DMSO-d6) .delta. ppm 1.93-1.99 (m, 1H)
2.02-2.07 (m, 1H) 3.49-3.57 (m, 1H) 3.61-3.73 (m, 3H) 4.39-4.50 (m,
1H) 5.04-5.15 (m, 1H) 5.90 (s, 2H) 7.53 (dd, J=8.34, 4.29 Hz, 1H)
7.76 (dd, J=8.72, 1.89 Hz, 1H) 7.93 (s, 1H) 8.00 (d, J=8.59 Hz, 1H)
8.22 (s, 1H) 8.36 (d, J=8.34 Hz, 1H) 8.89 (dd, J=4.17, 1.64 Hz,
1H).
[0301] Step 2:
##STR00054##
[0302] To a cooled (-78.degree. C.) solution of oxalyl chloride
(1.5 mL, 17 mmol) in dichloromethane (15 mL) was added dimethyl
sulfoxide (2.45 mL, 34.5 mmol) drop wise keeping T<-70.degree.
C. After 30 minutes, a suspension of
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
in-3-ol (1.00 g, 2.88 mmol) in dichloromethane (35 mL) was added
keeping T<-70.degree. C. After 1 hour 15 minutes, triethylamine
(3.61 mL, 25.9 mmol) was added slowly, the dry-ice bath was
removed, and the reaction was stirred for 2 hours. The reaction was
quenched with water (50 mL), diluted with dichloromethane (150 ml),
and separated. The aqueous layer was extracted with dichloromethane
(2.times.50 mL) and the organics were combined and concentrated.
The crude product was purified by flash chromatography using a
Horizon purification system on a 40M column eluting with
chloroform/methanol (0.5-8%) to afford
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
in-3-one (401 mg, 40%).
[0303] .sup.1H NMR (400 MHz, DMSO-d6) .delta.ppm 2.75 (t, J=7.71
Hz, 2H) 4.00 (t, J=7.58 Hz, 2H) 4.07 (s, 2H) 5.95 (s, 2H) 7.53 (dd,
J=8.21, 4.17 Hz, 1H) 7.78 (dd, J=8.72, 1.89 Hz, 1H) 7.97 (s, 1H)
8.01 (d, J=8.59 Hz, 1H) 8.32 (s, 1H) 8.37 (d, J=8.34 Hz, 1H) 8.89
(dd, J=4.17, 1.64 Hz, 1H).
[0304] Step 3:
##STR00055##
[0305] A suspension of
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
in-3-one (50 mg, 0.15 mmol) and 3,3-difluoropyrrolidine (42 mg,
0.29 mmol) in tetrahydrofuran/methanol/dimethylacetamide (1.0 mL
each) was heated to 80.degree. C. for 2 hours then NaBCNH.sub.3 (18
mg, 0.29 mmol) was added. After 2 hours the solution was cooled to
room temperature and concentrated. The crude product was purified
by flash chromatography using a Horizon purification system on a
25S column eluting with chloroform/acetone (5-50%) followed by a
second column on a 12M cartridge eluting with chloroform/ethyl
acetate (25-100%) to afford the title compound (25 mg, 40%).
Method 32:
Synthesis of
7-fluoro-6-{[6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazi-
n-1-yl]methyl}-quinoline
##STR00056##
[0307] A mixture of
6-[(6-chloro[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]-7-fluoroquinolin-
e (200 mg, 0.557 mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan)-1H-pyrazole
(139 mg, 0.668 mmol), and sodium carbonate (177 mg, 1.67 mmol) in
dimethoxyethane (4.8 mL) and water (1.2 mL) was degassed by
alternating between vacuum and nitrogen (5.times.).
Bis(triphenylphosphine)-palladium(II)chloride (20 mg, 0.028 mmol)
was added and the mixture was degassed again (3.times.). The
resulting mixture was refluxed for 3 hours, cooled to room
temperature and filtered. The precipitate was slurried in 1:1
methanol/chloroform, filtered and the filtrate was concentrated.
The residue was dissolved in methanol/chloroform with
trifluoroacetic acid and purified by flash chromatography using a
Horizon purification system on a 25M column eluting with
chloroform/7 N ammonia in methanol (0.1-10%) The resulting solid
was dissolved in methanol/chloroform and filtered through celite to
afford the title compound (161 mg, 80%).
Synthesis of
6-[(6-chloro[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]-7-fluoroquinolin-
e
##STR00057##
[0309] Step 1:
##STR00058##
[0310] A mixture of compound A (90 g, 0.60 mol), glycerol (1800 g,
1.9 mol), ferrous sulfate (27 g, 0.0954 mol), nitrobenzene (99 mL,
0.95 mol) and concentrated sulfuric acid (261 mL, 4.77 mol) was
heated at 130.degree. C. for 14 h. The reaction mixture was allowed
to cool to room temperature and basified to pH about 8 by 28%
NH.sub.3 solution. The resulting mixture was extracted with
CH.sub.2Cl.sub.2 (1000 mL.times.3). The combined organic phases was
evaporated and the residue was dried in vacuo to afford crude
compound B, which was purified by column chromatography (silica
gel, EtOAc/Petroleum ether=1:10) to yield compound B (56 g, 51.9%)
as a yellow solid.
[0311] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.929 (dd, 1H),
8.072 (m, 2H), 7.813 (d, 1H), 7.397 (dd, 1H).
[0312] Step 2:
##STR00059##
[0313] A suspension of compound B (25 g, 0.11 mol) and CuCN (12 g,
0.14 mol) in DMF (400 mL) was degassed by passing through N.sub.2,
then Pd(PPh.sub.3).sub.4 (6.5 g, 0.0056 mol) was added. The
reaction mixture was heated to 120.degree. C. for 12 h. The mixture
was allowed to cool to room temperature and DMF was evaporated in
vacuum. The residue was poured into water (100 mL) and extracted
with CH.sub.2Cl.sub.2 (1000 mL.times.2). The combined organic
phases were evaporated and the residue was dried in vacuo to afford
crude compound C, which was purified by column chromatography
(silica gel, EtOAc/Petroleum ether=1:15) to yield compound C (9 g,
47.6%) as a yellow solid.
[0314] .sup.1H NMR (400 MHz, MeOH): .delta. 9.014 (dd, 1H), 8.664
(d, 1H), 8.495 (d, 1H), 7.981 (d, 1H), 7.626 (dd, 1H).
[0315] Step 3:
##STR00060##
[0316] A mixture of compound C (18 g, 0.105 mol) and Raney Ni (40
g) in saturated NH.sub.3-EtOH (2 L) was stirred under 1 atm of
H.sub.2 at room temperature for 16 h. The reaction mixture was
filtered and the filtrate was concentrated in vacuum to afford
crude compound D (17 g, 92.4%) as a yellow solid, which was used
for the next step without purification.
[0317] .sup.1H NMR (400 MHz, MeOH): .delta. 8.726 (s, 1H), 8.373
(d, 1H), 7.867 (d, 1H), 7.506 (d, 1H), 7.386 (dd, 1H), 3.966 (s,
2H).
[0318] Step 4:
##STR00061##
[0319] A mixture of compound D (17 g, 0.0966 mol), compound G (129
g, 0.116 mol) and DIPEA (18.6 mL, 0.106 mol) in DMF (320 mL) was
heated at 130.degree. C. for 14 h. Then the reaction mixture was
allowed to cool to room temperature and the DMF was evaporated in
vacuum. The residue was poured into ice-water and extracted with
EtOAc (200 mL.times.3). The combined organic phases were washed
with brine (200 mL), dried over anhydrous Na.sub.2SO.sub.4 and
concentrated in vacuo to give crude compound E, which was purified
by column chromatography (silica gel, EtOAc/Petroleum ether=1:5) to
yield compound E (10 g, 29.8%) as a yellow solid.
[0320] .sup.1H NMR (400 MHz, MeOH): .delta. 9.091 (dd, 1H), 8.920
(d, 1H), 8.339 (d, 1H), 7.908 (dd, 1H), 7.221 (s, 1H), 4.916 (d,
2H).
[0321] Step 5:
##STR00062##
[0322] To a suspension of compound E (10 g, 0.0288 mol) in AcOH
(200 mL) and water (200 mL) was added dropwise a solution of
NaNO.sub.2 (3 g, 0.0433 mol) in water (5 mL) at 0.degree. C. After
the addition, the resulting mixture was stirred at 0.degree. C. for
4 h. Then the mixture was concentrated in vacuo and HBr (12 mL) was
added to the mixture. The resulting mixture was stirred at room
temperature for 16 h. The reaction mixture was quenched by addition
of water (300 mL) and extracted with CH.sub.2Cl.sub.2 (200
mL.times.3). The combined organic layers were washed with saturated
aq. Na.sub.2CO.sub.3 (200 mL) and brine (200 mL), dried over
anhydrous Na.sub.2SO.sub.4 and concentrated in vacuo to afford
crude compound F. The crude compound F was pre-purified via column
chromatography (silica gel, EtOAc/Petroleum ether=1:5), and the
product was washed with MeOH (20 mL) and dried to yield F (3.1 g,
30.0%) as a yellow solid.
[0323] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.901 (dd, 1H),
8.761 (s, 1H), 8.101 (d, 1H), 7.776 (s, 1H), 7.752 (d, 1H), 7.393
(dd, 1H), 6.107 (s, 2H).
[0324] Step 6:
##STR00063##
[0325] A mixture of
6-[(6-chloro[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]-7-fluoroquinolin-
e (6) (200 mg, 0.557 mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan)-1H-pyrazole
(139 mg, 0.668 mmol), and sodium carbonate (177 mg, 1.67 mmol) in
dimethoxyethane (4.8 mL) and water (1.2 mL) was degassed by
alternating between vacuum and nitrogen (5.times.).
Bis(triphenylphosphine)palladium(II)chloride (20 mg, 0.028 mmol)
was added and the mixture was degassed again (3.times.). The
resulting mixture was refluxed for 3 hours, cooled to room
temperature and filtered. The precipitate was slurried in 1:1
methanol/chloroform, filtered and the filtrate was concentrated.
The residue was dissolved in methanol/chloroform with
trifluoroacetic acid and purified by flash chromatography using a
Horizon purification system on a 25M column eluting with
chloroform/7 N ammonia in methanol (0.1-10%) The resulting solid
was dissolved in methanol/chloroform and filtered through celite to
afford the title compound (7) (161 mg, 80%).
Method 33:
Synthesis of
1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine-6-carbonitrile
##STR00064##
[0327] To a suspension of
6-[(6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl]quinoline
(1.0 g, 2.93 mmol) in DMAC (70 ml) were added zinc cyanide (413 mg,
3.52 mmol). The reaction mixture was degassed then
PdCl.sub.2(dppf).CH.sub.2Cl.sub.2 (240 mg, 0.29 mmol) was added
followed with triethylamine (0.828 ml) at R.T. The reaction mixture
was degassed again. After heating at 85.degree. C., the reaction
mixture was filtered through a celite pad and washed with 5.0 ml of
CH.sub.2Cl.sub.2. The solvents were concentrated under reduced
pressure. The resulting residue was purified via flash column
chromatography eluted with 1-3% 7N NH.sub.3 in
MeOH:CH.sub.2Cl.sub.2 to give the desired product (740 mg, 88%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 6.28 (s, 2H) 7.55
(dd, J=8.34, 4.29 Hz, 1H) 7.81 (dd, J=8.72, 2.15 Hz, 1H) 7.99-8.04
(m, 2H) 8.33-8.37 (m, 1H) 8.91 (dd, J=4.04, 1.77 Hz, 1H) 9.41 (s,
1H) APCI (Mz+1) 288.2.
Method 34:
Synthesis of methyl
1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine-6-carboxylate
##STR00065##
[0329] To a suspension of
1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine-6-carbonitrile
(280 mg, 0.975 mmol) in MeOH (17 ml), H.sub.2O (1.0 ml), DMSO (0.1
ml) was saturated with HCl(g) at R.T. After refluxing for 2.5 h,
reaction mixture was stopped and solvents were removed under
reduced pressure to give an off white solid which then was diluted
in CH.sub.2Cl.sub.2 (100 ml) and washed with sat' NaHCO.sub.3 (7
ml.times.3). The aqueous was extracted with CH.sub.2Cl.sub.2
(4.times.30 ml). The organic layers were combined and dried with
K.sub.2CO.sub.3, filtered and concentrated. The resulting residue
was purified via flash column chromatography eluted with 0-3% 7N
NH.sub.3 in MeOH: CH.sub.2Cl.sub.2 to give desired product (200 mg,
64%).
Method 35:
Synthesis of
1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine-6-carboxylic
acid
##STR00066##
[0331] To a suspension of the methyl
1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine-6-carboxylate
(200 mg, 0.624 mmol) in THF (40 ml) cooled to 5.degree. C. with ice
bath was added potassium trimethylsilanoate (80.1 mg, 0.62 mmol).
After stirring for 20 mins at 5.degree. C., the reaction mixture
was concentrated. The resulting residue was dissolved in 7 ml of
DMAC and purified via reversed phase column eluted with 5-75% 0.1%
TFA H.sub.2O and 0.1% TFA ACN to afford the desired product (100
mg, 66%).
Method 36:
Synthesis of
N-methyl-1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine-6-carb-
oxamide
##STR00067##
[0333] To a solution of
1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine-6-carboxylic
acid (47 mg, 0.154 mmol) in DMAC (2 ml) and N-methyl morpholine
(0.202 ml, 1.84 mmol) was added CDMT (40.4 mg, 0.23 mmol) at R.T.
After stirring at R.T. for 45 mins, to the reaction mixture
methylamine 2M solution in THF (0.153 ml, 0.31 mmol) was added.
After stirring at R.T. for 16, to the reaction mixture HATU (58 mg,
0.15 mmol) was added. After stirring at R.T. for 30 mins to the
reaction mixture another 0.2 ml of methylamine 2M solution in THF
was added. After stirring for 1.2 h at R.T. the reaction mixture
was stopped reaction and purified as was via reversed phase eluted
with 5-75% 0.1% TFA in ACN: 0.1% TFA in H.sub.2O to give the
desired product (10 mg, 20%).
Method 37:
Synthesis of
3-[(methylamino)methyl]-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-
-b]pyrazin-6-yl]pyrrolidin-3-ol
##STR00068##
[0335] To a solution of
6-{[6-(1-oxa-5-azaspiro[2.4]hept-5-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-
-yl]methyl}quinoline (130 mg, 0.36 mmol) in 2:1 MeOH:DMSO (3 ml)
were added methylamine (24.7 mg, 0.80 mmol) and potassium iodide
(300.4 mg, 1.81 mmol) at R.T. After heating at 80.degree. C. for
3.5 h, the reaction mixture was cooled to R.T. and concentrated
under reduced pressure. The resulting residue was purified via
flash column chromatography eluted with 0-5% 7N NH.sub.3 in MeOH:
CH.sub.2Cl.sub.2 to give the desired product (35 mg, 25%).
Preparation of
6-{[6-(1-oxa-5-azaspiro[2.4]hept-5-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-
-yl]methyl}quinoline
##STR00069##
[0337] To a flamed dry 3N round bottom flask fitted with a
thermometer and condenser was added 95% NaH (69 mg, 2.69 mmol) and
anhydrous DMSO (5.0 ml). After stirring for 2 min at R.T. and
70.degree. C. for 45 mins, the reaction mixture was cooled to
3.degree. C. and a solution of trimethylsulfonium iodide (504.1 mg,
2.47 mmol) in DMSO (3.6 ml) was added. After stirring for 30 mins
at 3.degree. C., to the reaction mixture, a suspension of
1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]pyrrolid-
in-3-one (200 mg, 0.58 mmol) in 1:1 THF:DMSO (16 ml) was added
dropwise. After stirring at 0.degree. C. for 3 h, the reaction
mixture was poured into an ice cold water (15 ml) and extracted
with CH.sub.2Cl.sub.2 (4.times.60 ml). The organic layer was washed
with brine and dried with MgSO.sub.4 and concentrated under reduced
pressure. The resulting residue was purified via flash column
chromatography eluted with 10% MeOH:CH.sub.2Cl.sub.2 to give the
desired product (130 mg 63%).
Method 38:
Synthesis of
2-({(3R)-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl-
]pyrrolidin-3-yl}amino)ethanol
##STR00070##
[0339] To a solution of tert-butyl
{(3R)-1-[1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]py-
rrolidin-3-yl}carbamate (300 mg, 0.672 mmol) in anhydrous DMF (2.0
ml) was added 95% NaH (25.4 mg, 1.01 mmol). After stirring at R.T.
for 10 mins, to the reaction mixture was added iodoethanol (288.9
mg, 1.68 mmol). After stirring at 70.degree. C. for 16 h, to the
reaction mixture was added iodoethanol (288.9 mg, 1.68 mmol). After
stirring at 90.degree. C. for 7 h, 105.degree. C. for 32 h, the
reaction mixture was quenched with water and filtered. The eluent
was extracted with 2:1 EtOAc:toluene (2.times.30 ml). The organic
layer was dried with K.sub.2CO.sub.3, filtered and concentrated.
The resulting residue was dissolved in CH.sub.2Cl.sub.2 (10 ml) and
TFA (0.5 ml) and MeOH (1 pipet drop) were added. After stirring at
R.T for 16 h, the reaction mixture was concentrated. The resulting
residue was purified via reversed phase column eluted with 0.1% TFA
CAN: water to give the desired product (1.6 mg).
Method 39:
Synthesis of
2-(4-{1-[(7-fluoroquinolin-6-yl)methyl]-1H-[1,2,3]triazolo[4,5-b]pyrazin--
6-yl}-1H-pyrazol-1-yl)ethanol
##STR00071##
[0341]
7-fluoro-6-{[6-(1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-
-yl]methyl}quinoline (95 mg, 0.274 mmol), 2-iodoethanol (378 mg,
2.198 mmol), K.sub.2CO.sub.3 (75.8 mg, 0.548 mmol), DMAC 95 ml)
were combined and heated in microwave at 120.degree. C. for 4 h.
The reaction mixture was concentrated and the resulting residue was
purified via flash column chromatography eluted with 0-5%
MeOH:CH.sub.2Cl.sub.2 to give the desired product as a solid (33.9
mg, 31%).
Preparation of
7-fluoro-6-{[6-(1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl]me-
thyl}-quinoline
##STR00072##
[0343] To a suspension of
6-[(6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl]-7-fluoroquinoli-
ne (250 mg, 0.696 mmol) and
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyrazole-1-carboxylic
acid tert-butyl ester (225 mg, 0.766 mmol) in dimethoxyethane (8.0
ml) was added CsF (317 mg, 2.09 mmol) and water (1.05 ml) at R.T.
After degassed several times, to the suspension,
1,1'-bis(diphenylphosphino)ferrocenedichloro palladium (II) 1:1
complex with CH.sub.2Cl.sub.2 (25.5 mg, 0.04 mmol) was added and
the reaction mixture was degassed again. After stirring at
85.degree. C. for 16 h, the reaction mixture was cooled down to
R.T. diluted with water (10 ml) and filtered. The aqueous layer was
extracted with CH.sub.2Cl.sub.2 (2.times.50 ml) EtOAc (1.times.10
ml). The combined the organic layer was dried with K.sub.2CO.sub.3
filtered and combined this with the solid filtered initially, and
concentrated under reduced pressure. The resulting residue was
purified via flash column chromatography eluted with 0-7%
CH.sub.2Cl.sub.2:MeOH to give the desired product (220 mg 91%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 6.18 (s, 2H) 7.53
(dd, J=8.21, 4.17 Hz, 2H) 7.84 (d, J=11.37 Hz, 1H) 8.17 (d, J=8.59
Hz, 1H) 8.29 (s, 1H) 8.41-8.46 (m, 1H) 8.70 (s, 1H) 8.92 (dd,
J=4.29, 1.77 Hz, 1H) 9.25 (s, 1H).
Method 40
##STR00073##
[0345] The racemic
1-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-6-(1-methyl-1H-pyrazol-4--
yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine was purified by a chiral
column (Chiralpak IA 4.6.times.250 mm 5u column) eluting with 50%
MeOH and a flow rate of 2.5 uL/min to give
1-[(S)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-6-(1-methyl-1H-pyrazo-
l-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine with an optical rotation
of 0.146.degree. in dichloromethane (5.6 mg/mL) and
1-[(R)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-6-(1-methyl-1H-pyrazo-
l-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine with an optical rotation
of 0.26.degree. in dichloromethane (9.32 mg/mL).
Method 41
##STR00074##
[0347] To a solution of
6-[(6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl]quinoline
(100 mg, 0.29 mmol) in anhydrous DMF (2.0 ml) was added
4,4-difluoro-1-[(3S)-pyrrolidin-3-yl]piperidine (61.2 mg, 0.32
mmol) and K.sub.2CO.sub.3 (202.5 mg, 1.46 mmol). After stirring at
100.degree. C. for 16 hours the reaction mixture was filtered and
the resulting residue was purified using reversed phase column
eluted with acetonitrile in water and trifluoroacetic acid. The
titled compound was obtained as a solid (80.4 mg).
Method 42
##STR00075## ##STR00076##
[0349] Step 1:
##STR00077##
[0350] In a round bottom flask was added 4-iodopyrazole (10.22 g,
52.70 mmol), Cs.sub.2CO.sub.3 (20.6 g, 63.2 mmol), and anhydrous
DMF (100 mL). The suspension was stirred at 23.degree. C. for 5
min. 2-(2-bromoethoxy)tetrahydro-2H pyran (9.95 mL, 63.2 mmol) was
added and the reaction was stirred at 70.degree. C. for 16 hours.
After cooling down, EtOAc (100 mL) and water (100 mL) was added to
the reaction. The organic layer was collected, and the aqueous
layer was extracted with EtOAc (3.times.100 mL). The combined
organic layers were washed with water (3.times.100 mL), dried over
Na.sub.2SO.sub.4, and concentrated to afford dark brown oil. The
crude product was purified on a silica gel column eluting with
ethyl acetate and hexanes to provide
4-iodo-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazole as yellow
oil (14.78 g, 87% yield). .sup.1H NMR (300 MHz, DMSO-d6) .delta.
7.89 (s, 1H) 7.52 (s, 1H) 4.47-4.56 (m, 1H) 4.25-4.35 (m, 2H)
3.81-3.96 (m, 1H) 3.66-3.75 (m, 1H) 3.45-3.57 (m, J=2.83 Hz, 1H)
3.32-3.40 (m, 1H) 1.34-1.71 (m, 6H).
[0351] Step 2:
##STR00078##
[0352] To a solution of
4-iodo-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazole (1.0 g,
3.1 mmol) in anhydrous THF (8 mL) was added iPrMgCl (2M in THF,
3.10 mL, 6.21 mmol) at 0.degree. C. drop by drop under nitrogen.
The reaction was stirred for 1 hour at 0.degree. C. under nitrogen.
To the solution was added
2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.736 g, 4.66
mmoL) at 0.degree. C. and the resulting yellow solution was allowed
to stir for 1 hour at ambient temperature under nitrogen. The
reaction was quenched with sat. aqueous solution of NH.sub.4Cl (10
mL). EtOAc (50 mL) and sat aqueous NH.sub.4Cl solution (10 mL) were
added. The organic layer was separated, and the aqueous layer was
extracted with EtOAc (3.times.50 mL), dried over Na.sub.2SO.sub.4,
and concentrated to give the crude product as yellow oil. The oil
was purified a silica gel column eluting with EtOAc and hexanes to
provide
1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-4-(4,4,5,5-tetramethyl-[1,3,2]diox-
aborolan-2-yl)-1H-pyrazole as clear oil (800 mgs, 80% yield).
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.91 (s, 1H) 4.48-4.54
(m, 1H) 4.26-4.33 (m, 2H) 3.86-3.90 (m, 1H) 3.66-3.76 (m, 1H)
3.45-3.57 (m, 1H) 3.33-3.39 (m, 1H) 1.33-1.70 (m, 6H) 1.24 (s,
12H).
[0353] Step 3:
##STR00079##
[0354] To a solution of
6-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl)-quinoline (845
mg, 2.48 mmol) in DME (16 mL) was added
1-[2-(tetrahydro-pyran-2-yloxy)-ethl]-4-(4,4,5,5-tetramethyl-[1,3,2]dioxa-
borolan-2-yl)-1H-pyrazole (800 mgs, 2.48 mmol) and Cs.sub.2CO.sub.3
(2.42 g, 7.43 mmol) in H.sub.2O (4 mL). The reaction mixture was
degassed and charged with nitrogen for three times. The palladium
catalyst Pd(dppf).CH.sub.2Cl.sub.2 (101 mg, 0.124 mmol) was added
and the reaction mixture was degassed and charged with nitrogen for
three times, and stirred for 16 hours at 80.degree. C. under
nitrogen. The reaction mixture was then filtered over a pad of
Celite, and washed with EtOAc (50 mL) and water (25 mL). The
filtrate was extracted with EtOAc (3.times.50 mL). The organics
were dried over Na.sub.2SO.sub.4, filtered, and concentrated in
vacuo. The crude product was purified with a Biotage silica gel
column chromatography (40+S, 0-50% EtOAc/Hexanes 5CV (column
volume), 50-100% EtOAc/Hexanes 10 CV, 100% EtOAc 10 CV) to provide
6-(6-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-[1,2,3]tria-
zolo[4,5-b]pyrazin-1-ylmethyl)-quinoline (910 mgs, 81% yield) as a
solid. .sup.1H NMR (300 MHz, DMSO-d6) .delta. 9.23 (s, 1H)
8.82-8.95 (m, 1H) 8.67 (s, 1H) 8.28-8.45 (m, 2H) 7.92-8.08 (m, 2H)
7.77-7.90 (m, 1H) 7.53 (dd, J=8.29, 4.14 Hz, 1H) 6.15 (s, 2H)
4.49-4.62 (m, 2H) 4.30-4.47 (m, 2H) 3.91-4.00 (m, 1H) 3.67-3.87 (m,
J=5.46 Hz, 1H) 3.47-3.60 (m, 1H) 3.35-3.42 (m, 1H) 1.48-1.66 (m,
2H) 1.32-1.45 (m, 3H).
[0355] Step 4:
##STR00080##
[0356] To a solution of
6-(6-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-[1,2,3]tria-
zolo[4,5-b]pyrazin-1-ylmethyl)-quinoline (780 mg, 1.71 mmol) in
CH.sub.2Cl.sub.2 (20 mL) was added the anhydrous HCl dioxane
solution dropwise (4N, 1.07 mL, 4.27 mmol). A white solid was
precipitated out. The reaction mixture was stirred for 1 hour and
the LCMS showed the completion of the reaction. The reaction
mixture was concentrated, and the residue was dissolved in
distilled water (15 mL). The solution was adjusted to pH 7 with
Na.sub.2CO.sub.3. An off-white solid was crashed out, which was
filtered, washed with water, and dried on a high vacuum for 1 hour.
The solid was re-crystallized from EtOH (50 mL) to provide
2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol (400, 63% yield) as a white crystalline solid with
a melting point of 222.degree. C. .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 9.22 (s, 1H) 8.89 (dd, J=4.14, 1.70 Hz, 1H) 8.63 (s, 1H)
8.37 (dd, J=8.38, 1.04 Hz, 1H) 8.32 (s, 1H) 7.98-8.04 (m, 2H) 7.82
(dd, J=8.67, 2.07 Hz, 1H) 7.53 (dd, J=8.29, 4.14 Hz, 1H) 6.15 (s,
2H) 4.96 (t, J=5.27 Hz, 1H) 4.24 (t, J=5.46 Hz, 2H) 3.78 (q, J=5.46
Hz, 2H).
[0357] Step 5:
##STR00081##
[0358] In an Erlenmyer flask (500 mL) containing
2-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazo-
l-1-yl]-ethanol (3.76 mmol, 1.469 g) was added EtOH (180 mL). The
solution was heated until it started boiling (not all of solid was
dissolved), and a freshly prepared ethanol solution of methane
sulfonic acid (1.28 M, 3.09 mL, 3.95 mmol) was added. A clear
solution was obtained after addition of acid. The solution was then
heated to boil, and cooled to ambient temperature naturally with
stirring for overnight. The small crystals began to form after
cooling about 5 minutes. After stirring for overnight at ambient
temperature, the crystalline solid was filtered, washed with small
amount of ethanol, and dried under high vacuum for 3 hours. A white
crystalline solid was obtained (1.623 g, 92% yield); melting point:
202-203.degree. C. Elemental Analysis Calc: C, 51.28%, H, 4.30%, N,
23.92%; Found: C, 51.27%, H-4.32%, N, 24.04%; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 9.24 (s, 1H) 9.12 (d, J=4.71 Hz, 1H) 8.79 (d,
J=8.48 Hz, 1H) 8.64 (s, 1H) 8.33 (s, 1H) 8.10-8.22 (m, 2H)
7.98-8.09 (m, 1H) 7.83 (dd, J=8.48, 4.71 Hz, 1H) 6.22 (s, 2H) 4.24
(t, J=5.27 Hz, 2H) 3.79 (t, J=5.37 Hz, 2H), 2.32 (s, 3H).
Method 43
##STR00082##
[0360] To a solution of
[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol--
1-yl]-acetic acid methyl ester (242 mgs, 0.60 mmol) in MeOH (4 mL)
was added a freshly prepared solution of LiOH (72 mgs, 3.02 mmol)
in water (1 mL). The reaction was stirred for 16 hours at ambient
temperature. The white suspension was then neutralized to pH 7 with
1 N HCl, and a white solid precipitated out. The solid was
filtered, washed with water, and dried under a high vacuum for 16
hours to afford
[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol--
1-yl]-acetic acid (131 mgs, 56% yield).
Method 44
##STR00083## ##STR00084##
[0362] Step 1:
##STR00085##
[0363] To a solution of quinoline-6-carboxylic acid (10 g, 57.75
mmol) in DMF (200 mL) was added carbonyl diimidazole (10.3 g, 62.5
mmol) under nitrogen. The reaction was stirred for 1 hour. To the
solution was added N,O-dimethyl hydroxylamine (5.6 g, 57.75 mmol),
and the reaction was stirred at ambient temperature for 16 hours.
The reaction was diluted with EtOAc (150 mL) and water (150 mL).
The organic layer was separated, and the aqueous layer was
extracted with EtOAc (5.times.100 mL). The organics were combined
and washed with water (3.times.100 mL), brine (2.times.100 mL),
dried over Na.sub.2SO.sub.4, filtered and concentrated to give
quinoline-6-carboxylic acid methoxy-methyl-amide (11.97 g, 97%
yield).
[0364] To a solution of quinoline-6-carboxylic acid
methoxy-methyl-amide (11.97 g, 55.35 mmol) in anhydrous THF (200
mL) was added MeMgBr (1.5 M in THF, 55 mL, 83 mmol) at 0.degree. C.
under nitrogen. The reaction was allowed to warm to ambient
temperature over 16 hours. Sat. NH.sub.4Cl (20 mL) was added to
quench the reaction. The reaction solution was then extracted with
EtOAc (3.times.50 mL). The combined organics were dried over
Na.sub.2SO.sub.4, filtered, and concentrated to give
1-quinolin-6-yl-ethanone (9.2 g, 97% yield).
[0365] Step 2:
##STR00086##
[0366] To a suspension of hydroxylamine hydrochloride in EtOH (150
mL) was added a suspension of NaOH (2.4 g, 59.7 mmol) in EtOH (25
mL). The reaction mixture was stirred at ambient temperature for 15
minutes. The precipitated sodium hydrochloride was filtered off. A
solution of 1-quinolin-6-yl-ethanone (9.3 g, 54.25 mmol) in EtOH
(150 mL) was added. The reaction solution was stirred for 16 hours
at ambient temperature. EtOH was removed in vacuum to give
1-quinolin-6-yl-ethanone oxime (10.1 g, >99% yield).
[0367] Step 3:
##STR00087##
[0368] To a solution of 1-quinolin-6-yl-ethanone oxime (4.54 g,
24.4 mmol) in EtOH (50 mL) was added methanol solution of NH.sub.3
(7N, 12 mL, 80 mmol). A slurry of Raney Nickel (washed 3.times.
with EtOH) about 2 g was added followed by a hydrogen-filled
balloon. The reaction was stirred at ambient temperature for 16
hours under hydrogen-filled balloon. The reaction mixture was
filtered over a pad of celite and the mother liquor was
concentrated to give quantitative 1-quinolin-6-yl-ethylamine (4.1
g).
[0369] Step 4:
##STR00088##
[0370] To a solution of 2-amino-dibromopyrazine (5.1 g, 20 mmol)
and 1-quinolin-6-yl-ethylamine (3.43 g, 20 mmol) in n-BuOH (5 mL)
was added DIPEA (10.5 mL, 60 mmol). The reaction was irradiated in
a microwave at 225.degree. C. for 1 hour. The reaction mixture was
concentrated and purified by column chromatography Biotage 40+M
0-50% EtOAc:Hexanes (7 column volume), 50-100% (10 column volume),
and EtOAc with 10% MeOH to give
5-bromo-N*3*-(1-quinolin-6-yl-ethyl)-pyrazine-2,3-diamine (2.1 g,
66%).
[0371] Step 5:
##STR00089##
[0372] To a solution of the
5-bromo-N*3*-(1-quinolin-6-yl-ethyl)-pyrazine-2,3-diamine in
anhydrous DMF (25 mL) was added isoamyl nitrile (0.98 mL, 1.2 mmol)
at 0.degree. C. The reaction was stirred at 0.degree. C. for 5 min,
then the ice bath was removed and allowed to stir at ambient
temperature for 5 min. The reaction was then heated at 70.degree.
C. for 1 hour, cooled and quenched with sat. aqueous solution of
Na.sub.2SO.sub.3 (10 mL). Water (50 mL) and EtOAc (50 mL) were
added. The organic layer was separated and the aqueous layer was
extracted with EtOAc (4.times.100 mL). The combined organics were
washed with NaHCO.sub.3 (50 mL) and water (3.times.50 mL), dried
over Na.sub.2SO.sub.4, filtered and concentrated to give
6-[1-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)-ethyl]-quinoline
(1.56 g, 72% yield).
[0373] Step 6:
##STR00090##
[0374] Racemic
6-[1-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)-ethyl]-quinoline
was purified on a chiral SFC column using MeOH and liquid CO2 as
elution system to provide
6-[(R)-1-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl]-quinoline
with an [.alpha.].sub.D of +204.94.degree., and
6-[(S)-1-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)-ethyl]-quinoline
with an [.alpha.].sub.D of -212.73.degree..
Method 45
##STR00091##
[0376] Step 1:
[0377] To the solution of C-quinazolin-6-yl-methylamine (1.2 g,
7.916 mmol) and 2.06 gram of 3,5-dibromo-pyrazin-2-ylamine (2.06 g,
7.916 mmol) in n-BuOH (18 mL) was added diisopropylethylamine (7.0
mL, 40 mmol) at room temperature. The reaction mixture was heated
up to 120.degree. C. for two days under nitrogen. The reaction was
cooled down, n-BuOH is evaporated directly via rotavapor, followed
by purification via a silica gel column to get
5-Bromo-N*3*-quinazolin-6-ylmethyl-pyrazine-2,3-diamine (1.02 g,
yield 42%).
[0378] Step 2:
[0379] To the solution of
5-bromo-N*3*-quinazolin-6-ylmethyl-pyrazine-2,3-diamine (1.02 g) in
anhydrous DMF (12 mL) was added isoamyl nitrite (0.5 mL, 1.2 eq) at
0.degree. C. dropwise. The ice bath was removed and the mixture was
stirred for 5 minutes at room temperature, then at 70.degree. C.
for three hours. The reaction was cooled down to ambient
temperature and quenched by 3 ml Sat'd Na.sub.2SO.sub.3. A
precipitate was formed, and filtered. The mother liquor was
extracted with ethyl acetate (2.times.200 ml) twice, and the
combined extracts were washed twice by Sat'd NaHCO.sub.3
(2.times.100 ml), dried over Na.sub.2SO.sub.4, and concentrated to
get the crude product which was dissolved in MeOH (10 ml), and a
precipitate was formed. The solid was filtered to get
6-(6-Bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl)-quinazoline
(0.112 g, yield 13%).
Method 46
##STR00092##
[0381] To the solution of
6-(6-bromo-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl)-quinazoline
(100 mg, 0.32 mmol) and
1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole
(130 mg, 0.6 mmol) in 5 ml DME was added a freshly prepared
solution of Cs.sub.2CO.sub.3 (306.9 mg, 0.96 mmol)) in water (0.45
mL) and the catalyst PdCl.sub.2(dppf)CH.sub.2Cl.sub.2 (13 mg, 0.15
mmol)). The mixture was degassed and charged with nitrogen for
three times, then was heated at 85.degree. C. for overnight. The
solvent was evaporated directly, and the crude product was
suspended in CH.sub.2Cl.sub.2 (5 mL) and filtered. The mother
liquor was concentrated, and MeOH (2 mL) was added. The suspension
was filtered, and the solid was then washed by ether (2.times.10
ml) to get the product (37 mg, yield 37%).
TABLE-US-00003 TABLE 3 Ex- am- ple Structure Name NMR/LC-MS Method
1 ##STR00093## 6-((6-(1-(azetidin-3- yl)-1H-pyrazol-4-
yl)-1H-[1,2,3]- triazolo[4,5- b]pyrazin-1- yl)methyl)- quinoline 1H
NMR (400 MHz, DMSO- d6) .delta. ppm 9.27 (s, 1 H), 9.12 (s, 1 H),
8.93 (dd, J = 4.29, 1.77 Hz, 1 H), 8.89 (s, 1 H), 8.79 (s, 1 H),
8.55 (s, 1 H), 8.42 (d, J = 7.83 Hz, 1 H), 8.05 (d, J = 8.84 Hz, 1
H), 8.00 (s, 1 H), 7.85 (dd, J = 8.72, 1.89 Hz, 1 H), 7.58 (dd, J =
8.34, 4.29 Hz, 1 H), 6.17 (s, 2 H), 5.47-5.57 (m, 1 H), 4.35-4.47
(m, 4 H). LC-MS 383. 1 2 ##STR00094## 2-(4-(3-(quinolin-6-
ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5-yl)-1H-
pyrazol-1-yl)ethan- amine 1H NMR (400 MHz, DMSO- d6) .delta. ppm
9.26 (s, 1 H), 8.92 (dd, J = 4.29, 1.77 Hz, 1 H), 8.71 (s, 1 H),
8.43 (s, 1 H), 8.40 (d, J = 8.34 Hz, 1 H), 8.04 (d, J = 8.59 Hz, 1
H), 7.99 (s, 1 H), 7.91 (s, 2 H), 7.84 (dd, J = 8.59, 2.02 Hz, 1
H), 7.56 (dd, J = 8.34, 4.29 Hz, 1 H), 6.17 (s, 2 H), 4.45 (t, J =
6.06 Hz, 2 H), 3.29- 3.38 (m, 3 H). LC-MS 371. 1 3 ##STR00095##
N,N-dimethyl-3-(4- (3-(quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5-yl)-1H- pyrazol-1-yl)propan-
1-amine 1H NMR (400 MHz, DMSO- .delta. ppm 9.47 (s, 1 H), 9.24 (s,
1 H), 8.94 (dd, J = 4.29, 1.77 Hz, 1 H), 8.70 (s, 1 H), 8.44 (d, J
= 7.83 Hz, 1 H), 8.38 (s, 1 H), 8.06 (d, J = 8.59 Hz, 1 H), 8.00
(s, 1 H), 7.85 (dd, J = 8.72, 1.89 Hz, 1 H), 7.59 (dd, J = 8.34,
4.29 Hz, 1 H), 6.17 (s, 2 H), 4.30 (t, J = 6.69 Hz, 2 H), 3.07 (dt,
J = 10.55, 5.21 Hz, 2 H), 2.77 (d, J = 4.55 Hz, 6 H), 2.16- 2.25
(m, 2 H). LC-MS 413. 1 4 ##STR00096## 6-((6-(1-(piperidin-
4-ylmethyl)-1H- pyrazol-4-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, DMSO- d6) .delta. ppm 9.23
(s, 1 H), 8.99 (dd, J = 4.29, 1.52 Hz, 1 H), 8.70 (s, 1 H), 8.58
(s, 1 H), 8.53 (d, J = 8.59 Hz, 1 H), 8.36 (s, 1 H), 8.24 (d, J =
9.09 Hz, 1 H), 8.08 (d, J = 8.59 Hz, 1 H), 8.05 (s, 1 H), 7.90 (dd,
J = 8.72, 1.89 Hz, 1 H), 7.65 (dd, J = 8.34, 4.55 Hz, 1 H), 6.18
(s, 2 H), 4.17 (d, J = 6.82 Hz, 2 H), 3.26 (d, J = 12.38 Hz, 2 H),
2.80-2.91 (m, 2 H), 2.17 (s, 1 H), 1.68 (d, J = 1 3.39 Hz, 2 H),
1.32- 1.43 (m, 2 H). LC-MS 426. 2 5 ##STR00097## N,N-dimethyl-2-(4-
(3-(quinolin-6- ylmethyl)-3H- [1,2,3]triazolo[4,5-
b]pyrazin-5-yl)-1H- pyrazol-1-yl)- ethanamine 1H NMR (400 MHz, DMSO
d6) .delta. ppm 9.51 (s, 1 H), 9.27 (s, 1 H), 8.93 (dd, J = 4.17,
1.64 Hz, 1 H), 8.76 (s, 1 H), 8.46 (s, 1 H), 8.43 (d, J = 8.34 Hz,
1 H), 8.05 (d, J = 8.59 Hz, 1 H) 8.00 (d, J = 1.26 Hz, 1 H), 7.85
(dd, J = 8.72, 1.89 Hz, 1 H), 7.58 (dd, J = 8.21, 4.17 Hz, 1 H),
6.17 (s, 2 H), 4.64 (t, J = 6.19 Hz, 2 H), 3.63 (s, 2 H), 2.83 (s,
6 H). LC-MS 399. 2 6 ##STR00098## 6-((6-(1-(2- methoxyethyl)-1H-
pyrazol-4-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, DMSO- d6) .delta. ppm 9.23
(s, 1 H), 8.92- 8.97 (m, 1 H), 8.64 (s, 1 H), 8.46 (s, 1 H), 8.33
(s, 1 H), 8.02-8.07 (m, 2 H), 7.88 (dd, J = 8.59, 1.77 Hz, 1 H),
7.60 (dd, J = 8.34, 4.29 Hz, 1 H), 6.17 (s, 2 H), 4.36 (t, J = 5.18
Hz, 2 H), 3.73 (t, J = 5.18 Hz, 2 H), 3.23 (s, 3 H). LC-MS 386. 2 7
##STR00099## 6-((6-(1-methyl-1H- pyrazol-4-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl)methyl)-quinoline 1H NMR (400
MHz, DMSO- d6) .delta. ppm 9.21 (s, 1 H), 8.98 (dd, J = 4.29, 1.52
Hz, 1 H), 8.64 (s, 1 H), 8.52 (d, J = 7.83 Hz, 1 H), 8.30 (s, 1 H),
8.04-8.10 (m, 2 H), 7.91 (dd, J = 8.72, 1.89 Hz, 1 H), 7.64 (dd, J
= 8.34, 4.29 Hz, 1 H), 6.17 (s, 2 H), 3.94 (s, 3 H). LC-MS 342. 2 8
##STR00100## 6-((6-(1-((R)- pyrrolidin-3-yl)-1H- pyrazol-4-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl)methyl)-quinoline 1H NMR (400
MHz, DMSO- d6) .delta. ppm 9.26 (s, 1 H), 9.17 (s, 2 H), 8.93-8.97
(m, 1 H), 8.82 (s, 1 H), 8.44 (s, 2 H), 8.06 (d, J = 8.84 Hz, 1 H),
8.01 (s, 1 H), 7.86 (d, J = 8.84 Hz, 1 H), 7.59 (ddd, J = 6.19,
4.17, 2.02 Hz, 1 H), 6.17 (s, 2 H), 5.27-5.35 (m, 1 H), 3.69 (dt, J
= 12.69, 6.41 Hz, 1 H), 3.58-3.64 (m, 1H), 3.38-3.49 (m, 2 H),
2.43-2.48 (m, 1 H), 2.32-2.39 (m, 1H), 2.30 (s, 1 H). LC-MS 397. 2
9 ##STR00101## 6-((6-(1-((S)- pyrrolidin-3-yl)-1H-
pyrazol-4-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, DMSO- d6) .delta. ppm 9.26
(s, 1 H), 9.16 (s, 2 H), 8.94 (dd, J = 4.29, 1.52 Hz, 1 H), 8.82
(s, 1 H), 8.42-8.47 (m, 2 H), 8.06 (d, J = 8.84 Hz, 1 H), 8.01 (d,
J = 1.52 Hz, 1 H), 7.86 (dd, J = 8.84, 2.02 Hz, 1 H), 7.59 (dd, J =
8.34, 4.29 Hz, 1 H), 6.18 (s, 2 H), 5.27-5.34 (m, J = 7.17, 7.17,
3.92, 3.73 Hz, 1 H), 3.64-3.73 (m, J = 12.73, 6.69, 6.46, 6.46 Hz,
1 H), 3.57-3.64 (m, 1 H), 3.38-3.49 (m, 2 H), 2.46 (d, J = 7.33 Hz,
1 H), 2.43 (s, 1 H), 2.29- 2.38 (m, 1 H). LC-MS 397. 2 10
##STR00102## N-(piperidin-4-yl)- 4-(3-(quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)benzamide 1H NMR (400 MHz,
MeOD) .delta. ppm 1.81-1.93 (m, 2 H) 2.23 (d, J = 11.37 Hz, 2 H)
3.14 (td, J = 12.82, 2.91 Hz, 2 H) 3.42-3.52 (m, 2 H) 4.16- 4.25
(m, J = 11.05, 11.05, 3.92, 3.79 Hz, 1 H) 6.31 (s, 2 H) 7.58 (dd, J
= 8.46, 4.42 Hz, 1 H) 7.97 (dd, J = 8.84, 2.02 Hz, 1 H) 8.02-8.09
(m, 3 H) 8.12 (d, J = 1.52 Hz, 1 H) 8.35-8.43 (m, 3 H) 8.88 (dd, J
= 4.42, 1.64 Hz, 1 H) 9.44 (s, 1 H). LC-MS 465. 5 & 8 11
##STR00103## N-(2-aminoethyl)-4- (3-(quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazine-5- yl)benzamide 1H NMR (400 MHz,
MeOD) .delta. ppm 3.17 (t, J = 5.94 Hz, 2 H) 3.69 (t, J = 6.06 Hz,
2 H) 6.30 (s, 2 H) 7.57 (dd, J = 8.34, 4.29 Hz, 1 H) 7.96 (dd, J =
8.72, 1.89 Hz, 1 H) 8.04- 8.13 (m, 4 H) 8.39 (ddd, J = 6.69, 2.27,
2.15 Hz, 3 H) 8.87 (dd, J = 4.42, 1.64 Hz, 1 H) 9.43 (s, 1 H).
LC-MS 425. 5 & 8 12 ##STR00104## N-(2-dimethyl- amino)ethyl)-N-
methyl-4-(3- (quinolin-6- ylmethyl)-3H- [1,2,3]triazolo[4,5-
b]pyrazin-5- yl)benzamide 1H NMR (400 MHz, MeOD) .delta. ppm 3.08
(s, 6 H) 3.13 (s, 3 H) 3.52 (t, J = 6.19 Hz, 2 H) 3.98 (t, J = 5.94
Hz, 2 H) 6.34 (s, 2 H) 7.70-7.78 (m, 3 H) 8.06-8.11 (m, 1H) 8.11-
8.16 (m, 1 H) 8.22 (s, 1 H) 8.40 (d, J = 8.59 Hz, 2 H) 8.66 (d, J =
8.08 Hz, 1 H) 8.99 (dd, J = 4.80, 1.52 Hz, 1 H) 9.44 (s, 1 H).
LC-MS 467. 5 13 ##STR00105## N-(2-(dimethyl- amino)ethyl)-4-(3-
(quinolin-6- ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5-
yl)benzamide 1H NMR (400 MHz, MeOD) .delta. ppm 3.03 (s, 6 H) 3.44
(t, J = 5.94 Hz, 2 H) 3.82 (t, J = 5.81 Hz, 2 H) 6.34 (s, 2 H) 7.76
(dd, J = 8.34, 4.55 Hz, 1 H) 8.06-8.11 (m, 3 H) 8.12- 8.17 (m, 1 H)
8.23 (d, J = 1.52 Hz, 1 H) 8.40 (d, J = 8.59 Hz, 2 H) 8.68 (d, J =
7.58 Hz, 1 H) 9.00 (dd, J = 4.67, 1.64 Hz, 1 H) 9.45 (s, 1 H).
LC-MS 453. 5 14 ##STR00106## ethyl 1-(3-(quinolin- 6-ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5-yl)- 1H-pyrazole-4- carboxylate 1H
NMR (400 MHz, DMSO- d6) .delta. ppm 1.33 (t, J = 7.07 Hz, 3 H) 4.33
(q, J = 7.07 Hz, 2 H) 6.25 (s, 2 H) 7.55 (dd, J = 8.34, 4.29 Hz, 1
H) 7.88 (dd, J = 8.72, 1.89 Hz, 1 H) 8.03 (d, J = 8.84 Hz, 1 H)
8.07 (d, J = 1.52 Hz, 1 H) 8.35-8.39 (m, 1 H) 8.41 (s, 1 H) 8.91
(dd, J = 4.17, 1.64 Hz, 1 H) 9.27 (s, 1 H) 9.48 (s, 1 H). LC-MS
401. 9 15 ##STR00107## 6-((6-(1-(piperidin- 4-yl)-1H-pyrazol-4-
yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1- yl)methyl)-quinoline 1H
NMR (400 MHz, DMSO- d6) .delta. ppm 1.83 (qd, J = 12.00, 3.92 Hz, 2
H) 2.01 (d, J = 10.1 1Hz, 2 H) 2.57-2.68 (m, 2 H) 3.07 (d, J =
12.63 Hz, 2 H) 4.26-4.36 (m, J = 11.56, 11.56, 4.04, 3.92 Hz, 1 H)
6.16 (s, 2H) 7.54 (dd, J= 8.34, 4.04 Hz, 1 H) 7.84 (dd, J = 8.59,
2.02 Hz, 1 H) 7.99- 8.06 (m, 2 H) 8.31 (s, 1 H) 8.38 (d, J = 8.59
Hz, 1 H) 8.73 (s, 1 H) 8.90 (dd, J = 4.17, 1.64 Hz, 1 H) 9.24 (s, 1
H). LC-MS 412. 6 & 8 16 ##STR00108## 6-((6-(4-methyl-1H-
imidazol-1-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, DMSO- .delta. ppm 2.22 (s, 3
H) 6.17 (s, 2 H) 7.55 (dd, J = 8.34, 4.04 Hz, 1 H) 7.81-7.90 (m, 2
H) 8.00-8.08 (m, 2 H) 8.38 (d, J = 7.58 Hz, 1 H) 8.74 (s, 1 H) 8.90
(dd, J = 4.17, 1.64 Hz, 1 H) 9.35 (s, 1 H). LC-MS 343. 9 17
##STR00109## morpholino(4-(3- (quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)phenyl)- methanone 1H NMR (400
MHz, CHLOROFORM-d) .delta. ppm 3.52 (s, 2 H) 3.69 (s, 2 H) 3.82 (s,
4 H) 6.17 (s, 2 H) 7.43 (dd, J = 8.34, 4.04 Hz, 1 H) 7.60-7.70 (m,
2 H) 7.84- 7.92 (m, 1 H) 7.95 (d, J = 1.52 Hz, 1 H) 8.13 (dd, J =
16.29, 8.46 Hz, 2 H) 8.19 (d, J = 8.34 Hz, 2 H) 8.92 (dd, J = 4.17,
1.64 Hz, 1 H) 9.23 (s, 1 H). LC-MS 452. 6 18 ##STR00110##
N-methyl-3-(3- (quinolin-6- ylmethyl)-3H- [1,2,3]triazolo[4,5-
b]pyrazin-5- yl)benzamide 1H NMR (400 MHz, DMSO d6) .delta. ppm
2.85 (d, J = 4.55 Hz, 3 H) 6.32 (s, 2 H) 7.68- 7.78 (m, 2 H)
7.98-8.07 (m, 2 H) 8.16 (d, J = 12.13 Hz, 2 H) 8.43 (d, J = 7.83
Hz, 1 H) 8.70 (d, J = 18.69 Hz, 3 H) 9.06 (d, J = 4.55 Hz, 1 H)
9.58 (s, 1 H). LC-MS 396. 6 19 ##STR00111## N-methyl-4-(3-
(quinolin-6- ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5-
yl)benzamide 1H NMR (400 MHz, DMSO d6) .delta. ppm 2.82 (d, J =
4.29 Hz, 3 H) 6.34 (s, 2 H) 7.85 (dd, J = 8.21, 4.67 Hz, 1 H)
8.02-8.13 (m, 3 H) 8.19-8.30 (m, 2 H) 8.40 (d, J = 8.34 Hz, 2 H)
8.66 (d, J = 4.29 Hz, 1 H) 8.81 (d, J = 8.08 Hz, 1 H) 9.13 (d, J =
4.55 Hz, 1 H) 9.59 (s, 1 H). LC-MS 396. 6 20 ##STR00112##
6-((6-(3-methoxy- phenyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, DMSO- d6) .delta. ppm 3.86
(d, J = 1.77 Hz, 3 H) 6.33 (s, 2 H) 7.17 (d, J = 8.08 Hz, 1 H)
7.48- 7.55 (m, 1 H) 7.79-7.90 (m, 3 H) 8.07 (d, J = 8.84 Hz, 1 H)
8.18-8.25 (m, 2 H) 8.79 (d, J = 8.34 Hz, 1 H) 9.12 (d, J = 4.80 Hz,
1 H) 9.54 (d, J = 1.77 Hz, 1 H). LC-MS 369. 6 21 ##STR00113##
6-((6-(4-methoxy- phenyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, DMSO- d6) .delta. ppm 3.86
(s, 3 H) 6.29 (s, 2 H) 7.13-7.17 (m, 2 H) 7.82 (dd, J = 8.34, 4.55
Hz, 1 H) 8.05 (dd, J = 8.72, 1.90 Hz, H) 8.16-8.23 (m, 2 H)
8.27-8.32 (m, 2 H) 8.77 (d, J = 8.34 Hz, 1 H) 9.11 (dd, J = 4.67,
1.39 Hz, 1 H) 9.48 (s, 1 H). LC-MS 369. 6 22 ##STR00114##
6-((6-(1H-parazol-1- yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, DMSO- d6) .delta. ppm 6.12
(s, 2 H) 6.67- 6.72 (m, 1 H) 7.47 (dd, J = 8.34, 4.29 Hz, 1 H) 7.80
(dd, J = 8.59, 2.02 Hz, 1 H) 7.94- 8.01 (m, 3 H) 8.30 (s, 1 H) 8.74
(d, J = 2.78 Hz, 1 H) 8.83 (dd, J = 4.29, 1.77 Hz, 1 H) 9.38 (s,1
H). LC-MS 329. 9 23 ##STR00115## 6-((6-(2-fluoro- phenyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl)methyl)-quinoline 1H NMR (400
MHz, DMSO- d6) .delta. ppm 6.26 (s, 2 H) 7.44- 7.56 (m, 3 H)
7.59-7.70 (m, 1 H) 7.85 (dd, J = 8.84, 2.02 Hz, 1 H) 7.98-8.06 (m,
3 H) 8.34-8.40 (m, 1 H) 8.90 (dd, J = 4.17, 1.64 Hz, 1 H) 9.25 (d,
J = 2.27 Hz, 1 H). LC-MS 357. 6 24 ##STR00116## 6-((6-(1H-pyrazol-
4-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1- yl)methyl)-quinoline 1H
NMR (400 MHz, DMSO- d6) .delta. ppm 6.16 (s, 2 H) 7.54 (dd, J =
8.34, 4.29 Hz, 1 H) 7.84 (dd, J = 8.97, 1.64 Hz, 1 H) 8.00-8.07 (m,
2 H) 8.38 (d, J = 8.59 Hz, 1 H) 8.56 (s, 1 H) 8.90 (dd, J = 4.17,
1.64 Hz, 1 H) 9.26 (s, 1 H) 13.47 (s, 1 H). LC-MS 329. 7 25
##STR00117## 6-((6-(4-fluoro- phenyl)-1H- [1,2,3]trazolo[4,5-
b]pyrazin-1- yl)methyl)-quinoline 1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 6.15 (s, 2 H) 7.24-7.30 (m, 3 H) 7.43 (dd, J = 8.34,
4.29 Hz, 1 H) 7.86 (dd, J = 8.84, 2.02 Hz, 1 H) 7.93 (d, J = 1.77
Hz, 1 H) 8.10-8.17 (m, 3 H) 8.92 (dd, J = 4.17, 1.64 Hz, 1 H) 9.18
(s, 1 H). LC-MS 357. 6 26 ##STR00118## 6-((6-4-methyl-
piperazin-1-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl)-quinoline 1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm
2.39 (s, 3 H) 2.54-2.65 (m, 4 H) 3.79-3.89 (m, 4 H) 5.88 (s, 2 H)
7.41 (dd, J = 8.34, 4.29 Hz, 1 H) 7.77 (dd, J = 8.72, 1.89 Hz, 1 H)
7.80-7.85 (m, 1 H) 8.08 (d, J = 8.84 Hz, 1 H) 8.10-8.13 (m, 1 H)
8.30 (s, 1 H) 8.88-8.98 (m, 1 H). LC-MS 361. 11 27 ##STR00119##
N,N-dimethyl-1-(3- (quinolin-6- ylmethyl)-3H- [1,2,3]triazolo[4,5-
b]pyrazin-5- yl)piperidin-4-amine 1H NMR (400 MHz, CHLOROFORM-d)
.delta. ppm 1.50-1.62 (m, 2 H) 2.01 (d, J = 11.87 Hz, 2 H) 2.34 (s,
6 H) 2.49-2.60 (m, 1 H) 3.04- 3.14 (m, 2 H) 4.49-4.60 (m, J = 13.39
Hz, 2 H) 5.87 (s, 2 H) 7.41 (dd, J = 8.34, 4.29 Hz, 1 H) 7.78 (dd,
J = 8.72, 1.89 Hz, 1 H) 7.83 (s, 1 H) 8.08 (d, J = 8.84 Hz, 1 H)
8.12 (d, J = 8.34 Hz, 1 H) 8.32 (s, 1 H) 8.91 (dd, J = 4.04, 1.52
Hz, 1 H). LC-MS 389. 11 28 ##STR00120## 1-(3-(quinolin-6-
ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl)piperidin-4-ol
1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.61-1.71 (m, J = 12.69,
8.56, 8.56, 3.79 Hz, 2 H) 1.97-2.05 (m, J = 9.54, 6.44, 3.54, 3.38,
3.38 Hz, 2 H) 2.23 (s, 1 H) 3.49-3.57 (m, 2 H) 4.03- 4.10 (m, J =
7.86, 7.86, 3.85, 3.66 Hz, 1 H) 4.16 (ddd, J = 13.33, 6.63, 4.04
Hz, 2 H) 5.88 (s, 2 H) 7.45 (dd, J = 8.34, 4.29 Hz, 1 H) 7.81 (dd,
J = 8.72, 1.89 Hz, 1 H) 7.85 (s, 1 H) 8.15 (dd, J = 12.76, 8.46 Hz,
2 H) 8.32 (s, 1 H) 8.92 (dd, J = 4.29, 1.77 Hz, 1 H). LC-MS 362. 11
29 ##STR00121## (S)-N,N-dimethyl-1- (3-(quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)pyrrolidin-3- amine 1H NMR
(400 MHz, CHLOROFORM-d) .delta. ppm 1.95-2.07 (m, 1 H) 2.26- 2.32
(m, 1 H) 2.35 (s, 6 H) 2.85-2.95 (m, 1 H) 3.41 (dd, J = 10.36, 8.59
Hz, 1 H) 3.58 (td, J = 10.48, 7.07 Hz, 1 H) 3.81-3.92 (m, 2 H) 5.88
(s, 2 H) 7.41 (dd, J = 8.34, 4.29 Hz, 1 H) 7.78-7.84 (m, 2 H) 8.04
(s, 1 H) 8.05-8.13 (m, 2 H) 8.90 (dd, J = 4.17, 1.64 Hz, 1 H).
LC-MS 375. 11 30 ##STR00122## (R)-N,N-dimethyl- 1-(3-(quinolin-6-
ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl)pyrrolidin-3-
amine 1H NMR (400 MHz, CHLOROFORM-d) .delta. ppm 1.94-2.06 (m, 1 H)
2.25-2.33 (m, 1 H) 2.35 (s, 6 H) 2.85- 2.95 (m, 1 H) 3.40 (dd, J =
10.48, 8.46 Hz, 1 H) 3.58 (td, J = 10.42, 7.20 Hz, 1 H) 3.81-3.91
(m, 2 H) 5.88 (s, 2 H) 7.40 (dd, J = 8.34, 4.29 Hz, 1 H) 7.78-7.84
(m, 2 H) 8.04 (s, 1 H) 8.09 (dd, J = 17.56, 8.46 Hz, 2) 8.90 (dd, J
= 4.29, 1.52 Hz, 1 H). LC-MS 375. 11 31 ##STR00123##
(R)-1-(3-(quinolin- 6-ylmethyl)-3H- [1,2,3]triazolo[4,5-
b]pyrazin-5- yl)piperidin-3-amine dihydrochloride 1 H NMR (400 MHz,
MeOD) .delta. ppm 1.71-1.82 (m, 2 H) 1.88- 1.98 (m, 1 H) 2.12-2.21
(m, 1 H) 3.41-3.47 (m, 1 H) 3.51- 3.62 (m, 2 H) 4.15 (td, J = 8.97,
4.29 Hz, 1 H) 4.48 (dd, J = 13.52, 3.66 Hz, 1 H) 6.08 (s, 2 H) 8.09
(dd, J = 8.34, 5.56 Hz, 1 H) 8.21- 8.27 (m, 2 H) 8.35 (s, 1 H) 8.52
(s, 1 H) 9.17-9.22 (m, 2 H). LC-MS 361. 10
32 ##STR00124## (S)-1-(3-(quinolin- 6-ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)piperidin-3-amine
dihydrochloride 1H NMR HCl salt (400 MHz, MeOD) .delta. ppm
0.15-0.25 (m, 2 H) 0.33-0.41 (m, 1 H) 0.57- 0.65 (m, 1 H) 1.84-1.91
(m, 1 H) 1.94-2.06 (m, 2 H) 2.54- 2.62 (m, 1 H) 2.92 (dd, J =
13.39, 3.54 Hz, 1 H) 4.52 (s, 2 H) 6.51 (dd, J = 8.46, 5.43 Hz, 1
H) 6.64-6.70 (m, 2 H) 6.78 (s, 1 H) 6.96 (s, 1 H) 7.59-7.64 (m, 2
H). LC-MS 361. 10 33 ##STR00125## 6-((6-(piperazin- 1-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl)methyl)quinoline (400 MHz,
MeOD) .delta. ppm 2.90-2.95 (m, 4 H) 3.76- 3.81 (m, 4 H) 5.93 (s, 2
H) 7.52 (dd, J = 8.34, 4.29 Hz, 1 H) 7.80 (dd, J = 8.84, 2.02 Hz, 1
H) 7.94 (d, J = 1.26 Hz, 1 H) 7.99 (d, J = 8.84 Hz, 1 H) 8.33 (dd,
J = 8.34, 0.76 Hz, 1 H) 8.44 (s, 1 H) 8.82 (dd, J = 4.29, 1.77 Hz,
1 H). LC-MS 347. 10 34 ##STR00126## tert-butyl 1-(3- (quinolin-6-
ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl)piperidin-4-
ylcarbamate 400 MHz, DMSO-d.sub.6) .delta. ppm 1.30-1.40 (m, 2 H)
1.39 (s, 9H) 1.78-1.87 (m, 2 H) 3.12- 3.22 (m, 2 H) 3.53-3.63 (m, 1
H) 4.44 (d, J = 13.64 Hz, 2 H) 5.91 (s, 2H) 6.88 (d, J = 7.33 Hz, 1
H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.76 (dd, J = 8.84, 2.02 Hz, 1
H) 7.96 (d, J = 1.52 Hz, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.36 (d, J
= 7.58 Hz, 1 H) 8.58 (s, 1 H) 8.89 (dd, J = 4.29, 1.77 Hz, 1 H).
LC-MS 461. 10 35 ##STR00127## (R)-1-(3-(quinolin- 6-ylemthyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)pyrrolidin-3- amine (400 MHz,
MeOD) .delta. ppm 1.85-1.96 (m, 1 H) 2.19- 2.30 (m, 1 H) 3.37-3.44
(m, H) 3.63-3.72 (m, 2 H) 3.74- 3.83 (m, 2 H) 5.92 (s, 2 H) 7.52
(dd, J = 8.34, 4.29 Hz, 1 H) 7.81 (dd, J = 8.72, 1.89 Hz, 1 H) 7.92
(s, 1 H) 7.98 (d, J = 8.84 Hz, 1 H) 8.12 (s, 1 H) 8.32 (d, J = 7.58
Hz, 1 H) 8.81 (dd, J = 4.42, 1.64 Hz, 1 H). LC-MS 347. 10 36
##STR00128## (4-(3-(quinolin-6- ylmethyl)-3H- [1,2,3]triazolo[4,5-
b]pyrazin-5- yl)phenyl)methanol (400 MHz, DMSO-d.sub.6) .delta. ppm
4.60 (d, J = 5.56 Hz, 2 H) 5.37 (t, J = 5.68 Hz, 1 H) 6.25 (s, 2 H)
7.54 (dt, J = 8.34, 2.02 Hz, 3 H) 7.86 (dd, J = 8.72, 1.89 Hz, 1 H)
8.01- 8.05 (m, 2 H) 8.28 (d, J = 8.34 Hz, 2 H) 8.38 (d, J = 7.33
Hz, 1 H) 8.90 (dd, J = 4.29, 1.77 Hz, 1 H) 9.50 (s, 1 H). LC-MS
369. 12 37 ##STR00129## (3-(3-(quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)phenyl)methanol (400 MHz,
DMSO-d6) .delta. ppm 4.62 (d, J = 5.56 Hz, 2 H) 5.38 J = 5.68 Hz, 1
H) 6.25 (s, 2 H) 7.52-7.59 (m, 3 H) 7.85 (dd, J = 8.72, 1.89 Hz, 1
H) 8.01-8.06 (m, 2 H) 8.17 (d, J = 6.82 Hz, 1 H) 8.24 (s, 1 H) 8.38
(d, J = 8.34 Hz, 1 H) 8.90 (dd, J = 4.17, 1.64 Hz, 1 H) 9.49 (s, 1
H). LC-MS 369. 12 38 ##STR00130## (4-(3-(quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)phenyl)- methanamine (400 MHz,
MeOD) .delta. ppm 3.88 (s, 2 H) 6.23 (s, 2 H) 7.51-7.55 (m, 3 H)
7.91 (dd, J = 8.84, 2.02 Hz, 1 H) 8.02 (d, J = 8.84 Hz, 1 H) 8.07
(d, J = 1.77 Hz, 1 H) 8.19-8.23 (m, 2 H) 8.34-8.38 (m, 1 H) 8.83
(dd, J = 4.29, 1.77 Hz, 1 H) 9.32 (s, 1 H). LC-MS 368. 12 39
##STR00131## 2-chloro-4-(3- (quinolin-6- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)benzoic acid (400 MHz,
DMSO-d.sub.6) .delta. ppm 6.26 (s, 2 H) 7.43 (d, J = 7.83 Hz, 1 H)
7.54 (dd, J = 8.21, 4.17 Hz, 1 H) 7.85 (dd, J = 8.84, 2.02 Hz, 1 H)
8.03 (d, J = 8.84 Hz, 1 H) 8.05 (d, J = 1.52 Hz, 1 H) 8.13 (dd, J =
7.96, 1.64 Hz, 1 H) 8.19 (d, J = 1.77 Hz, 1 H) 8.37 (dd, J = 8.34,
1.01 Hz, 1 H) 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 9.50 (s, 1 H).
LC-MS 417. 12 40 ##STR00132## 3-fluoro-5-(3- (quinolin-6-
ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl)benzoic acid
(400 MHz, DMSO-d6) .delta. ppm 6.28 (s, 2 H) 7.54 (dd, J = 8.34,
4.04 Hz, 1 H) 7.86 (dd, J = 8.84, 2.02 Hz, 1 H) 8.02 (s, 1 H)
8.04-8.07 (m, 2 H) 8.24 (s, 1 H) 8.25-8.28 (m, 1 H) 8.38 (dd, J =
8.21, 0.88 Hz, 1 H) 8.90 (dd, J = 4.17, 1.64 Hz, 1 H) 9.60 (s, 1 H)
13.55 (s, 1 H). LC-MS 401. 12 41 ##STR00133## 6-Bromo-1-(2,3-
dihydro-benzofuran- 5-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazine
1H NMR (400 MHz, DMSO- D6) .delta. ppm 8.97 (s, 1 H) 7.25 (s, 1 H)
7.16 (dd, J = 8.34, 1.77 Hz, 1 H) 6.73 (d, J = 8.34 Hz, 1 H) 4.48
(t, J = 8.72 Hz, 2 H) 3.11 (t, J = 8.72 Hz, 2 H). LC-MS 332, 334.
14 42 ##STR00134## (R)-1-[3-(2,3- Dihydro- benzofuran-5-
ylmethyl)-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl]pyrrolidin-3-
ylamine 1H NMR (400 MHz, DMSO- D6) .delta. ppm 8.17 (s, 1 H) 7.24
(s, 1 H) 7.14 (d, J = 8.34 Hz, 1 H) 6.70 (d, J = 8.08 Hz, 1 H) 5.56
(s, 2 H) 4.47 (t, J = 8.72 Hz, 3 H) 3.59-3.76 (m, 2 H) 3.26-3.41
(m, 2 H) 3.11 (t, J = 8.72 Hz, 2 H) 2.04-2.15 (m, 1 H) 1.84-1.91
(m, 1 H) 1.77-1.82 (m, 1 H). LC-MS 338. 16 43 ##STR00135##
{(R)-1-[3-(2,3- Dihydro- benzofuran-5- ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl]-pyrrolidin-3- yl}-dimethyl-
amine 1H NMR (400 MHz, DMSO- D6) .delta. ppm 8.20 (s, 1 H) 7.25 (s,
1 H) 7.14 (d, J = 8.08 Hz, 1 H) 6.70 (d, J = 8.08 Hz, 1 H) 5.56 (2,
2 H) 4.47 (t, J = 8.72 Hz, 2 H) 3.83-3.96 (m, 1 H) 3.75-3.84 (m, 1
H) 3.43- 3.58 (m, 2 H) 3.11 (t, J = 8.72 Hz, 2 H) 2.75-2.92 (m, 1
H) 2.21 (s, 6 H) 1.79-1.88 (m, 1 H). LC-MS 366. 15 44 ##STR00136##
1-(2,3-Dihydro- benzofuran-5- ylmethyl)-6-(1- methyl-1H-pyrazol-
4-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazine 1H NMR (400 MHz, DMSO-
D6) .delta. ppm 9.17 (s, 1 H) 8.64 (s, 1 H) 8.30 (s, 1 H) 7.30 (s,
1 H) 7.18-7.26 (m, 1 H) 6.72 (d, J = 8.08 Hz, 1 H) 5.80 (s, 2 H)
4.47 (t, J = 8.72 Hz, 2 H) 3.94 (s, 3 H) 3.11 (t, J = 8.72 Hz, 2
H). LC-MS 334. 17 45 ##STR00137## 2-Methyl-1-[4-(3- quinolin-6-
ylmethyl-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl)pyrazol-1-yl]-
propan-2-ol 1H NMR (400 MHz, DMSO- D6) .delta. ppm 9.24 (s, 1 H)
8.88 (dd, J = 4.17, 1.64 Hz, 1 H) 8.56 (s, 1 H) 8.35-8.37 (m, 1 H)
8.31 (s, 1 H) 8.02 (d, J = 8.59 Hz, 1 H) 7.98 (d, J = 1.52 Hz, 1 H)
7.82 (dd, J = 8.59, 2.02 Hz, 1 H) 7.52 (dd, J = 8.21, 4.17 Hz, 1 H)
6.15 (s, 2 H) 4.80 (s, 1 H) 4.11 (s, 2 H) 1.10 (s, 6 H). LC-MS 401.
18 46 ##STR00138## 6-{6-[1-(2- Pyrrolidin-1-yl- ethyl)-1H-pyrazol-
4-yl]- [1,2,3]triazolo[4,5- b]pyrazin-1- ylmethyl}-quinoline 1H NMR
(400 MHz, DMSO- D6) .delta. ppm 9.20 (s, 1 H) 8.88 (dd, J = 4.29,
1.77 Hz, 1 H) 8.66 (s, 1 H) 8.34-8.38 (m, 1 H) 8.30 (s, 1 H)
7.97-8.04 (m, 2 H) 7.82 (dd, J = 8.59, 2.02 Hz, 1 H) 7.52 (dd, J =
8.34, 4.04 Hz, 1 H) 6.14 (s, 2 H) 4.29 (t, J = 6.44 Hz, 2 H) 2.85
(t, J = 6.44 Hz, 2 H) 1.59-1.65 (m, 4 H). LC-MS 426. 18 47
##STR00139## 6-{6-[1-(2- Morpholin-4-yl- ethyl)-1H-pyrazol- 4-yl]-
[1,2,3]triazolo[4,5- b]pyrazin-1- ylmethyl}-quinoline 1H NMR (400
MHz, DMSO- D6) .delta. ppm 9.15 (s, 1 H) 8.83 (dd, J = 4.04, 1.77
Hz, 1 H) 8.62 (s, 1 H) 8.28-8.33 (m, 1 H) 8.25 (s, 1 H) 7.92-7.98
(m, 2 H) 7.77 (dd, J = 8.59, 2.02 Hz, 1 H) 7.47 (dd, J = 8.34, 4.29
Hz, 1 H) 6.09 (s, 2 H) 4.26 (t, J = 6.44 Hz, 2 H) 3.44-3.49 (m, 4
H) 2.69 (t, J = 6.32 Hz, 2 H) 2.33- 2.38 (m, 4 H). LC-MS 442. 18 48
##STR00140## 1-{2-[4-(3-Quinolin- 6-ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- pyrazol-1-yl]- ethyl}-pyrrolidin-
2-one 1H NMR (400 MHz, DMSO- D6) .delta. ppm 9.21 (s, 1 H) 8.88
(dd, J = 4.04, 1.77 Hz, 1 H) 8.67 (s, 1 H) 8.36 (d, J = 7.33 Hz, 1
H) 8.32 (s, 1 H) 7.97- 8.04 (m, 2 H) 7.82 (dd, J = 8.84, 2.02 Hz, 1
H) 7.52 (dd, J = 8.34, 4.29 Hz, 1 H) 6.14 (s, 2 H) 4.32 (t, J =
5.94 Hz, 2 H) 3.60 (t, J = 5.94 Hz, 2 H) 3.16 (t, J = 6.95 Hz, 2 H)
2.10 (t, J = 7.96 Hz, 2 H) 1.77-1.85 (m, J = 7.58 Hz, 2 H). LC-MS
440. 18 49 ##STR00141## 6-(6-Methyl- [1,2,3]triazolo[4,5-
b]pyrazin-1- ylmethyl)-quinoline 1H NMR (400 MHz, DMSO- D6) .delta.
ppm 8.78 (s, 1 H) 8.35 (d, J = 7.58 Hz, 1 H) 8.00 (d, J = 8.84 Hz,
1 H) 7.91 (d, J = 1.52 Hz, 1 H) 7.74 (dd, J = 8.59, 2.02 Hz, 1 H)
7.52 (dd, J = 8.34, 4.29 Hz, 1 H) 6.16 (s, 2 H) 2.73 (s, 1 H).
LC-MS 277. 17 50 ##STR00142## 6-(6-Vinyl- [1,2,3]triazolo[4,5-
b]pyrazin-1- ylmethyl)-quinoline 1H NMR (400 MHz, DMSO- D6) .delta.
ppm 9.08 (s, 1 H) 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 8.31-8.40 (m, 1
H) 8.01 (d, J = 8.84 Hz, 1 H) 7.95 (d, J = 1.52 Hz, 1 H) 7.79 (dd,
J = 8.84, 2.02 Hz, 1 H) 7.52 (dd, J = 8.34, 4.04 Hz, 1 H) 7.10 (dd,
J = 17.56, 10.99 Hz, 1 H) 6.58-6.64 (m, 1 H) 6.17 (s, 2 H) 5.86 (d,
J = 11.87 Hz, 1 H). LC-MS 289. 17 51 ##STR00143## 3-Quinolin-6-
ylmethyl-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- ylamine 1H NMR (400
MHz, DMSO- D6) .delta. ppm 8.88 (dd, J = 4.17, 1.64 Hz, 1 H)
8.30-8.38 (m, 1 H) 8.02 (s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 7.78
(d, J = 1.52 Hz, 1 H) 7.67 (dd, J = 8.84, 2.02 Hz, 1 H) 7.48- 7.56
(m, 3 H) 5.86 (s, 2 H). LC-MS 278. 15 52 ##STR00144## 6-(6-Ethyl-
[1,2,3]triazolo[4,5- b]pyrazin-1- ylmethyl)-quinoline 1H NMR (400
MHz, DMSO- D6) .delta. ppm 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 8.81
(s, 1 H) 8.34 (d, J = 8.34 Hz, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 7.95
(s, 1 H) 7.77 (dd, J = 8.59, 2.02 Hz, 1 H) 7.52 (dd, J =8.34, 4.04
Hz, 1 H) 6.16 (s, 2 H) 3.05 (q, J = 7.58 Hz, 2 H) 1.31 (t, J = 7.58
Hz, 3 H). LC-MS 291. 17 53 ##STR00145## 6- [1,2,3]Triazolo[4,5-
b]pyrazin-1- ylmethyl-quinoline 1H NMR (400 MHz, DMSO- D6) .delta.
ppm 8.82-9.00 (m, 3 H) 8.34 (dd, J = 8.56, 1.01 Hz, 1 H) 8.00 (d, J
= 8.81 Hz, 1 H) 7.95 (d, J = 1.51 Hz, 1 H) 7.76 (dd, J = 8.69, 2.14
Hz, 1 H) 7.52 (dd, J = 8.31, 4.28 Hz, 1 H) 6.22 (s, 2 H). LC-MS
263. 17 54 ##STR00146## 6-Bromo-1- [1-(2,3-dihydro-
benzo[1,4]-dioxin- 6-yl)-ethyl]-1H- [1,2,3]triazolo[4,5- b]pyrazine
1H NMR (400 MHz, DMSO- d6) .delta. ppm 8.97 (s, 1 H) 6.94 (d, J =
2.02 Hz, 1 H) 6.85- 6.90 (m, 1 H) 6.79-6.84 (m, 1 H) 6.21-6.29 (m,
J = 7.07 Hz, 1 H) 2.00-2.05 (m, 3 H). LC-MS 362, 364. 14 55
##STR00147## 6-[6-(1-Ethoxy- vinyl)- [1,2,3]triazolo[4,5-
b]pyrazin-1- ylmethyl]-quinoline 1H NMR (400 MHz, DMSO- d6) .delta.
ppm 9.12 (s, 1 H) 8.90 (s, 1 H) 8.35 (d, J = 8.34 Hz, 1 H)
7.92-8.07 (m, 2 H) 7.81 (dd, J = 8.59, 2.02 Hz, 1 H) 7.54 (dd, J =
8.34, 4.04 Hz, 1 H) 6.20 (s, 2 H) 5.54 (d, J = 2.27 Hz, 1H) 4.75
(d, J = 2.53 Hz, 1 H) 4.03 (q, J = 6.99 Hz, 2 H) 1.41 (t, J = 6.95
Hz, 3 H). LC-MS 333. 20 56 ##STR00148## 1-[1-(2,3-Dihydro-
benzo[1,4]dioxin-6- yl)-ethyl]-6-(1- methyl-1H-pyrazol- 4-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazine 1H NMR (400 MHz, DMSO- D6) .delta.
ppm 9.16 (s, 1 H) 8.63 (s, 1 H) 8.29 (s, 1H) 7.00 (d, J = 2.27 Hz,
1 H) 6.93 (dd, J = 8.46, 2.15 Hz, 1 H) 6.81 (d, J = 8.34 Hz, 1 H)
6.23 (d, J = 7.33 Hz, 1 H) 4.18 (s, 4 H) 3.94 (s, 3 H) 2.07 (d, J =
7.33 Hz, 3 H). LC-MS 364. 17 57 ##STR00149## Methyl-(3-quinolin-
6-ylmethyl-3H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl)-amine 1H NMR
(400 MHz, DMSO- D6) .delta. ppm 8.88 (dd, J = 4.17, 1.64 Hz, 1 H)
8.34 (s, 1 H) 8.19 (s, 1 H) 8.03 (s, 1 H) 7.97-8.03 (m, 1 H) 7.90
(s, 1 H) 7.74 (dd, J = 8.59, 1.77 Hz, 1 H) 7.52 (dd, J = 8.34, 4.04
Hz, 1 H) 5.84-5.91 (m, 2 H) 2.88 (dd, J = 4.80 Hz, 3 H). LC-MS 292.
15 58 ##STR00150## 2-[4-(3-Quinolin- 6-ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)-pyrazol-1-yl]- ethanol 1H NMR
(400 MHz, DMSO- d6) .delta. ppm 9.06-9.30 (m, 1 H) 8.89 (dd, J =
4.17, 1.64 Hz, 1 H) 8.64 (s, 1 H) 8.33-8.40 (m, 1 H) 8.33 (s, 1 H)
7.94- 8.09 (m, 2 H) 7.82 (dd, J = 8.59, 2.02 Hz, 1 H) 7.53 (dd, J =
8.34, 4.04 Hz, 1 H) 6.15 (s, 2 H) 5.01 (s, 1 H) 4.24 (t, J = 5.31
Hz, 2 H) 3.78 (t, J = 5.31 Hz, 2 H). LC-MS 373. 18 59 ##STR00151##
1-[4-(3-Quinoline- 6-ylmethyl-3H- [1,2,3]triazolo[4,5- b]pyrazin-5-
yl)-pyrazol-1-yl]- propan-2-ol 1H NMR (400 MHz, DMSO- d6) .delta.
ppm 9.24 (s, 1 H) 8.90 (dd, J = 4.17, 1.64 Hz, 1 H) 8.62 (s, 1 H)
8.38 (d, J = 7.58 Hz, 1 H) 8.33 (s, 1 H) 7.93- 8.08 (m, 2 H) 7.83
(dd, J = 8.59, 2.02 Hz, 1 H) 7.54 (dd, J = 8.34, 4.04 Hz, 1H) 6.16
(s, 2 H) 4.88-5.17 (m, 1 H) 3.93-4.24 (m, 3 H) 1.08 (d, J = 6.06
Hz, 3 H). LC-MS 387. 18 60 ##STR00152## 1-[(S)-1- (2,3-Dihydro-
benzo[1,4]dioxin-6- yl)-ethyl]-6-(1- methyl-1H-pyrazol- 4-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazine 1H NMR (400 MHz, DMSO- D6) .delta.
ppm 9.16 (s, 1 H) 8.63 (s, 1 H) 8.29 (s, 1H) 7.00 (d, J = 2.27 Hz,
1 H) 6.93 (dd, J = 8.46, 2.15 Hz, 1 H) 6.81 (d, J = 8.34 Hz, 1 H)
6.23 (d, J = 7.33 Hz, 1 H) 4.18 (s, 4 H) 3.94 (s, 3 H) 2.07 (d, J =
7.33 Hz, 3 H). LC-MS 364. 25 61 ##STR00153## 6-{6-[(R)-1-
(Tetrahydro-furan- 3-yl)-1H-pyrazol- 4-yl]- [1,2,3]triazolo[4,5-
b]pyrazin-1- ylmethyl}-quinoline 1H NMR (300 MHz, DMSO- d6) .delta.
ppm 9.23 (s, 1 H) 8.88 (dd, J = 4.14, 1.70 Hz, 1 H) 8.72 (s, 1 H)
8.34 (s, 1 H) 8.33 (s, 1 H) 7.97-8.05 (m, 2 H) 7.81 (dd, J = 8.85,
2.07 Hz, 1 H) 7.52 (dd, J = 8.19, 4.24 Hz, 1 H) 6.15 (s, 2 H)
5.08-5.19 (m, 1 H) 3.91-4.12 (m, 3 H) 3.79-3.88 (m, J = 5.46 Hz, 1
H) 2.29-2.43 (m, 1 H). LC-MS 399. 18 62 ##STR00154## 6-{6-[(S)-1-
(Tetrahydro-furan- 3-yl)-1H-pyrazol- 4-yl]- [1,2,3]triazolo[4,5-
b]pyrazin-1- ylmethyl}-quinoline 1H NMR (300 MHz, DMSO- d6) .delta.
ppm 9.25 (s, 1 H) 8.90 (dd, J = 4.14, 1.70 Hz, 1 H) 8.73 (s, 1 H)
8.37 (d, J = 8.85 Hz, 1 H) 8.34 (s, 1 H) 7.98- 8.07 (m, 2 H) 7.83
(dd, J = 8.67, 2.07 Hz, 1 H) 7.53 (dd, J = 8.29, 4.14 Hz, 1 H) 6.16
(s, 2 H) 5.09-5.20 (m, J = 7.91 Hz, 1 H) 3.94-4.07 (m, 3 H)
3.80-3.91 (m, 1 H) 2.26- 2.44 (m, 2 H). LC-MS 399. 18 63
##STR00155## 6-[6-(3,5-Dimethyl- 1H-pyrazol-4-yl)-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl methyl]-quinoline 1H NMR (400
MHz, DMSO- d6) .delta. ppm 8.94 (dd, J = 4.42, 1.64 Hz, 1 H) 8.91
(s, 1 H) 8.43-8.49 (m, 1 H) 8.01-8.09 (m, 2 H) 7.84 (dd, J = 8.72,
1.89 Hz, 1 H) 7.61 (dd, J = 8.34, 4.29 Hz, 1 H) 6.18 (s, 2 H) 2.38
(s, 6 H). LC-MS 357. 17 64 ##STR00156## 6-[6-(2-Methyl-5-
trifluoromethyl-2H- pyrazol-3-yl)- [1,2,3]triazolo[4,5-
b]pyrazin-1- ylmethyl]-quinoline 1H NMR (400 MHz, DMSO- d6) .delta.
ppm 9.39 (s, 1 H) 8.82- 8.97 (m, 1 H) 8.31-8.44 (m, 1 H) 8.10 (d, J
= 1.77 Hz, 1 H) 8.03 (d, J = 8.84 Hz, 1 H) 7.79-7.89 (m, 2 H) 7.55
(dd, J = 8.21, 4.17 Hz, 1 H) 6.28 (s, 2 H) 4.22 (s, 3 H). LC-MS
411. 20 65 ##STR00157## 2-Methyl-2- [4-(3-quinolin- 6-ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl]-propionic acid methyl ester
1H NMR (400 MHz, DMSO- d6) .delta. ppm 9.29 (s, 1 H) 8.82- 8.98 (m,
2 H) 8.38 (d, J = 7.33 Hz, 1 H) 8.35 (s, 1 H) 7.99-8.06 (m, 2 H)
7.83 (dd, J = 8.72, 1.89 Hz, 2 H) 7.54 (dd, J = 8.34, 4.04 Hz, 2 H)
6.17 (s, 2 H) 3.64 (s, 3 H) 1.85 (s, 6 H). LC-MS 429. 17 66
##STR00158## [4-(3-Quinolin-6- ylmethyl-3H-
[1,2,3]triazolo[4,5-
b]pyrazin-1- yl)-pyrazol-1-yl]- acetic acid methyl ester 1H NMR
(400 MHz, DMSO- d6) .delta. ppm 9.24 (s, 1 H) 8.89 (dd, J = 4.17,
1.64 Hz, 1 H) 8.68 (s, 1 H) 8.33-8.41 (m, 2 H) 8.02 (d, J = 8.84
Hz, 1 H) 7.99 (s, 1 H) 7.83 (dd, J = 8.59, 2.02 Hz, 1 H) 7.53 (dd,
J =8.34, 4.29 Hz, 1 H) 6.16 (s, 2 H) 5.23 (s, 2 H) 3.70 (s, 3 H).
LC-MS 401. 17 67 ##STR00159## 2-[4-(3-Quinolin-6- ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl)-pyrazol-1-yl]- isobutyramide
1H NMR (400 MHz, DMSO- d6) .delta. ppm 9.29 (s, 1 H) 8.89 (dd, J =
4.17, 1.64 Hz, 1 H) 8.80 (s, 1 H) 8.35-8.42 (m, 1 H) 8.33 (s, 1 H)
7.98-8.05 (m, 2 H) 7.83 (dd, J = 8.72, 1.89 Hz, 1 H) 7.53 (dd, J =
8.34, 4.29 Hz, 1 H) 7.26 (s, 1 H) 7.07 (s, 1 H) 6.17 (s, 2 H) 1.78
(s, 6 H). LC-MS 414. 24 68 ##STR00160## 2-Methyl-2- [4-(3-quinolin-
6-ylmethyl-3H- [1,2,3]triazolo[4,5- b]pyrazin-1- yl)-pyrazol-1-yl]-
propionic acid 1H NMR (400 MHz, DMSO- d6) .delta. ppm 9.25 (s, 1 H)
8.88 (dd, J = 4.04, 1.77 Hz, 1 H) 8.73 (s, 1 H) 8.37 (dd, J = 8.34,
1.52 Hz, 1 H) 8.24 (s, 1 H) 7.98-8.05 (m, 2 H) 7.82 (dd, J = 8.84,
2.02 Hz, 1 H) 7.52 (dd, J = 8.34, 4.04 Hz, 1 H) 6.15 (s, 2 H) 1.70
(s, 6 H). LC-MS 415. 24 69 ##STR00161## 6-[6-(2H- Pyrazol-3-yl)-
[1,2,3]triazolo[4,5- b]pyrazin-1- ylmethyl]-quinoline 1H NMR (300
MHz, DMSO- d6) .delta. ppm 13.53 (s, 1 H) 9.45 (s, 1 H) 8.90 (dd, J
= 3.96, 1.70 Hz, 1 H) 8.36 (d, J = 1.32 Hz, 1 H) 7.93-8.11 (m, 2 H)
7.85 (dd, J = 8.67, 1.88 Hz, 1 H) 7.54 (dd, J = 8.29, 4.14 Hz, 1 H)
6.98-7.11 (m, 1 H) 6.21 (s, 2 H). LC-MS 329. 17
TABLE-US-00004 TABLE 4 Ex- am- ple Structure Name NMR/LC-MS Method
70 ##STR00162## 1-[1-(quinolin-6- ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-3-ol 1H NMR (500
MHz, DMSO- d6) .delta. ppm 3.63-3.72 (m, 4 H) 4.40-4.49 (m, 1 H)
5.91 (s, 2 H) 7.54 (dd, J = 8.52, 4.12 Hz, 1H) 7.77 (dd, J = 8.52,
1.92 Hz, 1 H) 7.94 (s, 1 H) 8.02 (d, J = 8.52 Hz, 1 H) 8.21 (br.
s., 1 H) 8.36 (d, J = 7.97 Hz, 1 H) 8.85-8.93 (m, 1 H) (two
aliphatic protons not resolved, due to water peak). LC-MS 348. 26
71 ##STR00163## N-(2-methoxyethyl)- 1-(quinolin-6- ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (400 MHz, DMSO- d6)
.delta. ppm 3.21 (s, 3 H) 3.45- 3.54 (m, 4 H) 5.88 (s, 2 H) 7.53
(dd, J = 8.34, 4.29 Hz, 1 H) 7.74 (dd, J = 8.84, 2.02 Hz, 1 H) 7.92
(d, J = 1.26 Hz, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.10 (s, 1 H) 8.29
(t, J = 5.05 Hz, 1 H) 8.36 (d, J = 7.33 Hz, 1 H) 8.89 (dd, J =
4.17, 1.64 Hz, 1 H). LC-MS 335. 26 72 ##STR00164## N-{(3S)-1-[1-
(quinolin-6- ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]pyrrolidin-3- yl}acetamide 1H NMR (500 MHz, DMSO- d6) .delta.
ppm 1.79-1.84 (m, 3 H) 3.64-3.74 (m, 2 H) 3.76-3.84 (m, 2 H)
4.35-4.44 (m, 1 H) 5.91 (s, 2 H) 7.54 (dd, J = 8.20, 4.40 Hz, 1 H)
7.77 (dd, J = 8.20, 2.20 Hz, 1 H) 7.95 (s, 1 H) 8.01 (d, J = 8.79
Hz, 1 H) 8.16 (br. s., 1 H) 8.22 (br. s., 1 H) 8.36 (d, J = 8.24
Hz, 1 H) 8.87-8.93 (m, 1 H) (two aliphatic proton not resolved, due
to solvent peak). LC-MS-389. 26 73 ##STR00165## 2-{isopropyl[1-
(quinolin-6- ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]amino}ethanol 1H NMR (500 MHz, DMSO- d6) .delta. ppm 1.20 (d, J
= 6.32 Hz, 6 H) 3.54-3.66 (m, 4 H) 3.87-3.96 (m, 1 H) 5.84-5.96 (m,
2 H) 7.54 (dd, J = 8.10, 4.26 Hz, 1 H) 7.78 (dd, J = 8.50, 1.80 Hz,
1 H) 7.98-8.03 (m, 2 H) 8.35 (d, J = 8.52 Hz, 1 H) 8.40-8.43 (m, 1
H) 8.87- 8.91 (m, 1 H). LC-MS 364. 26 74 ##STR00166## 2-{ethyl[1-
(quinolin-6- ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]amino}ethanol 1H NMR (500 MHz, DMSO- d6) .delta. ppm 1.13 (t, J
= 7.20 Hz, 3 H) 3.62-3.71 (m, 4 H) 5.89 (s, 2 H) 7.54 (dd, J =
8.10, 4.37 Hz, 1 H) 7.78 (dd, J = 8.10, 1.95 Hz, 1 H) 7.98- 8.01
(m, 1 H) 8.01-8.03(m, 1 H) 8.33-8.36 (m, 1 H) 8.37 (d, J = 5.50 Hz,
1 H) 8.89 (d, J = 3.57 Hz, 1 H) (two aliphatic protons not
resolved, due to water peak). LC-MS 350. 26 75 ##STR00167##
3-methyl-4-[1- (quinolin-6- ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]piperazin-2-one 1H NMR (500 MHz, DMSO- d6) .delta.
ppm 1.38 (d, J = 6.59 Hz, 3 H) 3.52 (br. s., 2 H) 5.95 (s, J = 5.22
Hz, 2 H) 7.54 (dd, J = 8.10, 4.12 Hz, 1 H) 7.77 (dd, J = 8.40, 2.00
Hz, 1 H) 7.95-8.03 (m, 2 H) 8.10 (s, 1 H) 8.35 (d, J = 8.24 Hz, 1
H) 8.48-8.54 (m, 1 H) 8.89 (d, J = 4.12 Hz, 1 H) (three aliphatic
protons not resolved, due to water peak). LC-MS 375. 26 76
##STR00168## {(2S)-1-[1- (quinolin-6- ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-2- yl}methanol 1H
NMR (500 MHz, DMSO- d6) .delta. ppm 1.97 (br. s., 2 H) 2.03 (br.
s., 2 H) 3.65 (s, 2 H) 5.89 (s, 2 H) 7.54 (dd, J = 8.10, 3.85 Hz, 1
H) 7.79 (dd, J = 8.10, 2.20 Hz, 1 H) 7.96- 8.03 (m, 2 H) 8.23-8.31
(m, 1 H) 8.37 (d, J = 7.14 Hz, 1 H) 8.86-8.94 (m, 1 H) (three
aliphatic protons not resolved, due to water peak). LC-MS 362. 26
77 ##STR00169## 2,2'-{[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]imino}diethanol 1H NMR (500
MHz, DMSO- d6) .delta. ppm 3.64 (t, J = 4.67 Hz, 4 H) 3.75 (t, J =
5.20 Hz, 4 H) 5.89 (s, 2 H) 7.54 (dd, J = 8.10, 4.12 Hz, 1 H) 7.79
(dd, J = 8.24, 1.37 Hz, 1 H) 7.99-8.04 (m, 2 H) 8.37 (d, J = 8.24
Hz, 1 H) 8.40-8.43 (m, 1 H) 8.87-8.92 (m, 1 H). LC-MS 366. 26 78
##STR00170## 2-{methyl[1- (quinolin-6- ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}ethanol 1H NMR (500 MHz,
DMSO- d6) .delta. ppm 3.23 (br. s., 3 H) 3.64 (t, J = 5.22 Hz, 2 H)
3.75 (t, J = 5.22, 0.01 Hz, 2 H) 5.90 (s, 2 H) 7.54 (dd, J = 8.10,
4.26 Hz, 1 H) 7.78 (d, J = 8.52 Hz, 1 H) 7.98 (s, 1 H) 8.01 (d, J =
8.52 Hz, 1 H) 8.36 (d, J = 8.52 Hz, 1 H) 8.41 (s, 1 H) 8.84-8.95
(m, 1 H). LC-MS 336. 26 79 ##STR00171## 1-[1-(quinolin-6-
ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]-14-diazepan-
5-one 1H NMR (500 MHz, DMSO- d6) .delta. ppm 2.65-2.74 (m, 2 H)
3.83-4.06 (m, 2 H) 5.93 (s, 2 H) 7.54 (dd, J = 8.20, 3.85 Hz, 1 H)
7.61 (br. s., 1 H) 7.80 (dd, J = 8.40, 2.00 Hz, 1 H) 7.98-8.03 (m,
2 H) 8.32- 8.41 (m, 1 H) 8.53-8.56 (m, 1 H) 8.85-8.93 (m, 1 H)
(four aliphatic protons not resolved, due to water peak). LC-MS
375. 26 80 ##STR00172## {1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]piperidin-4- yl}methanol 1H
NMR (500 MHz, DMSO- d6) .delta. ppm 1.12-1.21 (m, 2 H) 1.71-1.80
(m, 3 H) 5.91 (s, 2 H) 7.54 (dd, J = 8.24, 4.12 Hz, 1 H) 7.76 (dd,
J = 8.00, 1.92 Hz, 1 H) 7.96 (s, 1 H) 8.01 (d, J = 8.79 Hz, 1 H)
8.35 (d, J = 7.97 Hz, 1 H) 8.52-8.57 (m, 1 H) 8.90 (d, J = 4.40 Hz,
1 H) (six aliphatic protons not resolved, due to water peak). LC-MS
376. 26 81 ##STR00173## 6-({6-[3- (methylsulfonyl)-
pyrrolidin-1-yl]-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl}methyl)quinoline 1H NMR (500 MHz, DMSO- d6) .delta. ppm 3.10 (s,
3 H) 3.68- 3.76 (m, 1 H) 3.79-3.87 (m, 1 H) 3.92-4.09 (m, 2 H)
4.11- 4.22 (m, 1 H) 5.94 (s, 2 H) 7.53 (dd, J = 8.10, 4.26 Hz, 1 H)
7.78 (dd, J = 8.38, 1.79 Hz, 1 H) 7.97 (s, 1 H) 8.01 (d, J = 8.52
Hz, 1 H) 8.24- 8.31 (m, 1 H) 8.36 (d, J = 7.97 Hz, 1 H) 8.89 (d, J
= 4.12 Hz, 1 H)(two aliphatic protons not resolved, due to solvent
peak). LC-MS 410. 26 82 ##STR00174## 1-ethyl-3-methyl-4-
[1-(quinolin-6- ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]piperazin-2-one 1H NMR (500 MHz, DMSO- d6) .delta. ppm 1.06 (t,
J = 7.00 Hz, 3 H) 1.38 (d, J = 6.59 Hz, 3 H) 5.94 (s, 2 H) 7.54
(dd, J = 8.20, 4.12 Hz, 1 H) 7.77 (d, J = 8.52 Hz, 1 H) 7.96- 8.05
(m, 2 H) 8.35 (d, J = 7.69 Hz, 1 H) 8.47-8.54 (m, 1 H) 8.86-8.92
(m, 1 H) (seven aliphatic protons not resolved, due to water peak).
LC-MS 403. 26 83 ##STR00175## 4-[1-(quinolin-6- ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]piperazin-2-one 1H NMR (500
MHz, DMSO- d6) .delta. ppm 3.88-3.99 (m, J = 1.10 Hz, 2 H)
4.21-4.32 (m, 2 H) 5.95 (s, 2 H) 7.54 (dd, J = 8.24, 4.40 Hz, 1 H)
7.78 (d, J = 8.52 Hz, 1 H) 7.97 (s, 1 H) 8.02 (d, J = 9.61 Hz, 1 H)
8.16-8.23 (m, 1 H) 8.36 (d, J = 7.97 Hz, 1 H) 8.47-8.57 (m, 1 H)
8.86-8.94 (m, 1 H) (two aliphatic protons not resolved, due to
water peak). LC-MS 361. 26 84 ##STR00176## 2{propyl[1- (quinolin-6-
ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}ethanol 1H
NMR (500 MHz, DMSO- d6) .delta. ppm 0.85 (t, J = 7.00 Hz, 3 H)
1.52-1.63 (m, 2 H) 3.57 (t, J = 9.89 Hz, 2 H) 3.60-3.65 (m, 2 H)
3.69 (t, J = 4.94 Hz, 2 H) 5.89 (s, 2 H) 7.54 (dd, J = 8.38, 3.98
Hz, 1 H) 7.77 (d, J = 6.87 Hz, 1 H) 7.97-8.03 (m, 2 H) 8.32-8.40
(m, 2 H) 8.89 (d, J = 4.12 Hz, 1 H). LC-MS 364. 26 85 ##STR00177##
N-methyl-N-[2- methylsulfonyl)- ethyl]-1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6)
.delta. ppm 3.01 (s, 3 H) 3.49- 3.51 (m, 2 H) 4.07 (d, J = 6.59 Hz,
2 H) 5.82-6.06 (m, 2 H) 7.54 (dd, J = 8.10, 4.12 Hz, 1 H) 7.80 (d,
J = 8.79 Hz, 1 H) 7.98-8.04 (m, 2 H) 8.37 (d, J = 8.24 Hz, 1 H)
8.39- 8.42 (m, 1 H) 8.90 (d, J = 5.77 Hz, 1 H) (three aliphatic
protons not resolved, due to water and solvent peaks). LC-MS 398.
26 86 ##STR00178## 1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl piperidine-4- carbonitrile 1H
NMR (500 MHz, DMSO- d6) .delta. ppm 1.75-1.83 (m, 2 H) 1.95-2.02
(m, 2 H) 3.58- 3.62 (m, 4 H) 5.92-5.94 (m, 2 H) 7.54 (dd, J = 8.20,
4.12 Hz, 1 H) 7.77 (dd, J = 8.20, 2.00 Hz, 1 H) 7.94-7.99 (m, 1 H)
8.02 (d, J = 8.52 Hz, 1 H) 8.36 (d, J = 8.24 Hz, 1 H) 8.51-8.61 (m,
1 H) 8.83-8.95 (m, 1 H) (one aliphatic proton not resolved, due to
solvent peak). LC-MS 371. 26 87 ##STR00179## N-[(5-ethyl-124-
oxadiazol-3- yl)methyl]-N- methyl-1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6)
.delta. ppm 1.20 (t, J = 7.42 Hz, 3 H) 2.85 (q, J = 7.42 Hz, 2 H)
5.06 (s, 2 H) 5.90 (s, 2 H) 7.54 (dd, J = 8.20, 4.10 Hz, 1 H) 7.73
(dd, J = 8.20, 1.65 Hz, 1 H) 7.92-7.98 (m, 2 H) 8.33 (d, J = 7.69
Hz, 1 H) 8.49-8.54 (m, 1 H) 8.90 (d, J = 4.00 Hz, 1 H) (three
aliphatic protons not resolved, due to water and solvent peaks).
LC-MS 402. 26 88 ##STR00180## 13-dimethyl-4- [1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]piperazin-2-one 1H NMR (500 MHz, DMSO- d6) .delta. ppm 1.38 (d,
J = 6.59 Hz, 3 H) 2.89-2.91 (m, 3 H) 5.94 (s, 2 H) 7.54 (dd, J =
8.20, 4.12 Hz, 1 H) 7.78 (d, J = 8.52 Hz, 1 H) 7.94-8.05 (m, 2 H)
8.35 (d, J = 7.97 Hz, 1 H) 8.48-8.59 (m, 1 H) 8.89 (br. s., 1 H)
(five aliphatic protons not resolved, due to water peak). LC-MS
389. 26 89 ##STR00181## 1-methyl- 4-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]piperazin-2-one 1H NMR (500
MHz, DMSO- d6) .delta. ppm 2.92 (s, 3 H) 3.46- 3.54 (m, 2 H) 4.03
(t, J = 5.22 Hz, 2 H) 4.28-4.37 (m, 2 H) 5.96 (s, 2 H) 7.54 (dd, J
= 8.20, 4.40 Hz, 1 H) 7.78 (dd, J = 8.20, 1.92 Hz, 1 H) 7.96- 7.99
(m, 1 H) 8.02 (d, J = 9.06 Hz, 1 H) 8.37 (d, J = 7.97 Hz, 1 H)
8.53-8.56 (m, 1 H) 8.85 - 8.95 (m, 1 H). LC-MS 375. 26 90
##STR00182## {3-methyl-1- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- piperidin-3- yl}methanol 1H NMR
(500 MHz, DMSO- d6) .delta. ppm 0.73-0.91 (m, 3 H) 1.22-1.40 (m, 1
H) 1.55- 1.66 (m, 3 H) 3.12-3.23 (m, 2 H) 3.59-3.69 (m, 2 H) 3.78-
3.88 (m, 2 H) 5.89 (s, 2 H) 7.54 (dd, J = 8.38, 3.98 Hz, 1 H) 7.77
(dd, J = 8.10, 2.33 Hz, 1 H) 7.97 (s, 1 H) 8.01 (d, J = 8.79 Hz, 1
H) 8.35 (d, J = 7.97 Hz, 1 H) 8.47-8.55 (m, 1 H) 8.84-8.94 (m, 1
H). LC-MS 390. 26 91 ##STR00183## N-[(3-ethyl-124- oxadiazol-5-
yl)methyl]-N- methyl-1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6)
.delta. ppm 1.10 (t, J = 7.14 Hz, 3 H) 5.21 (s, 2 H) 5.87 (s, 2 H)
7.54 (dd, J = 8.52, 4.40 Hz, 1 H) 7.66 (d, J = 7.97 Hz, 1 H) 7.90
(s, 1 H) 7.94 (d, J = 8.24 Hz, 1 H) 8.32 (d, J = 7.42 Hz, 1 H)
8.49-8.60 (m, 1 H) 8.84-8.94 (m, 1 H) (five aliphatic protons not
resolved, due to water peak). LC-MS 402. 26 92 ##STR00184##
6-[(6-{4-[2-(1H- pyrazol-1- yl)ethyl]piperidin- 1-yl}-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl)methyl]quinoline 1H NMR (500
MHz, DMSO- d6) .delta. ppm 1.17 (s, 2 H) 1.47- 1.58 (m, 1 H)
1.67-1.81 (m, 4 H) 4.16 (t, J = 6.87 Hz, 2 H) 5.91 (s, 2 H) 6.23
(s, 1 H) 7.42 (s, 1 H) 7.54 (dd, J = 8.24, 4.12 Hz, 1 H) 7.72 (s, 1
H) 7.76 (d, J = 8.79 Hz, 1 H) 7.96 (s, 1 H) 8.01 (d, J = 8.24 Hz, 1
H) 8.35 (d, J = 8.24 Hz, 1 H) 8.51-8.58 (m, 1 H) 8.85-8.92 (m, 1 H)
(four aliphatic protons not resolved, due to water or solvent
peaks). LC-MS 440. 26 93 ##STR00185## N-methyl-N-[(3- pyridin-2-
ylisoxazol-5- yl)methyl]- 1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6)
.delta. ppm 5.18 (s, 2 H) 5.92 (s, 2 H) 6.90-6.96 (m, 1 H) 7.41
(dd, J = 8.24, 3.30 Hz, 1 H) 7.47-7.53 (m, 1 H) 7.74 (dd, J = 8.40,
1.60 Hz, 1 H) 7.89 (d, J = 9.06 Hz, 1 H) 7.94 (d, J = 6.32 Hz, 3 H)
8.23 (d, J = 7.69 Hz, 1 H) 8.54 (d, J = 8.20 Hz, 1 H) 8.59-8.65 (m,
1 H) 8.78-8.85 (m, 1 H) (three aliphatic protons not resolved, due
to water peak). LC-MS 450. 26 94 ##STR00186## {4-methyl-1-[1-
(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]piperidin-4- yl}methanol 1H NMR (500 MHz, DMSO- d6) .delta. ppm
0.73-0.91 (m, 3 H) 1.22-1.40 (m, 1 H) 1.55- 1.66 (m, 3 H) 3.12-3.23
(m, 2 H) 3.59-3.69 (m, 2 H) 3.78 3.88 (m, 2 H) 5.89 (s, 2 H) 7.54
(dd, J = 8.38, 3.98 Hz, 1 H) 7.77 (dd, J = 8.10, 2.33 Hz, 1 H) 7.97
(s, 1 H) 8.01 (d, J = 8.79 Hz, 1 H) 8.35 (d, J = 7.97 Hz, 1 H)
8.47-8.55 (m, 1 H) 8.84-8.94 (m, 1 H) (four aliphatic protons not
resolved, due to water peak). LC-MS 390. 26 95 ##STR00187##
N-[(5-cyclopropyl- 1,2,4-oxadiazol-3- yl)methyl]N-methyl-
1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
amine 1H NMR (500 MHz, DMSO- d6) .delta. ppm 0.97-1.04 (m, 2 H)
1.15-1.22 (m, J = 7.97, 2.75 Hz, 2 H) 5.02 (s, 2 H) 5.89 (s, 2 H)
7.54 (dd, J = 8.20, 4.40 Hz, 1 H) 7.72 (d, J = 7.42 Hz, 1 H)
7.89-8.00 (m, 2 H) 8.32 (d, J = 7.69 Hz, 1 H) 8.43-8.59 (m, 1 H)
8.79- 8.99 (m, 1 H) (four aliphatic proton not resolved, due to
solvent and water peaks). LC-MS 414. 26 96 ##STR00188##
{(2S,4S)-4-fluoro- 1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-2- yl}methanol 1H
NMR (500 MHz, DMSO- d6) .delta. ppm 2.08-2.42 (m, 2 H) 3.79-3.86
(m, 2 H) 3.89- 3.96 (m, 1 H) 4.04-4.14 (m, 1 H) 4.37-4.48 (m, 1 H)
5.02- 5.10 (m, 1 H) 5.92 (s, 2 H) 7.54 (dd, J = 8.24, 4.40 Hz, 1 H)
7.75-7.83 (m, 1 H) 7.96- 8.07 (m, 2 H) 8.32-8.43 (m, J =8.24 Hz, 2
H) 8.83-8.95 (m, 1 H). LC-MS 380. 26 97 ##STR00189## 3-ethyl-4-
[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]piperazin-2-one 1H NMR (500 MHz, DMSO- d6) .delta. ppm 0.85 (t,
J = 7.14 Hz, 3 H) 1.78-2.03 (m, 2 H) 3.52-3.66 (m, 4 H) 4.24-4.46
(m, 1 H) 5.94 (s, 2 H) 7.54 (dd, J = 8.24, 4.40 Hz, 1 H) 7.76 (dd,
J = 8.20, Hz, 1 H) 7.95-8.02 (m, 2 H) 8.05 (s, 1 H) 8.34 (d, J =
8.24 Hz, 1 H) 8.49-8.56 (m, 1 H) 8.86-8.92 (m, 1 H). LC-MS 389. 26
98 ##STR00190## 6-{[6-(1,4,6,7- tetrahydro-5H- pyrazolo[4,3-
c]pyridin-5-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl]methyl}quinoline 1H NMR (500 MHz, DMSO- d6) .delta. ppm
2.77-2.83 (m, 2 H) 4.07-4.13 (m, 2 H) 4.77- 4.82 (m, 2 H) 5.94 (s,
2 H) 7.47-7.50 (m, 1 H) 7.54 (dd, J = 8.20, 4.12 Hz, 1 H) 7.75-
7.82 (m, 1 H) 7.96-8.04 (m, 2 H) 8.37 (d, J = 8.36 Hz, 1 H)
8.59-8.67 (m, 1 H) 8.85- 8.93 (m, 1 H). LC-MS 384. 26 99
##STR00191## (3R,4R)-1- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]piperidine-3,4- diol 1H NMR
(500 MHz, DMSO- d6) .delta. ppm 1.34-1.47 (m, 1 H) 1.87-2.00 (m, 1
H) 3.59- 3.66 (m, 2 H) 3.90-3.99 (m, 2H) 4.05-4.14 (m, 2 H) 5.90
(s, 2 H) 7.54 (dd, J = 8.24, 4.40 Hz, 1 H) 7.78 (dd, J = 8.20, 1.65
Hz, 1 H) 7.97 (s, 1 H) 8.02 (d, J = 8.79 Hz, 1 H) 8.36 (d, J = 8.52
Hz, 1 H) 8.50-8.57 (m, 1 H) 8.84-8.94 (m, 1 H). LC-MS 378. 26 100
##STR00192## 6-{[6-(3,4,6,7- tetrahydro-5H- imidazo[4,5-
c]pyridin-5-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]methyl}quinoline 1H NMR (500 MHz, DMSO- d6) .delta. ppm
2.74-2.88 (m, 2 H) 4.06-4.20 (m, 2 H) 4.73- 4.91 (m, 2 H) 5.95 (s,
2 H) 7.54 (dd, J = 8.24, 3.85 Hz, 1 H) 7.79 (dd, J = 8.20, 1.92 Hz,
1 H) 7.97 (s, 1 H) 7.99- 8.09 (m, 2 H) 8.36 (d, J = 7.69 Hz, 1 H)
8.63-8.70 (m, 1 H) 8.85-8.93 (m, 1 H). LC-MS 384. 26 101
##STR00193## 4-methyl-1- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]piperidin-4-ol 1H NMR (500
MHz, DMSO- d6) .delta. ppm 1.14 (s, 3 H) 1.42- 1.61 (m, 4 H)
4.01-4.22 (m, 4 H) 5.90 (s, 2 H) 7.54 (dd, J = 8.38, 4.26 Hz, 1 H)
7.76 (d, J = 6.32 Hz, 1 H) 7.96 (s, 1 H) 8.01 (d, J = 8.24 Hz, 1 H)
8.35 (d, J = 8.52 Hz, 1 H) 8.52-8.57 (m, 1 H) 8.86-8.91 (m, 1 H).
LC-MS 376. 26 102 ##STR00194## 6-({6-[4-(3-ethyl- 124-oxadiazol-5-
yl)piperidin-1- yl]-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl}methyl)quinoline 1H NMR (500 MHz, DMSO- D6) .delta. ppm 1.21 (t,
3 H) 1.69- 1.83 (m, 2 H) 2.09-2.17 (m, 2 H) 2.40-2.44 (m, 1 H)
2.65- 2.73 (m, 4 H) 4.43-4.58 (m, 2 H) 5.93 (s, 2 H) 7.52 (dd, J =
8.52, 4.40 Hz, 1 H) 7.73- 7.85 (m, 1H) 7.95-8.09 (m, 2 H) 8.29-8.40
(m, 1 H) 8.55- 8.67 (m, 1 H) 8.89 (d, J = 4.40 Hz, 1 H). LC-MS 442.
26 103 ##STR00195## {1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-2- yl}methanol 1H
NMR (500 MHz, DMSO- D6) .delta. ppm 1.91-2.01 (m, 2 H) 2.01-2.11
(m, 2 H) 3.61- 3.72 (m, 3 H) 4.23-4.37 (m, 2 H) 4.74-5.04 (m, 1 H)
5.89 (s, 2 H) 7.46-7.62 (m, 1 H) 7.79 (d, J = 6.59 Hz, 1 H) 7.94-
8.09 (m, 2 H) 8.27 (s, 1 H) 8.37 (d, 1 H) 8.89 (s, 1 H). LC-MS 362.
26 104 ##STR00196## 3-[(2-methyl-1H- imidazol-1- yl)methyl]-1-[1-
(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]pyrrolidin-3-ol 1H NMR (500 MHz, DMSO- D6) .delta. ppm 1.91-2.01
(m, 1 H) 2.12-2.25 (m, 1 H) 2.66 (s, 3 H) 3.65-3.93 (m, J = 82.13
Hz, 4 H) 4.32-4.47 (m, 2 H) 5.57-5.68 (m, 1 H) 5.92 (s, 2 H)
7.50-7.66 (m, 3 H) 7.70-7.80 (m, 1H) 7.89-7.96 (m, 1 H) 7.98-8.06
(m, 1 H) 8.20-8.28 (m, 1 H) 8.31-8.40 (m, 1 H) 8.90 (s, 1 H). LC-MS
442. 26 105 ##STR00197## (7R,8aS)-2- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]octahydro- pyrrolo[12-
a]pyrazin-7-ol 1H NMR (500 MHz, DMSO- D6) .delta. ppm 1.82-2.04 (m,
2 H) 2.44 (s, 2 H) 2.66-2.70 (m, 2 H) 3.14-3.20 (m, 2 H) 3.61-3.72
(m, 2 H) 4.38-4.48 (m, 2 H) 5.92-5.95 (m, 1 H) 5.95 (s, 2 H) 7.55
(dd, J = 8.52, 3.85 Hz, 1H) 7.73-7.83 (m, 1 H) 7.98 (s, 1 H) 8.02
(d, J = 8.79 Hz, 1 H) 8.33-8.41 (m, J = 1.37 Hz, 1 H) 8.53 (s, 1 H)
8.90 (d, J = 3.85 Hz, 1 H). LC-MS 403. 26 106 ##STR00198## 2-{3-
(hydroxymethyl)- 1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-3- yl}ethanol 1H
NMR (500 MHz, DMSO- D6) .delta. ppm 1.61-1.73 (m, 2 H) 1.76-1.87(m,
1 H) 1.92- 2.08 (m, 1 H) 2.44 (m, 2 H) 2.65-2.70 (m, 2 H) 3.15-3.22
(m, 2 H) 3.62-3.74 (m, 4H) 4.46-4.60 (m, 1 H) 4.78-4.99 (m, 1 H)
7.54 (dd, J = 8.24, 4.12 Hz, 1 H) 7.71-7.80 (m, 1 H) 7.94 (s, 1 H)
7.97-8.06 (m, J =8.52 Hz, 1 H) 8.14-8.21 (m, 1 H) 8.29-8.40 (m, 1
H) 8.89 (s, 1 H). LC-MS 406. 26 107 ##STR00199## {(3R,4R)-
3,4-dimethyl- 1-[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]pyrrolidin-3- yl}methanol 1H NMR (500 MHz, DMSO-
D6) .delta. ppm 0.88 (s, 3 H) 0.95 (d, J = 6.59 Hz, 4 H) 3.08- 3.24
(m, 2 H) 3.62-3.70 (m, 2 H) 3.80-3.95 (m, 2 H) 4.80 4.93 (m, 1 H)
5.90 (s, 2 H) 7.48-7.58 (m, 1 H) 7.72-7.81 (m, 1 H) 7.88-7.96 (m, 1
H) 7.97-8.05 (m, 1 H) 8.16 (s, 1 H) 8.27-8.40 (m, 1 H) 8.83- 8.97
(m, 1 H). LC-MS 390. 26 108 ##STR00200## 6-({6-[3-
(difluoromethyl)- 5,6-dihydro[1,2,4]- triazolol[4,3-
a]pyrazin-7(8H)- yl]-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl}methyl)quinoline 1H NMR (500 MHz, DMSO- D6) .delta. ppm 4.31 (s,
5 H) 5.24 (s, 2 H) 6.00 (s, 2 H) 7.51- 7.56 (m, 1 H) 7.78-7.83 (m,
1 H) 7.99-8.04 (m, 2 H) 8.35- 8.39 (m, 1 H) 8.70-8.77 (m, 1 H) 8.89
(d, J = 4.12 Hz, 1 H). LC-MS 435. 26 109 ##STR00201##
2-(dimethylamino)- 2-{1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrazin-6 -yl]piperidin-4-
yl}acetamide 1H NMR (500 MHz, DMSO- D6) .delta. ppm 1.24-1.37 (m, 2
H) 1.68-1.77 (m, 1 H) 1.86- 2.00 (m, 1 H) 2.27-2.36 (m, 1 H) 2.41
(s, 3 H) 2.67 (s, 3 H) 2.71-2.83 (m, 1 H) 3.01-3.13 (m, 2 H) 3.18
(s, 2 H) 4.55- 4.68 (m, 2 H) 5.86-5.96 (m, 2 2 H) 7.51-7.57 (m, J =
4.67 Hz, 1 H) 7.74-7.79 (m, 1 H) 7.96 (s, 1 H) 7.99-8.04 (m, 1 H)
8.33-8.38 (m, 1 H) 8.58 (s, 1 H) 8.88-8.92 (m, 1 H). LC-MS 446. 26
110 ##STR00202## 2-{(3R,4S)-4- (hydroxymethyl)- 1-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-3-
yl}ethanol 1H NMR (500 MHz, DMSO- D6) .delta. ppm 1.46-1.55 (m, J =
7.42 Hz, 1 H) 1.63-1.74 (m, 1 H) 2.38-2.45 (m, 2H) 3.61- 3.65 (m, 4
H) 3.67-3.79 (m, 4 H) 4.58-4.70 (m, 1 H) 5.87- 5.92 (m, 3 H) 7.54
(dd, J = 8.24, 4.39 Hz, 1 H) 7.75-7.80 (m, 1 H) 7.94 (s, 1 H) 8.01
(d, J = 8.52 Hz, 1 H) 8.16-8.21 (m, 1 H) 8.33-8.38 (m, 1 H) 8.89
(d, J = 4.12 Hz, 1 H). LC-MS 406. 26 111 ##STR00203##
N-(2-{[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]amino}ethyl)- acetamide 1H NMR (500 MHz, DMSO- D6)
.delta. ppm 1.72-1.87 (m, 3 H) 2.40-2.45 (m, 2 H) 3.15- 3.24 (m, 2
H) 5.88 (s, 2 H) 7.54 (dd, J = 8.24, 4.12 Hz, 1 H) 7.79 (d, J =
6.59 Hz, 1 H) 7.93 (s, 1 H) 7.96-8.08 (m, 3 H) 8.19 (s, 1 H) 8.36
(d, J = 7.97 Hz, 1 H) 8.89 (d, J = 4.12 Hz, 1 H). LC-MS 363. 26 112
##STR00204## 2-{[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]amino}butan-1-ol 1H NMR (500 MHz, DMSO- D6) .delta.
ppm 0.85 (t, J = 7.28 Hz, 3 H) 1.44-1.54 (m, 1 H) 1.61-1.73 (m, 1
H) 3.17-3.24 (m, 1 H) 3.63-3.64 (m, 2 H) 3.89-3.97 (m, 1 H)
5.79-5.91 (m, 2 H) 7.54 (dd, J = 8.52, 4.12 Hz, 1H) 7.75-7.80 (m, 1
H) 7.88-7.94 (m, 1 H) 7.97 (s, 1 H) 8.00 (d, J = 8.52 Hz, 1 H)
8.08-8.12 (m, 1 H) 8.33- 8.37 (m, 1 H) 8.87-8.92 (m, 1 H). LC-MS
350. 26 113 ##STR00205## 1-{[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}propan- 2-ol 1H NMR (500
MHz, DMSO- D6) .delta. ppm 1.08 (d, J = 5.77 Hz, 3 H) 2.41-2.44 (m,
2 H) 3.17-3.24 (m, 1 H) 3.79-3.90 (m, 1 H) 5.87 (s, 2 H) 7.54 (dd,
J = 8.24, 4.40 Hz, 1 H) 7.76 (d, J = 6.59 Hz, 1 H) 7.95 (s, 1 H)
8.01 (d, J = 8.79 Hz, 1 H) 8.10-8.17 (m, 2 H) 8.35 (d, J = 8.24 Hz,
1 H) 8.90 (d, J = 3.85 Hz, 1 H). LC-MS 336. 26 114 ##STR00206##
(2R)-1- {[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]amino}propan- 2-ol 1H NMR (500 MHz, DMSO- D6)
.delta. ppm 1.08 (d, J = 6.04 Hz, 3 H) 3.17-3.23 (m, 2 H) 3.79-3.91
(m, 4.60-5.03 (m, 1 H) 5.80-5.92 (m, 2 H) 7.54 (dd, J = 8.24, 4.12
Hz, 1 H) 7.76 (d, J = 6.04 Hz, 1 H) 7.95 (s, 1 H) 8.01 (d, J = 8.52
Hz, 1 H) 8.10-8.17 (m, 2 H) 8.32-8.39 (m, 1 H) 8.90 (d, J = 4.12
Hz, 1 H). LC-MS 336. 26 115 ##STR00207## 3-({[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}methyl)-
pyridin-2(1H)-one 1H NMR (500 MHz, DMSO- D6) .delta. ppm 4.31-4.42
(m, J = 5.49 Hz, 2 H) 5.85-5.89 (m, 2 H) 7.21-7.29 (m, 1H) 7.31-
7.38 (m, 1 H) 7.43-7.63 (m, J = 8.52, 4.40 Hz, 2 H) 7.71 (d, J =
6.87 Hz, 1 H) 7.90- 7.99 (m, 2 H) 8.11-8.19 (m, 1 H) 8.30-8.37 (m,
1 H) 8.48 (s, 1 H) 8.87-8.92 (m, 1 H) 11.65 (s, 1 H). LC- MS 385.
26 116 ##STR00208## (2R)-2- {[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}butan- 1-ol 1H NMR (500
MHz, DMSO- D6) .delta. 6 ppm 0.85 (t, J = 7.28 Hz, 3 H) 1.44-1.54
(m, 1 H) 1.61-1.73 (m, 1 H) 3.17-3.24 (m, 1 H) 3.63-3.64 (m, 2 H)
3.89-3.97 (m, 1 H) 5.79-5.91 (m, 2 H) 7.54 (dd, J= 8.52, 4.12 Hz,
1H) 7.75-7.80 (m, 1 H) 7.88-7.94 (m, 1 H) 7.97 (s, 1 H) 8.00 (d, J
= 8.52 Hz, 1 H) 8.08-8.12 (m, 1H) 8.33-8.37 (m, 1 H) 8.87-8.92 (m,
1 H). LC-MS 350. 26 117 ##STR00209## (2S)-1- {[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}propan-
2-ol 1H NMR (500 MHz, DMSO- D6) .delta. ppm 1.08 (d, J = 6.04 Hz, 3
H) 3.17-3.23 (m, 2 H) 3.79-3.91 (m, 1 H) 4.60-5.03 (m, 1 H)
5.80-5.92 (m, 2 H) 7.54 (dd, J = 8.24, 4.12 Hz, 1 H) 7.76 (d, J =
6.04 Hz, 1 H) 7.95 (s, 1 H) 8.01 (d, J = 8.52 Hz, 1 H) 8.10-8.17
(m, 2 H) 8.32-8.39 (m, 1 H) 8.90 (d, J = 4.12 Hz, 1 H). LC-MS 336.
26 118 ##STR00210## (2S)-2- {[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}propan- 1-ol 1H NMR (500
MHz, DMSO- D6) .delta. ppm 1.17 (d, J = 6.59 Hz, 3 H) 3.16-3.23 (m,
1 H) 3.61-3.67 (m, 2 H) 4.01-4.12 (m, 1 H) 5.79-5.91 (m, 2 H) 7.54
(dd, J = 8.24, 4.12 Hz, 1 H) 7.75-7.79 (m, 1 H) 7.93- 8.03 (m, 3H)
8.05-8.08 (m, 1 H) 8.33-8.38 (m, 1 H) 8.88- 8.91 (m, J = 1.65 Hz, 1
H). LC-MS 336. 26 119 ##STR00211## [(1S,6R)-6- {[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]amino}cyclohex- 3-en-1-yl]methanol 1H NMR (500 MHz, DMSO- D6)
.delta. 6 ppm 2.03-2.18 (m, 3 H) 2.24-2.33 (m, 1 H) 2.41- 2.44 (m,
2 H) 3.16-3.24 (m, 2 H) 4.39-4.47 (m, 1 H) 5.56- 5.63 (m, 1 H)
5.68-5.76 (m, 1 H) 5.84-5.92 (m, J = 7.42 Hz, 2 H) 7.54 (dd, J =
8.10, 4.26 Hz, 1 H) 7.75-7.83 (m, 2 H) 7.96-8.03 (m, 2 H) 8.17-
8.21 (m, 1 H) 8.32-8.38 (m, 1H) 8.90 (d, J = 4.40 Hz, 1 H). LC-MS
388. 26 120 ##STR00212## (2R)-2- {[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}propan- 1-ol 1H NMR (500
MHz, DMSO- D6) .delta. ppm 1.17 (d, J = 6.59 Hz, 3 H) 3.16-3.23 (m,
1 H) 3.61-3.67 (m, 2 H) 4.01-4.12 (m, 1 H) 5.79-5.91 (m, 2 H) 7.54
(dd, J = 8.24, 4.12 Hz, 1 H) 7.75-7.79 (m, 1 H) 7.93- 8.03 (m, 3H)
8.05-8.08 (m, 1 H) 8.33-8.38 (m, 1 H) 8.88- 8.91 (m, J = 1.65 Hz, 1
H). LC-MS 336. 26 121 ##STR00213## N,N-dimethyl- N~3~-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]-beta-alaninamide 1H NMR (500 MHz, DMSO- d6) .delta. ppm
2.79-2.80 (m, 8 H) 3.55-3.60 (m, J = 6.04 Hz, 2 H) 5.90 (s, 2 H)
7.54 (dd, J = 8.10, 4.26 Hz, 1 H) 7.74- 7.77 (m, J = 8.52 Hz, 1 H)
7.94 (s, 1 H) 7.97-8.03 (m, J = 8.52 Hz, 1 H) 8.05-8.10 (m, 1 H)
8.17 (s, 1 H) 8.36 (d, J = 8.79 Hz, 1 H) 8.89 (s, 1 H). LC-MS 377.
26 122 ##STR00214## N-(pyrazolo[15- a]pyrimidin-3-
ylethyl-1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6) .delta. ppm 4.74 (s,
2 H) 5.92 (s, 2 H) 6.99-7.05 (m, 1 H) 7.53 (dd, J = 8.38, 3.98 Hz,
1 H) 7.75 (dd, J = 8.65, 2.06 Hz, 1 H) 7.94 (s, 1 H) 7.96- 8.02 (m,
J = 8.79 Hz, 1 H) 8.08-8.11 (m, 1 H) 8.25-8.26 (m, 1 H) 8.33 (d, J
= 7.42 Hz, 1 H) 8.57-8.58 (m, 2 H) 8.89 (s,1 H) 9.00-9.08 (m, 1 H).
LC-MS 409. 26 123 ##STR00215## 1-(quinolin-6- ylmethyl)-N-
(tetrahydrofuran- 3-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- amine
1H NMR (500 MHz, DMSO- d6) .delta. ppm 1.81-1.90 (m, 1 H) 2.20-2.27
(m, 1 H) 3.56- 3.58 (m, 1 H) 3.71-3.77 (m, 1 H) 3.81-3.92 (m, 3 H)
5.90 (s, 2 H) 7.54 (dd, J = 8.52, 4.12 Hz, 1 H) 7.77 (d, J = 8.52
Hz, 1 H) 7.97 (s, 1 H) 7.99-8.03 (m, J = 8.52 Hz, H) 8.04-8.09 (m,
1 H) 8.31-8.41 (m, J = 8.52 Hz, 2 H) 8.89 (s, 1 H). LC-MS 348. 26
124 ##STR00216## N-[(5-cyclopropyl- 1H-pyrazol- 3-yl)methyl]-
1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
amine 1H NMR (500 MHz, DMSO- d6) .delta. ppm 0.48-0.63 (m, J = 4.40
Hz, 2 H) 0.75-0.90 (m, 2 H) 1.70-1.81 (m, 1 H) 4.48 (s, 2 H) 5.82
(s, 1 H) 5.90 (s, 2 H) 7.53 (dd, J = 8.38, 4.26 Hz, 1 H) 7.73-7.79
(m, 1 H) 7.93 (s, 1 H) 7.98-8.03 (m, 1 H) 8.09-8.13 (m, 1 H) 8.34
(d, J = 8.24 Hz, 1 H) 8.46 (s, 1 H) 8.85-8.92 (m, 1 H). LC-MS 398.
26 125 ##STR00217## N-methyl-N-3-[1- (quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]-beta-alaninamide 1H NMR (500
MHz, DMSO- d6) .delta. ppm 2.43 (t, J = 6.32 Hz, 2 H) 2.66 (s, 3 H)
3.58 (t, J = 6.32 Hz, 2 H) 5.89 (s, 2 H) 7.54 (dd, J = 8.24, 4.12
Hz, 1 H) 7.72-7.82 (m, 2 H) 7.98 (s, 1 H) 7.99-8.04 (m, J = 8.52
Hz, 1 H) 8.05-8.08 (m, 1 H) 8.19 (s, 1 H) 8.37 (d, J = 8.24 Hz, 1
H) 8.89 (s, 1 H). LC-MS 363. 26 126 ##STR00218## N-[(3R)-
1-acetylpyrrolidin- 3-yl]-1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6)
.delta. ppm 1.81-1.82 (m, 1 H) 1.97-1.99 (m, 1 H) 3.68- 3.79 (m, 2
H) 4.41-4.49 (m, 1 H) 5.90 (s, 2 H) 7.54 (dd, J = 8.10, 4.26 Hz, 1
H) 7.75- 7.82 (m, 1 H) 8.00 (s, 2 H) 8.07 (s, 1 H) 8.32-8.44 (m, 2
H) 8.85-8.92 (m, 1 H) (five aliphatic protons not resolved, due to
water and solvent peaks). LC-MS 389. 26 127 ##STR00219##
[(1R,2R)-2- ({[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]amino}methyl)- cyclopropyl]- methanol 1H NMR (500
MHz, DMSO- d6) .delta. ppm 0.29-0.50 (m, 2 H) 0.86-1.03 (m, 2 H)
3.15- 3.24 (m, 2 H) 5.88 (s, 2 H) 7.54 (dd, J = 8.10, 3.98 Hz, 1 H)
7.76 (d, J = 8.79 Hz, 1 H) 7.93 (s, 1 H) 8.01 (d, J = 8.52 Hz, 1 H)
8.08 (s, 1 H) 8.20 (s, 1 H) 8.35 (d, J = 8.24 Hz, 1 H) 8.89 (s, 1
H) (two aliphatic protons not resolved, due to water and solvent
peaks). LC-MS 362. 26 128 ##STR00220## N-[(15-dimethyl- 1H-pyrazol-
4-yl)methyl]- 1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6) .delta. ppm 2.19 (s,
3 H) 3.65 (s, 3 H) 4.31 (s, 2 H) 5.92 (s, 2 H) 7.34 (s, 1 H) 7.54
(dd, J = 8.24, 4.67 Hz, 1 H) 7.76 (d, J = 6.59 Hz, 1 H) 7.92 (s, 1
H) 7.99-8.03 (m, J = 8.24 Hz, 1 H) 8.04-8.07 (m, 1 H) 8.29-8.40 (m,
2 H) 8.89-8.90 (m, 1 H). LC-MS 386. 26 129 ##STR00221## [(1S,2S)-2-
({[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]amino}methyl)- cyclopropyl]- methanol 1H NMR (500 MHz, DMSO- d6)
.delta. ppm 0.24-0.50 (m, 2 H) 0.86-1.02 (m, 2 H) 3.16- 3.24 (m, 2
H) 5.88 (s, 2 H) 7.54 (dd, J = 8.10, 4.26 Hz, 1 H) 7.76 (dd, J =
8.20, 1.80 Hz, 1 H) 7.93 (s, 1 H) 7.97- 8.04 (m, J = 8.79 Hz, 1 H)
8.08 (s, 1 H) 8.16-8.23 (m, 1 H) 8.36 (d, J = 7.69 Hz, 1 H)
8.86-8.89 (m, 1 H) (two aliphatic protons not resolved, due to
water peak). LC-MS 362. 26 130 ##STR00222## N-[(3-methyloxetan-
3-yl)methyl]- 1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- amine 1H NMR (500 MHz, DMSO- d6) .delta. ppm 1.22 (s,
3 H) 3.61 (d, J = 5.77 Hz, 2 H) 4.15 (d, J = 5.49 Hz, 2 H) 4.41 (d,
J = 5.49 Hz, 2 H) 5.89 (s, 2 H) 7.54 (dd, J = 7.97, 4.12 Hz, 1 H)
7.74 (d, J = 8.79 Hz, 1 H) 7.93 (s, 1 H) 7.97-8.04 (m, J = 8.52 Hz,
1 H) 8.08-8.15 (m, 1 H) 8.24 (s, 1 H) 8.34 (d, J = 7.69 Hz, 1 H)
8.87-8.90 (m, 1 H). LC-MS 362. 26 131 ##STR00223## (3S4R)-4-
{[1-(quinolin- 6-ylmethyl)-1H- [123]triazolo[45- b]pyrazin-6-
yl]amino}tetra- hydrofuran-3-ol 1H NMR (500 MHz, DMSO- d6) .delta.
ppm 3.60 (d, J = 8.24 Hz, 1 H) 3.65 (d, J = 8.79 Hz, 1 H) 3.93 (dd,
J = 9.34, 4.67 Hz, 1 H) 4.07 (dd, J = 9.34, 4.94 Hz, 1 H) 4.23-4.24
(m, 2 H) 5.92 (s, 2 H) 7.54 (dd, J = 8.38, 3.98 Hz, 1 H) 7.81 (d, J
= 8.24 Hz, 1 H) 7.96-8.04 (m, 2 H) 8.09 (s, 1 H) 8.29- 8.39 (m, 2
H) 8.86-8.93 (m, 1 H). LC-MS 364. 26
132 ##STR00224## 1-ethoxy-3- {[1-(quinolin- 6-ylmethyl)-1H-
[123]triazolo[45- b]pyrazin-6- yl]amino}propan- 2-ol 1H NMR (500
MHz, DMSO- d6) .delta. ppm 1.05 (t, J = 6.87 Hz, 3 H) 3.81-3.92 (m,
2 H) 5.87 (s, 2 H) 7.54 (dd, J = 8.52, 4.12 Hz, 1 H) 7.78 (d, J =
6.87 Hz, 1 H) 7.95 (s, 1 H) 8.00 (d, J = 8.79 Hz, 1 H) 8.11-8.18
(m, 2 H) 8.35 (d, J = 7.97 Hz, 1 H) 8.86-8.89 (m, 1 H) (five
aliphatic protons not resolved, due to water and solvent peaks).
LC-MS 380. 26 133 ##STR00225## tert-butyl({(3R)- 1-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-3-
yl}methyl)- carbamate (400 MHz, MeOD) d ppm 1.41 (s, 9 H) 1.79-1.91
(m, 1 H) 2.13-2.23 (m, 1 H) 2.50- 2.61 (m, 1 H) 3.11-3.22 (m, 2 H)
3.39 (dd, J = 11.12, 6.82 Hz, 1 H) 3.58-3.67 (m, 1 H) 3.73-3.81 (m,
2 H) 5.93 (s, 2 H) 7.54 (dd, J = 8.46, 4.42 Hz, 1 H) 7.83 (dd, J =
8.84, 1.77 Hz, 1 H) 7.94 (s, 1 H) 8.01 (d, J = 8.84 Hz, 1 H) 8.13
(s, 1 H) 8.35 (d, J = 8.08 Hz, 1 H) 8.84 (dd, J = 4.29, 1.77 Hz, 1
H) 27 134 ##STR00226## (3R)-N-methyl- 1-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-3-
amine (400 MHz, MeOD) d ppm 2.33-2.43 (m, 1 H) 2.54-2.65 (m, 1 H)
2.83 (s, 3 H) 3.78- 3.88 (m, 1 H) 3.90- 4.01 (m, 2 H) 4.02-4.11 (m,
2 H) 6.10 (s, 2 H) 8.13 (dd, J = 7.96, 5.43 Hz, 1 H) 8.26 (s, 1 H)
8.28 (s, 2 H) 8.37 (s, 1 H) 9.22- 9.27 (m, 2 H) 27 135 ##STR00227##
N-methyl-1- [1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]piperidin-4-amine (400 MHz, MeOD) d ppm 1.60-1.71
(m, 2 H) 2.25 (d, J = 10.86 Hz, 2 H) 2.74 (s, 3 H) 3.12-3.22 (m, 2
H) 3.38- 3.49 (m, 1 H) 4.79 (d, J = 13.89 Hz, 2 H) 6.09 (s, 2 H)
8.13 (dd, J = 8.34, 5.56 Hz, 1 H) 8.23-8.31 (m, 2 H) 8.36 (s, 1 H)
8.56 (s, 1 H) 9.20- 9.27 (m, 2 H) 27 136 ##STR00228## 1-{(3R)-1-
[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]pyrrolidin-3- yl}methanamine (400 MHz, MeOD) d ppm 1.87-1.97 (m,
1 H) 2.31-2.41 (m, 1 H) 2.67-2.78 (m, 1 H) 3.08-3.19 (m, 2 H) 3.44
(dd, J = 11.24, 7.71 Hz, 1 H) 3.65- 3.73 (m, 1 H) 3.89 (ddd, J =
11.31, 8.02, 3.66 Hz, 1 H) 3.98 (dd, J = 10.74, 7.71 Hz, 1 H) 6.06
(s, 2 H) 8.07 (dd, J =8.34, 5.31 Hz, 1 H) 8.20 (s, 1 H) 8.23 (d, J
= 1.77 Hz, 1 H) 8.24 (s, 1 H) 8.30 (s, 1 H) 9.15 (d, J = 8.59 Hz, 1
H) 9.20 (dd, J = 5.31, 1.52 Hz, 1 H) 27 137 ##STR00229##
N-[1-(quinolin-6- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl[ethane- 1,2-diamine (400 MHz, MeOD) d ppm 3.27 (t, J = 5.94 Hz,
3 H) 3.81 (t, J = 5.81 Hz, 2 H) 6.11 (s, 2 H) 8.11-8.15 (m, 2 H)
8.24-8.27 (m, 1 H) 8.27- 8.31 (m, 1 H) 8.37 (d, J = 0.76 Hz, 1 H)
9.24 (d, J = 6.57 Hz, 2 H) 27 138 ##STR00230## 2-{[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}ethanol
(400 MHz, DMSO-d6) d ppm 3.44 (q, J = 5.73 Hz, 2 H) 3.58 (q, J =
5.64 Hz, 2 H) 4.82 (t, J = 5.31 Hz, 1 H) 5.87 (s, 2 H) 7.53 (dd, J
= 8.34, 4.29 Hz, 1 H) 7.76 (dd, J = 8.59, 2.02 Hz, 1 H) 7.93 (d, J=
1.01 Hz, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.10 (s, 1 H) 8.26 (t, J =
4.93 Hz, 1 H) 8.36 (d, J = 7.83 Hz, 1 H) 8.89 (dd, J = 4.04, 1.77
Hz, 1 H) 27 139 ##STR00231## 2-methyl-2- {[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]amino}ethanol
(400 MHz, DMSO-d6) d ppm 1.30 (s, 6 H) 3.58 (d, J = 6.06 Hz, 2 H)
4.74 (t, J = 6.06 Hz, 1 H) 5.87 (s, 2 H) 7.53 (dd, J = 8.34, 4.29
Hz, 1 H) 7.62 (s, 1 H) 7.75 (dd, J = 8.97, 1.89 Hz, 1 H) 7.98-8.01
(m, 2 H) 8.08 (s, 1 H) 8.34 (dd, J = 8.21, 1.14 Hz, 1 H) 8.89 (dd,
J = 4.17, 1.64 Hz, 1 H) 27 140 ##STR00232## N~2~-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]glycinamide
(400 MHz, DMSO-d6) d ppm 3.99 (d, J = 5.81 Hz, 2 H) 5.86 (s, 2 H)
7.17 (s, 1 H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.58 (s, 1 H) 7.80
(dd, J = 8.84, 2.02 Hz, 1 H) 7.95 (d, J = 1.52 Hz, 1 H) 8.02 (d, J
= 8.59 Hz, 1 H) 8.21 (s, 1 H) 8.37 (dd, J = 8.59, 1.01 Hz, 1 H)
8.42 (t, J = 5.18 Hz, 1 H) 8.89 (dd, J = 4.04, 1.77 Hz, 1 H) 27 141
##STR00233## 2-methyl-N~1~- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]propane-1,2- diamine (400 MHz,
MeOD) d ppm 1.41 (s, 6 H) 3.72 (s, 2 H) 6.14 (s, 2 H) 8.07 (dd, J =
8.34, 5.31 Hz, 1 H) 8.14 (s, 1 H) 8.16-8.21 (m, 1 H) 8.22- 8.27 (m,
1 H) 8.29 (d, J = 0.76 Hz, 1 H) 9.15 (d, J = 8.34 Hz, 1 H) 9.20
(dd, J = 5.31, 1.52 Hz, 1 H) 27 142 ##STR00234## 6-{[6-
(tetrahydro-2H- pyran-4-yloxy)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-1- yl]methyl}quinoline (400 MHz, DMSO-d6) d ppm 1.58-1.68
(m, J = 13.23, 9.22, 9.00, 4.17 Hz, 2 H) 1.92-1.99 (m, 2 H) 3.44
(ddd, J = 11.75, 9.47, 2.78 Hz, 2 H) 3.79 (ddd, J = 11.75, 4.42,
4.29 Hz, 2 H) 5.19 (ddd, J = 13.14, 8.72, 3.92 Hz, 1 H) 6.06 (s, 2
H) 7.55 (dd, J = 8.34, 4.29 Hz, 1 H) 7.76 (dd, J = 8.72, 2.15 Hz, 1
H) 7.99-8.02 (m, 2 H) 8.36 (dd, J = 8.46, 1.14 Hz, 1 H) 8.39 (s, 1
H) 8.90 (dd, J = 4.17, 1.64 Hz, 1 H) 28 143 ##STR00235##
1-(quinolin- 6-ylmethyl)- N-(tetrahyrdro- 2H-pyran-4-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine (400 MHz, DMSO-d6) d ppm
1.36-1.46 (m, 2 H) 1.79-1.86 (m, 2 H) 3.35-3.41 (m, 2 H) 3.77-3.84
(m, 2 H) 3.86-3.96 (m, 1 H) 5.88 (s, 2 H) 7.54 (dd, J = 8.21, 4.17
Hz, 1 H) 7.72 (dd, J = 8.59, 2.02 Hz, 1 H) 7.95 (d, J = 1.52 Hz, 1
H) 7.99 (d, J = 8.59 Hz, 1 H) 8.02 (s, 1 H) 8.14 (d, J = 6.82 Hz, 1
H) 8.34 (dd, J = 8.34, 1.01 Hz, 1 H) 8.89 (dd, J = 4.17, 1.64 Hz, 1
H) 27 144 ##STR00236## N-(2,2- difluoroethyl)- 1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- amine (400 MHz,
DMSO-d6) d ppm 3.78-3.89 (m, J = 15.66, 15.66, 5.05, 4.29 Hz, 2 H)
5.92 (s, 2 H) 6.20 (tt, J = 55.93, 3.79, 3.60 Hz, 1 H) 7.54 (dd, J
= 8.21, 4.17 Hz, 1 H) 7.77 (dd, J = 8.34, 1.26 Hz, 1 H) 7.96 (s, 1
H) 8.00 (d, J = 8.59 Hz, 1 H) 8.17 (s, 1 H) 8.34 (d, J = 8.34 Hz, 1
H) 8.55 (t, J = 5.18 Hz, 1 H) 8.89 (d, J = 4.04 Hz, 1 H) 27 145
##STR00237## 1-(quinolin- 6-ylmethyl)- N-(tetrahydro-
furan-3-yl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- amine (400 MHz,
DMSO-d6) d ppm 1.80-1.91 (m, 1 H) 2.18-2.28 (m, 1 H) 3.57 (dd, J =
9.09, 3.28 Hz, 1 H) 3.73 (td, J = 8.15, 5.68 Hz, 1 H) 3.80-3.92 (m,
2 H) 4.37-4.47 (m, 1 H) 5.89 (s, 2 H) 7.54 (dd, J = 8.34, 4.04 Hz,
1 H) 7.76 (dd, J = 8.72, 1.64 Hz, 1 H) 7.96 (s, 1 H) 8.00 (d, J =
8.59 Hz, 1 H) 8.06 (s, 1 H) 8.36 (d, J = 8.34 Hz, 1 H) 8.44 (d, J =
6.06 Hz, 1 H) 8.89 (dd, J = 4.17, 1.39 Hz, 1 H) 27 146 ##STR00238##
1-(quinolin- 6-ylmethyl)- N-(tetrahydro- furan-3-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine (400 MHz, DMSO-d6) d ppm
1.80-1.91 (m, 1 H) 2.18-2.28 (m, 1 H) 3.57 (dd, J = 9.09, 3.28 Hz,
1 H) 3.73 (td, J = 8.15, 5.68 Hz, 1 H) 3.80-3.92 (m, 2 H) 4.37-4.47
(m, 1 H) 5.89 (s, 2 H) 7.54 (dd, J = 8.34, 4.04 Hz, 1 H) 7.76 (dd,
J = 8.72, 1.64 Hz, 1 H) 7.96 (s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H)
8.06 (s, 1 H) 8.36 (d, J = 8.34 Hz, 1 H) 8.44 (d, J = 6.06 Hz, 1 H)
8.89 (dd, J = 4.17, 1.39 Hz, 1 H) 27 147 ##STR00239## 6-({6-[3-(4-
fluoropiperidin- 1-yl)pyrrolidin- 1-yl]-1H- [1,2,3]triazolo[4,5-
b]pyrazin-1- yl}methyl)quinoline (400 MHz, DMSO-d6) d ppm 1.67-1.78
(m, 2 H) 1.80-1.92 (m, 3 H) 2.18-2.29 (m, 1 H) 2.33-2.45 (m, 2 H)
2.52-2.74 (m, 3 H) 2.92-3.04 (m, 1 H) 3.44-3.55 (m, 1 H) 3.75-3.85
(m, 1 H) 3.85-3.97 (m, 1 H) 4.56-4.83 (m, 1 H) 5.90 (s, 2 H) 7.53
(dd, J = 8.34, 4.29 Hz, 1 H) 7.75 (dd, J = 8.72, 1.64 Hz, 1 H) 7.94
(s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.23 (s, 1 H) 8.36 (d, J = 8.34
Hz, 1 H) 8.89 (dd, J = 4.04, 1.52 Hz, 1 H) 27 148 ##STR00240##
1-{(3R)-1- [1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]pyrrolidin-3- yl}piperidine-4- carbonitrile (400
MHz, DMSO-d6) d ppm 1.67-1.77 (m, 2 H) 1.80-1.92 (m, 3 H) 2.18-2.27
(m, 1 H) 2.31-2.43 (m, 2 H) 2.56-2.62 (m, 1 H) 2.63-2.73 (m, 2 H)
2.83-2.94 (m, 1 H) 2.94-3.06 (m, 1 H) 3.43-3.54 (m, 1 H) 3.74-3.84
(m, 1 H) 3.84-3.96 (m, 1 H) 5.91 (s, 2 H) 7.53 (dd, J = 8.34, 4.04
Hz, 1 H) 7.75 (dd, J = 8.72, 1.89 Hz, 1 H) 7.94 (d, J = 1.01 Hz, 1
H) 8.00 (d, J = 8.59 Hz, 1 H) 8.23 (s, 1 H) 8.36 (d, J = 8.59 Hz, 1
H) 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 27 149 ##STR00241##
6-{[6-(3,3-difluoro- 1-3'-bipyrrolidin- 1'-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl]methyl}quinoline (400 MHz,
DMSO-d6) d ppm 1.90-2.01 (m, 1 H) 2.14-2.18 (m, 1 H) 2.19-2.29 (m,
2 H) 2.78 (t, J = 7.83 Hz, 2 H) 2.96-3.07 (m, 3 H) 3.46 (dd, J =
10.11, 6.57 Hz, 1 H) 3.50- 3.61 (m, 1 H) 3.70-3.81 (m, 2 H) 5.91
(s, 2 H) 7.53 (dd, J = 8.34, 4.04 Hz, 1 H) 7.73-7.79 (m, 1 H) 7.94
(s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.22 (s, 1 H) 8.34-8.39 (m, 1
H) 8.86- 8.92 (m, 1 H) 31 150 ##STR00242## 7-fluoro-6-
{[6-(1-methyl-1H- pyrazol-4-yl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-1- yl]methyl}quinoline (400 MHz, DMSO-d6) d ppm 3.94 (s,
3 H) 6.17 (s, 2 H) 7.54 (dd, J = 8.34, 4.04 Hz, 1 H) 7.84 (d, J =
11.37 Hz, 1 H) 8.13 (d, J = 8.34 Hz, 1 H) 8.27 (s, 1 H) 8.44 (d, J
= 8.34 Hz, 1 H) 8.62 (s, 1 H) 8.92 (dd, J = 4.17, 1.39 Hz, 1 H)
9.21 (s, 1 H) 32 151 ##STR00243## 1-{(3R)-1- [1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl}-4-(trifluoromethyl)piperidin- 4-ol (400 MHz, MeOD) d ppm
2.07-2.19 (m, 3 H) 2.30-2.42 (m, 1 H) 2.66-2.78 (m, 1 H) 3.40-3.51
(m, 3 H) 3.65-3.77 (m, 3 H) 3.78-3.88 (m, 1 H) 4.01-4.12 (m, 1 H)
4.12-4.23 (m, 1 H) 4.27 (dd, J = 11.24, 7.45 Hz, 1 H) 6.04 (s, 2 H)
7.81 (dd, J = 8.34, 4.80 Hz, 1 H) 8.00-8.07 (m, 1 H) 8.10- 8.16 (m,
2 H) 8.25 (s, 1 H) 8.74 (d, J = 8.59 Hz, 1 H) 9.03 (dd, J = 4.80,
1.52 Hz, 1 H) 27 152 ##STR00244## 1-[(7-fluroquinolin-
6-yl)methyl]- N-(tetrahydro- furan-3-yl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- amine (400 MHz, DMSO-d6) d ppm 1.76-1.85 (m, 1 H)
2.11-2.21 (m, 1 H) 3.52 (dd, J = 9.09, 3.28 Hz, 1 H) 3.70 (td, J =
8.21, 5.56 Hz, 1 H) 3.77-3.86 (m, 2 H) 4.29-4.38 (m, 1 H) 5.93 (s,
2 H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.81 (d, J = 11.37 Hz, 1 H)
8.05 (s, 1 H) 8.09 (d, J = 8.34 Hz, 1 H) 8.41 (d, J = 6.82 Hz, 2 H)
8.90-8.99 (m, 1 H) 27 153 ##STR00245## 6-({6- [(3R)-3-morpholin-
4-ylpyrrolidin- 1-yl]-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl}methyl)quinoline 1H NMR (400 MHz, MeOD) d ppm 2.45-2.56 (m, 1 H)
2.64-2.73 (m, 1 H) 3.33-3.42 (m, 2 H) 3.59-3.67 (m, 2 H) 3.68-3.75
(m, 1 H) 3.95-4.15 (m, 7 H) 4.26 (dd, J = 11.24, 7.45 Hz, 1 H) 6.10
(s, 2 H) 8.13 (dd, J = 8.34, 5.56 Hz, 1 H) 8.24-8.34 (m, 3 H) 8.39
(s, 1 H) 9.23-9.31 (m, 2 H) 27 154 ##STR00246## 1-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]pyrrolidin-3-one 1H NMR (400 MHz, DMSO- d6) d ppm 2.75 (t, J =
7.71 Hz, 2 H) 4.00 (t, J = 7.71 Hz, 2 H) 4.10 (ddd, J = 10.86,
5.81, 5.56 Hz, 2 H) 5.95 (s, 2 H) 7.53 (dd, J = 8.34, 4.04 Hz, 1 H)
7.78 (dd, J = 8.59, 2.02 Hz, 1 H) 7.94-8.03 (m, 2 H) 8.32 (s, 1 H)
8.35-8.40 (m, 1 H) 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 31 155
##STR00247## 3-[(methylamino)- methyl]- 1-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]pyrrolidin-3-ol 1H NMR (400 MHz, MeOD) d ppm 2.23 (s, 2 H) 2.80
(s, 3 H) 3.32-3.41 (m, 2 H) 3.69- 3.78 (m, 1 H) 3.83-3.94 (m, 3 H)
6.08 (s, 2 H) 8.13 (dd, J = 8.46, 5.43 Hz, 1 H) 8.20 (s, 1 H)
8.25-8.31 (m, 2 H) 8.37 (s, 1 H) 9.21-9.29 (m, 2 H) 37 156
##STR00248## (3R)-1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-3-ol 1H NMR (400
MHz, DMSO- d6) d ppm 1.96-2.04 (m, 1 H) 3.59-3.71 (m, 3 H) 4.44
(bs, 1 H) 5.14 (bs, 1 H) 5.89 (s, 2 H) 7.52 (dd, J = 8.34, 4.29 Hz,
1 H) 7.76 (dd, J = 8.59, 2.02 Hz, 1 H) 7.92 (d, J = 1.52 Hz, 1 H)
8.00 (d, J = 8.59 Hz, 1 H) 8.20 (s, 1 H) 8.35 (d, J = 7.58 Hz, 1 H)
8.88 (dd, J = 4.17, 1.64 Hz, 1 H) 27 157 ##STR00249##
(3S)-1-[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]pyrrolidin-3-ol 1H NMR (400 MHz, DMSO- d6) d ppm
1.96-2.07 (m, 2 H) 3.60-3.72 (m, 3 H) 4.44 (bs, 1 H) 5.10 (bs, 1 H)
5.90 (s, 2 H) 7.53 (dd, J = 8.34, 4.04 Hz, 1 H) 7.76 (dd, J = 8.72,
1.89 Hz, 1 H) 7.93 (d, J = 1.52 Hz, 1 H) 8.00 (d, J = 8.59 Hz, 1 H)
8.22 (s, 1 H) 8.33-8.40 (m, 1 H) 8.89 (dd, J = 4.04, 1.77 Hz, 1 H)
27 158 ##STR00250## 3-[(dimethylamino)- methyl]- 1- [1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]pyrrolidin-3-ol 1H NMR (400 MHz, MeOD) d ppm 2.13 (s, 2 H) 2.56
(s, 6 H) 2.86 (s, 2 H) 3.61 (d, J = 11.37 Hz, 1 H) 3.74-3.86 (m, 3
H) 5.94 (s, 2 H) 7.54 (dd, J = 8.34, 4.55 Hz, 1 H) 7.83 (dd, J =
8.72, 1.64 Hz, 1 H) 7.94 (s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.15
(s, 1 H) 8.34 (d, J = 8.34 Hz, 1 H) 8.81- 8.87 (m, 1 H) 37 159
##STR00251## N,N-dimethyl-1- (quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (400 MHz, MeOD) d
ppm 3.28 (s, 6 H) 6.02 (s, 2 H) 7.87 (dd, J = 8.34, 5.05 Hz, 1H)
8.04-8.12 (m, 1 H) 8.12-8.23 (m, 2 H) 8.35 (s, 1 H) 8.84 (d, J =
8.34 Hz, 1 H) 9.06 (dd, J = 5.05, 1.52 Hz, 1 H) 27 160 ##STR00252##
N,N-diethyl-1- (quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- amine 1H NMR (400 MHz, MeOD) d ppm 1.22 (t, J = 6.95
Hz, 6 H) 3.69 (q, J = 7.07 Hz, 4 H) 6.00 (s, 2 H) 7.85 (dd, J =
8.34, 5.05 Hz, 1 H) 8.03-8.08 (m, 1 H) 8.11-8.16 (m, 1 H) 8.19 (s,
1 H) 8.28 (s, 1 H) 8.81 (d, J = 8.08 Hz, 1 H) 9.01-9.09 (m, 1 H) 27
161 ##STR00253## 6-[(6-butoxy-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl)methyl]quinoline 1H NMR (400 MHz, MeOD) d ppm 0.95 (t, J = 7.33
Hz, 3 H) 1.48 (dq, J = 15.00, 7.46 Hz, 2 H) 1.75-1.83 (m, 2 H) 4.46
(t, J = 6.57 Hz, 2 H) 6.13 (s, 2 H) 7.92 (dd, J = 8.59, 5.05 Hz, 1
H) 8.08-8.13 (m, 1 H) 8.17-8.24 (m, 2 H) 8.29 (s, 1 H) 8.91 (d, J =
8.34 Hz, 1 H) 9.11 (d, J = 4.29 Hz, 1 H) 28 162 ##STR00254##
1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
carboxamide 1H NMR (400 MHz, MeOD) d ppm 6.03 (s, 2 H) 7.83 (dd, J
= 8.59, 4.80 Hz, 1 H) 8.05 (dd, J = 8.97, 1.89 Hz, 1 H) 8.11-8.18
(m, 2 H) 8.35 (s, 1 H) 8.77 (d, J = 8.08 Hz, 1 H) 9.03 (dd, J =
4.80, 1.52 Hz, 1 H) 36 163 ##STR00255## 1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- carboxamide 1H
NMR (400 MHz, DMSO- d6) d ppm 6.28 (s, 2 H) 7.55 (dd, J = 8.34,
4.29 Hz, 1 H) 7.81 (dd, J = 8.72, 2.15 Hz, 1 H) 7.99-8.04 (m, 2 H)
8.33- 8.37 (m, 1 H) 8.91 (dd, J = 4.04, 1.77 Hz, 1 H) 9.41 (s, 1 H)
33 164 ##STR00256## 6-[(6- pyrrolidin-1-yl-1H- [1,2,3]triazolo[4,5-
b]pyrazin-1- yl)methyl]quinoline 1H NMR (400 MHz, DMSO- d6) d ppm
1.90-2.00 (m, 4 H) 3.52-3.60 (m, 4 H) 5.90 (s, 2 H) 7.52 (dd, J =
8.34, 4.29 Hz, 1 H) 7.76 (dd, J = 8.59, 2.02 Hz, 1 H) 7.93 (d, J =
1.77 Hz, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.21 (s, 1 H) 8.34-8.38
(m, 1 H) 8.89 (dd, J = 4.04, 1.77 Hz, 1 H) 27
165 ##STR00257## 6-[(6-azetidin- 1-yl-1H- [1,2,3]triazolo[4,5-
b]pyrazin-1- yl)methyl]quinoline 1H NMR (400 MHz, DMSO- d6) d ppm
2.37-2.46 (m, J = 7.58, 7.58, 7.58, 7.58 Hz, 2 H) 4.22 (t, J = 7.45
Hz, 4 H) 5.90 (s, 2 H) 7.53 (dd, J = 8.21, 4.17 Hz, 1 H) 7.73 (dd,
J = 8.59, 2.02 Hz, 1 H) 7.89 (d, J = 1.52 Hz, 1 H) 7.99- 8.02 (m, 2
H) 8.34-8.38 (m, 1 H) 8.89 (dd, J = 4.29, 1.77 Hz, 1 H) 27 166
##STR00258## N-isopropyl- 1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (400 MHz, DMSO- d6)
d ppm 1.17 (d, J = 6.32 Hz, 6 H) 4.00-4.10 (m, J = 6.57, 6.57,
6.57, 6.57 Hz, 1 H) 5.87 (s, 2 H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H)
7.75 (dd, J = 8.84, 2.02 Hz, 1 H) 7.94 (d, J = 1.77 Hz, 1 H) 7.97-
8.02 (m, 2 H) 8.08 (d, J = 7.07 Hz, 1 H) 8.32-8.36 (m, 1 H) 8.88
(dd, J = 4.29, 1.77 Hz, 1 H) 27 167 ##STR00259## 2-methyl-1-
{[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]amino}propan- 2-ol 1H NMR (400 MHz, DMSO- d6) d ppm 1.08 (s, 6
H) 3.34- 3.36 (m, 2 H) 4.62 (s, 1 H) 5.87 (s, 2 H) 7.53 (dd, J =
8.34, 4.29 Hz, 1 H) 7.74 (dd, J = 8.72, 1.89 Hz, 1 H) 7.92 (s, 1 H)
7.99 (d, J = 8.59 Hz, 1 H) 8.08 (t, J = 5.18 Hz, 1 H) 8.23 (s, 1 H)
8.34 (d, J = 7.33 Hz, 1 H) 8.89 (dd, J = 4.04, 1.77 Hz, 1 H) 27 168
##STR00260## N-ethyl-1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amine 1H NMR (400 MHz, DMSO- d6)
d ppm 1.17 (t, J = 7.20 Hz, 3 H) 3.38 (td, J = 7.20, 5.31 Hz, 2 H)
5.88 (s, 2 H) 7.54 (dd, J = 8.34, 4.29 Hz, 1 H) 7.75 (dd, J = 8.84,
2.02 Hz, 1 H) 7.93 (d, J = 1.52 Hz, 1 H) 7.98-8.05 (m, 2 H) 8.20
(t, J = 4.80 Hz, 1 H) 8.32-8.38 (m, 1 H) 8.89 (dd, J = 4.17, 1.64
Hz, 1 H) 27 169 ##STR00261## 6-{[6-(2-methoxy- ethoxy)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl]methyl}quinoline 1H NMR (400
MHz, MeOD) d ppm 3.35 (s, 3 H) 3.70-3.80 (m, 2 H) 4.62 (dd, J =
5.43, 3.92 Hz, 2 H) 6.09 (s, 2 H) 7.57 (dd, J = 8.34, 4.29 Hz, 1 H)
7.87 (dd, J = 8.72, 1.89 Hz, 1 H) 7.98-8.06 (m, 2 H) 8.31-8.40 (m,
2 H) 8.87 (dd, J = 4.29, 1.52 Hz, 1 H) 28 170 ##STR00262##
1-{(3R)-1- [1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]pyrrolidin-3- yl}piperidin-4-ol 1H NMR (400 MHz,
DMSO- d6) d ppm 1.33-1.44 (m, 2 H) 1.69-1.77 (m, 3 H) 2.08-2.17 (m,
3 H) 2.66-2.76 (m, 1 H) 2.80 (d, J = 10.36 Hz, 1 H) 2.86-2.96 (m, 1
H) 3.40-3.48 (m, 3 H) 3.49-3.60 (m, 1 H) 3.80 (d, J = 8.59 Hz, 1 H)
4.58 (s, 1 H) 5.90 (s, 2 H) 7.52 (dd, J = 8.34, 4.04 Hz, 1 1 H)
7.92-7.97 (m, 1 H) 8.00 (d, J = 8.84 Hz, 1 H) 8.18- 8.27 (m, 1 H)
8.35 (d, J = 8.34 Hz, 1 H) 8.89 (dd, J = 4.29, 1.52 Hz, 1 H) 27 171
##STR00263## 7-fluoro-6-({6- [(3R)-3-morpholin- 4-ylpyrrolidin-
1-yl]-1H- [1,2,3]triazolo[4,5- b]pyrazin-1- yl}methyl)quinoline 1H
NMR (400 MHz, DMSO- d6) d ppm 1 .77-1.88 (m, 1 H) 2.15-2.26 (m, 1
H) 2.35-2.47 (m, 3 H) 2.85-2.96 (m, 1 H) 3.40-3.52 (m, 2 H)
3.53-3.63 (m, 5 H) 3.70-3.91 (m, 2 H) 5.93 (s, 2 H) 7.53 (dd, J =
8.34, 4.29 Hz, 1 H) 7.77-7.87 (m, 1 H) 8.08 (dd, J = 3.16, 1.64 Hz,
1 H) 8.21 (s, 1 H) 8.41 (d, J = 8.34 Hz, 1 H) 8.90-8.98 (m, 1 H) 27
172 ##STR00264## 1-({1-[(7- fluoroquinolin- 6-yl)methyl]-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- amino)-2-methyl- propan-2-ol 1H
NMR (400 MHz, DMSO- d6) d ppm 1.02 (s, 6 H) 3.27 (d, J = 4.04 Hz, 2
H) 5.96 (s, 2 H) 7.53 (dd, J = 8.46, 4.17 Hz, 1 H) 7.80 (d, J =
11.37 Hz, 1 H) 8.04 (d, J = 8.08 Hz, 2 H) 8.21 (s, 1 H) 8.39 (d, J
= 8.08 Hz, 1 H) 8.92 (d, J = 4.04 Hz, 1 H) 27 173 ##STR00265##
(2S)-1-({1-[(7- fluoroquinolin- 6-yl)methyl]-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl}amino)propan- 2-ol 1H NMR (400
MHz, DMSO- d6) d ppm 1.02 (d, J = 6.32 Hz, 3 H) 3.13-3.23 (m, 2 H)
3.26-3.31 (m, 1 H) 3.73-3.83 (m, 1 H) 4.79 (d, J = 4.80 Hz, 1 H)
5.95 (s, 2 H) 7.53 (dd, J =8.34, 4.29 Hz, 1 H) 7.80 (d, J = 11.37
Hz, 1 H) 8.05 (d, J = 8.34 Hz, 1 H) 8.09- 8.16 (m, 1 H) 8.20 (s, 1
H) 8.40 (d, J = 7.83 Hz, 1 H) 8.90-8.96 (m, 1 H) 27 174
##STR00266## 1-{[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]amino}propan- 2-ol (400 MHz, DMSO-d6) d ppm 1.07
(d, J = 6.32 Hz, 3 H) 3.23 (ddd, J = 13.14, 6.44, 6.19 Hz, 1 H)
3.36-3.41 (m, 1 H) 3.78-3.87 (m, J = 5.79, 5.79, 5.70, 5.70, 5.56,
5.56 Hz, 1 H) 4.82 (d, J = 4.80 Hz, 1 H) 5.87 (s, 2 H) 7.53 (dd, J
= 8.34, 4.29 Hz, 1 H) 7.75 (dd, J = 8.72, 1.64 Hz, 1 H) 7.94 (s, 1
H) 8.00 (d, J = 8.59 Hz, 1 H) 8.13 (s, 1 H) 8.17- 8.24 (m, 1 H)
8.35 (d, J = 8.08 Hz, 1 H) 8.89 (dd, J = 4.04, 1.52 Hz, 1 H) 27 175
##STR00267## 1-{[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]amino}propan- 2-ol (400 MHz, DMSO-d6) d ppm 1.07
(d, J = 6.32 Hz, 3 H) 3.23 (ddd, J = 13.14, 6.44, 6.19 Hz, 1 H)
3.36-3.41 (m, 1 H) 3.78-3.87 (m, J = 5.79, 5.79, 5.70, 5.70, 5.56,
5.56 Hz, 1 H) 4.82 (d, J = 4.80 Hz, 1 H) 5.87 (s, 2 H) 7.53 (dd, J
= 8.34, 4.29 Hz, 1 H) 7.75 (dd, J = 8.72, 1.64 Hz, 1 H) 7.94 (s, 1
H) 8.00 (d, J = 8.59 Hz, 1 H) 8.13 (s, 1 H) 8.17- 8.24 (m, 1 H)
8.35 (d, J = 8.08 Hz, 1 H) 8.89 (dd, J = 4.04, 1.52 Hz, 1 H) 27 176
##STR00268## 1-[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]pyrrolidin-3- carboxamide (400 MHz, DMSO-d6) d ppm
2.05-2.16 (m, 1 H) 2.17-2.28 (m, 1 H) 3.04-3.15 (m, 1 H) 3.53-3.62
(m, 1 H) 3.62-3.70 (m, 1 H) 3.70-3.75 (m, 1 H) 3.75-3.85 (m, 1 H)
5.90 (s, 2 H) 7.04 (s, 1 H) 7.50-7.59 (m, 2 H) 7.76 (dd, J = 8.46,
1.39 Hz, 1 H) 7.93 (s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.22 (s, 1
H) 8.36 (d, J = 8.08 Hz, 1 H) 8.86-8.93 (m, 1 H) 29 177
##STR00269## 1-[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]pyrrolidine-3 carboxamide (400 MHz, DMSO-d6) d ppm
2.05-2.16 (m, 1 H) 2.17-2.28 (m, 1 H) 3.04-3.15 (m, 1 H) 3.53-3.62
(m, 1 H) 3.62-3.70 (m, 1 H) 3.70-3.75 (m, 1 H) 3.75-3.85 (m, 1 H)
5.90 (s, 2 H) 7.04 (s, 1 H) 7.50-7.59 (m, 2 H) 7.76 (dd, J = 8.46,
1.39 Hz, 1 H) 7.93 (s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.22 (s, 1
H) 8.36 (d, J = 8.08 Hz, 1 H) 8.86-8.93 (m, 1 H) 29 178
##STR00270## 3-[1-(2,3-Dihydro- benzo[1,4]dioxin- 6-yl)-ethyl]-3H)-
[1,2,3]triazolo[4,5- b]pyrazin-5- ylamine 1H NMR (400 MHz, DMSO-
D6) .delta. ppm 7.99 (s, 1 H) 7.41 (s, 1 H) 6.71-6.84 (m, 4 H) 5.88
(d, J = 7.33 Hz, 1 H) 4.09-4.25 (m, 4 H) 1.92 (d, J =7.07 Hz, 3 H)
15 179 ##STR00271## 1-(3-Quinolin- 6-ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)-ethanone 1H NMR (400 MHz,
DMSO- D6) .delta. ppm 9.31 (s, 1 H) 8.91 (dd, J = 4.29, 1.77 Hz, 1
H) 8.37 (d, J = 8.34 Hz, 1 H) 8.01-8.11 (m, 2 H) 7.87 (dd, J =
8.84, 2.02 Hz, 1 H) 7.55 (dd, J = 8.34, 4.29 Hz, 1 H) 6.29 (s, 2 H)
2.74 (s, 3 H) 21 180 ##STR00272## 1-[1-(2,3-Dihydro-
benzo[1,4]dioxin- 6-yl)-ethyl]- 6-methyl-1H)- [1,2,3]triazolo[4,5-
b]pyrazine 1H NMR (400 MHz, DMSO- D6) .delta. ppm 8.74 (s, 1 H)
6.91 (d, J = 2.02 Hz, 1 H) 6.76- 6.88 (m, 2 H) 6.25 (q, J = 6.82
Hz, 1 H) 4.18 (s, 4 H) 2.72 (s, 3 H) 2.03 (d, J = 7.07 Hz, 3 H) 17
181 ##STR00273## (R)-1-{3-[1- (2,3-Dihydro- benzo[1,4]dioxin-
6-yl)-ethyl]-3H)- [1,2,3]triazolo[4,5- b]pyrazin-5-
yl}-pyrrolidin-3- ylamine 1H NMR (400 MHz, DMSO- D6) .delta. ppm
8.39 (s, 2 H) 8.15- 8.28 (m, 1 H) 6.86-6.98 (m, 2 H) 6.73-6.86 (m,
1 H) 6.00 (dd, J = 7.07, 3.03 Hz, 1 H) 4.13-4.27 (m, 4 H) 3.93-4.08
(m, 1 H) 3.66-3.90 (m, 4 H) 2.35 (s, 1 H) 2.20 (s, 1 H) 1.99 (d, J
= 7.07 Hz, 3 H) 16 182 ##STR00274## 2-(3-Quinolin-6- ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)-propan-2-ol 1H NMR (400 MHz,
DMSO- d6) .delta. ppm 9.15 (s, 1 H) 8.89 (dd, J = 4.17, 1.64 Hz, 1
H) 8.35 (d, J = 8.34 Hz, 1 H) 7.92 8.09 (m, 2 H) 7.76-7.85 (m, 1 H)
7.54 (dd, J = 8.34, 4.29 Hz, 1 H) 6.17 (s, 2 H) 5.79 (s, 1 H) 1.55
(s, 6 H) 22 183 ##STR00275## 1-(3-Quinolin-6- ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)-ethylamine 1H NMR (400 MHz,
DMSO- d6) .delta. ppm 9.04 (s, 1 H) 8.89 (dd, J = 4.29, 1.77 Hz, 1
H) 8.36 (dd, J = 8.34, 1.01 Hz, 1 H) 7.94-8.10 (m, 2 H) 7.79 (dd, J
= 8.72, 2.15 Hz, 1 H) 7.53 (dd, J =8.21, 4.17 Hz, 1 H) 6.17 (s, 2
H) 4.30 (q, J = 6.57 Hz, 1 H) 1.90 (s, 3 H) 1.36-1.50 (m, J = 6.44,
6.44 Hz, 3 H) 23 184 ##STR00276## 1-(3-Quinolin-6- ylmethyl-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)-ethanol 1H NMR (400 MHz,
DMSO- d6) .delta. ppm 9.01 (s, 1 H) 8.90 (dd, J = 4.04, 1.77 Hz, 1
H) 8.28-8.43 (m, 1 H) 8.02 (d, J = 8.59 Hz, 1 H) 7.97 (d, J = 1.77
Hz, 1 H) 7.79 (dd, J = 8.84, 2.02 Hz, 1 H) 7.54 (dd, J = 8.34, 4.04
Hz, 1 H) 6.19 (s, 2 H) 5.91 (d, J = 4.80 Hz, 1 H) 4.86-5.13 (m, 1
H) 1.43- 1.55 (m, 3 H) 23 185 ##STR00277## 1-[(R)-1-(2,3- Dihydro-
benzo[1,4]dioxin- 6-yl)-ethyl]- 6-(1-methyl-1H- pyrazol-4-yl)-1H-
[1,2,3]triazolo[4,5- b]pyrazine 1H NMR (400 MHz, DMSO- D6) .delta.
ppm 9.16 (s, 1 H) 8.63 (s, 1 H) 8.29 (s, 1H) 7.00 (d, J = 2.27 Hz,
1 H) 6.93 (dd, J = 8.46, 2.15 Hz, 1 H) 6.81 (d, J = 8.34 Hz, 1 H)
6.23 (d, J = 7.33 Hz, 1 H) 4.18 (s, 4 H) 3.94 (s, 3 H) 2.07 (d, J =
7.33 Hz, 3 H) 40 186 ##STR00278## 1-[1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]-D-prolinamide (400 MHz, MeOD)
.delta. ppm 2.12-2.23 (m, 3 H) 2.35-2.46 (m, 1 H) 3.72 (dt, J =
9.66, 7.55 Hz, 1 H) 3.89-3.96 (m, 1 H) 4.64 (dd, J = 8.34, 2.27 Hz,
1 H) 5.86-5.97 (m, 2H) 7.54 (dd, J =8.34, 4.29 Hz, 1 H) 7.89 (dd, J
= 8.72, 1.89 Hz, 1 H) 8.00-8.04 (m, 2 H) 8.21 (s, 1 H) 8.42 (d, J =
7.58 Hz, 1 H) 8.84 (dd, J = 4.29, 1.77 Hz, 1 H) 27 187 ##STR00279##
N,N-dimethyl-2- {[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl]oxy}ethanamine (400 MHz, DMSO-d6) .delta. ppm 2.13
(s, 6 H) 2.61 (t, J = 5.67 Hz, 2 H) 4.50 (t, J = 5.67 Hz, 2 H) 6.06
(s, 2 H) 7.54 (dd, J = 8.31, 4.03 Hz, 1 H) 7.78 (dd, J = 8.69, 2.14
Hz, 1 H) 7.97 (d, J = 1.76 Hz, 1 H) 8.01 (d, J = 8.81 Hz, 1 H) 8.36
(dd, J = 8.31, 1.01 Hz, 1 H) 8.42 (s, 1 H) 8.90 (dd, J = 4.15, 1.64
Hz, 1 H) 28 188 ##STR00280## tert-butyl(1,1- dimethyl-2-{[1-
(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]amino}ethyl)- carbamate (400 MHz, DMSO-d6) .delta. ppm 1.16 (s,
6 H) 1.34 (s, 9 H) 3.59 (d, J = 5.81 Hz, 2 H) 5.87 (s, 2 H) 6.57
(s, 1 H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.77 (dd, J = 8.59, 1.52
Hz, 1 H) 7.95-8.01 (m, 2 H) 8.04 (t, J = 5.43 Hz, 1 H) 8.16 (s, 1
H) 8.35 (dd, J = 8.34, 1.01 Hz, 1 H) 8.89 (dd, J = 4.29, 1.77 Hz, 1
H) 27 189 ##STR00281## 3-amino-1- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidine-3- carboxamide
(400 MHz, MeOD) .delta. ppm 2.03-2.13 (m, 1 H) 2.49-2.61 (m, 1 H)
3.68 (d, J = 11.87 Hz, 1 H) 3.83-3.94 (m, 2 H) 3.99 (d, J = 11.62
Hz, 1 H) 5.95 (s, 2 H) 7.54 (dd, J = 8.34, 4.55 Hz, 1 H) 7.84 (dd,
J = 8.72, 1.89 Hz, 1 H) 7.95 (d, J = 1.52 Hz, 1 H) 8.00 (d, J =
8.59 Hz, 1 H) 8.15 (s, 1 H) 8.35 (d, J = 8.34 Hz, 1 H) 8.84 (dd, J
= 4.29, 1.77 Hz, 1 H) 27 190 ##STR00282## 4,4-dimethyl-1-
[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]imidazolidin- 2-one (400 MHz, DMSO-d6) .delta. ppm 1.32 (s, 6 H)
3.79 (s, 2 H) 6.04 (s, 2 H) 7.54 (dd, J = 8.34, 4.29 Hz, 1 H) 7.79
(dd, J = 8.59, 2.02 Hz, 1 H) 7.97 (d, J = 1.77 Hz, 1 H) 8.00-8.04
(m, 2 H) 8.37 (dd, J = 8.34, 1.01 Hz, 1 H) 8.90 (dd, J = 4.17, 1.64
Hz, 1 H) 9.72 (s, 1 H) 30 191 ##STR00283## 6-({6-[3-(4-
fluoropiperidin- 1-yl)pyrrolidin- 1-yl]-1H- [1,2,3]triazolo[4,5-
b]pyrazin-6- yl}methyl)quinoline (400 MHz, DMSO-d6) .delta. ppm
1.67-1.78 (m, 2 H) 1.80-1.92 (m, 3 H) 2.17-2.29 (m, 1H) 2.35-2.46
(m, 2 H) 2.53-2.71 (m, 3 H) 2.93-3.03 (m, 1 H) 3.44-3.54 (m, 1 H)
3.76-3.85 (m, 1 H) 3.85-3.97 (m, 1 H) 4.54-4.83 (m, 1 H) 5.90 (s, 2
H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.75 (dd, J = 8.72, 1.89 Hz, 1
H) 7.94 (s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.23 (s, 1 H) 8.36 (d,
J = 8.34 Hz, 1 H) 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 27 192
##STR00284## N,N-dimethyl-N'- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]ethane-1,2,- diamine 1H NMR
(400 MHz, DMSO- d6) .delta. ppm 2.10 (s, 6 H) 2.39 (t, J = 6.44 Hz,
2 H) 3.42 (q, J = 6.23 Hz, 2 H) 5.88 (s, 2 H) 7.53 (dd, J = 8.34,
4.29 Hz, 1 H) 7.73 (dd, J = 8.72, 1.89 Hz, 1 H) 7.91 (s, 1 H) 7.99
(d, J = 8.84 Hz, 1 H) 8.07-8.16 (m, 2 H) 8.35 (d, J = 8.34 Hz, 1 H)
8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 27 193 ##STR00285##
6-[(6-methoxy-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl)methyl]quinoline 1H NMR (400 MHz, MeOD) .delta. ppm 4.08 (s, 3
H) 6.36 (s, 2 H) 7.95 (dd, J = 8.46, 5.18 Hz, 1 H) 8.14-8.22 (m, 2
H) 8.29 (s, 1 H) 8.94 (d, J = 7.83 Hz, 1 H) 9.13 (d, J = 4.04 Hz, 1
H) 9.40 (s, 1 H) 28 194 ##STR00286## 1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazine-6- carboxylic acid 1H NMR (400 MHz,
DMSO- d6) d ppm 6.24 (s, 2 H) 7.61 (dd, J = 8.34, 4.55 Hz, 1 H)
7.83 (dd, J = 8.72, 1.89 Hz, 1 H) 7.94 (s, 1 H) 8.02 (d, J = 8.84
Hz, 1 H) 8.47 (d, J = 8.08 Hz, 1 H) 8.95 (dd, J = 4.42, 1.64 Hz, 1
H) 9.34 (s, 1 H) 35 195 ##STR00287## N-methyl- 1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazine-6- carboxamide 1H
NMR (400 MHz, DMSO- d6) .delta. ppm 2.92 (d, J = 4.80 Hz, 3 H) 6.28
(s, 2 H) 7.69 (dd, J = 8.34, 4.55 Hz, 1 H) 7.98 (dd, J = 8.72, 1.89
Hz, 1 H) 8.08-8.13 (m, 2 H) 8.55 (d, J = 7.83 Hz, 1 H) 9.02 (dd, J
= 4.42, 1.64 Hz, 1 H) 9.13 (q, J = 4.46 Hz, 1 H) 9.41 (s, 1 H) 36
196 ##STR00288## methyl 1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazine-6- carboxylate 1H NMR (400 MHz,
DMSO- d6) .delta. ppm 3.95 (s, 3 H) 6.25 (s, 2 H) 7.49 (dd, J =
8.34, 4.29 Hz, 4 H) 7.75 (dd, J = 8.84, 2.02 Hz, 1 H) 7.88 (s, 1 H)
7.98 (d, J = 8.84 Hz, 1 H) 8.29 (d, J = 8.34 Hz, 1 H) 8.86 (dd, J =
4.17, 1.64 Hz, 1 H) 9.38 (s, 1 H) 34 197 ##STR00289## 2-(4-{1-[(7-
fluoroquinolin- 6-yl)methyl]-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl}-1H-pyrazol-1- yl)ethanol 1H NMR (400 MHz, DMSO- d6) .delta. ppm
3.78 (t, J = 5.43 Hz, 2 H) 4.24 (t, J = 5.43 Hz, 2 H) 6.18 (s, 2 H)
7.54 (dd, J = 8.34, 4.29 Hz, 1 H) 7.84 (d, J = 11.37 Hz, 1H) 8.15
(d, J = 8.34 Hz, 1 H) 8.29 (s, 1 H) 8.44 (d, J = 7.33 Hz, 1 H) 8.62
(s, 1 H) 8.93 (dd, J = 4.29, 1.52 Hz, 1 H) 9.23 (s, 1 H) 39 198
##STR00290## N-{(3S)-1- [1-(quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-3- yl}acetamide 1H
NMR (400 MHz, DMSO- d6) .delta. ppm 1.81 (s, 3 H) 1.87- 1.98(m, 1
H) 2.13-2.24 (m, 1 H) 3.41-3.50 (m, 2 H) 3.60- 3.78 (m, 2 H) 4.39
(bs, 1 H) 5.91 (s, 2 H) 7.52 (dd, J = 8.34, 4.29 Hz, 1 H) 7.76 (dd,
J = 8.72, 1.89 Hz, 1 H) 7.94 (d, J = 1.77 Hz, 1 H) 8.00 (d, J =
8.84 Hz, 1 H) 8.19 (d, J = 6.57 Hz, 1 H) 8.22 (s, 1 H) 8.35 (d, J =
7.33 Hz, 1 H) 8.89 (dd, J = 4.04, 1.77 Hz, 1 H) 27
199 ##STR00291## 6-({6-[(3S)-3- methylmorpholin- 4-yl]-1H-
[123]triazolo[45- b]pyrazin-1- yl}methyl)quinoline 1H NMR (500 MHz,
DMSO- d6) d ppm 1.21 (d, J = 6.04 Hz, 3 H) 3.73-3.77 (m, 5 H)
5.92-5.93 (m, 2 H) 7.49-7.58 (m, 1 H) 7.73-7.82 (m, 1 H) 7.94-8.04
(m, 2 H) 8.30-8.39 (m, 1 H) 8.46-8.53 (m, 1 H) 8.84-8.93 (m, 1 H)
(two aliphatic protons not resolved, due to water peak) 27 200
##STR00292## (R)-tert-butyl-1- (3-(quinolin- 6-ylmethyl)-3H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)pyrrolidin-3- ylcarbamate (400
MHz, DMSO-d6) .delta. ppm 1.38 (s, 9 H) 1.88-1.99 (m, 1 H)
2.10-2.22 (m, 1 H) 3.44 (dd, J = 11.49, 4.42 Hz, 1 H) 3.61-3.73 (m,
3 H) 4.12-4.23 (m, 1 H) 5.91 (s, 2 H) 7.27 (d, J = 5.56 Hz, 1 H)
7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.76 (dd, J = 8.72, 1.89 Hz, 1 H)
7.93 (d, J = 1.26 Hz, 1 H) 8.00 (d, J = 8.84 Hz, 1 H) 8.21 (s, 1 H)
8.33-8.38 (m, 1 H) 8.89 (dd, J = 4.29, 1.77 Hz, 1 H) 26 201
##STR00293## tert-butyl 4-(3- (quinolin- 6-ylmethyl)-1H-
[1,2,3]triazolo[4,5- b]pyrazin-5- yl)piperazine-1- carboxylate (400
MHz, DMSO-d6) .delta. ppm 1.42 (s, 9 H) 3.41-3.49 (m, 4 H)
3.75-3.82 (m, 4 H) 5.93 (s, 2 H) 7.54 (dd, J = 8.34, 4.29 Hz, 1 H)
7.76 (dd, J = 8.84, 2.02 Hz, 1 H) 7.96 (d, J = 1.52 Hz, 1 H) 8.01
(d, J = 8.84 Hz, 1 H) 8.37 (d, J = 7.33 Hz, 1 H) 8.56 (s, 1 H) 8.89
(dd, J = 4.17, 1.64 Hz, 1 H) 26 202 ##STR00294## (R)-tert-butyl 1-
(3-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-5-
yl)piperidin-3- ylcarbamate (400 MHz, MeOD) .delta. ppm 1.43 (s, 9
H) 1.54-1.65 (m, 2 H) 1.79-1.89 (m, 1 H) 1.94- 2.03 (m, 1 H)
3.24-3.27 (m, 1 H) 3.35-3.45 (m, 1 H) 3.50- 3.61 (m, 1 H) 4.10-4.18
(m, 1 H) 4.37 (dd, J = 13.52, 3.41 Hz, 1 H) 5.93 (s, 2 H) 7.53 (dd,
J = 8.34, 4.29 Hz, 1 H) 7.87 (d, J = 7.83 Hz, 1 H) 7.98-8.03 (m, 2
H) 8.37 (d, J = 7.83 Hz, 1 H) 8.42 (s, 1 H) 8.83 (dd, J = 4.29,
1.77 Hz, 1 H) 26 203 ##STR00295## (S)-tert-butyl 1- (3-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-5- yl)piperidin-3-
ylcarbamate (400 MHz, DICHLOROMETHANE-d2) .delta. ppm 1.43 (s, 9 H)
1.58-1.69 (m, 2 H) 1.76-1.86 (m, 1 H) 1.95-2.04 (m, 1 H) 3.30-3.40
(m, 1 H) 3.46-3.57 (m, 1 H) 3.63-3.73 (m, 1 H) 3.92-4.01 (m, 1 H)
4.23 (dd, J = 13.14, 3.28 Hz, 1 H) 5.86 (s, 2 H) 7.40 (dd, J =
8.34, 4.29 Hz, 1 H) 7.81 (d, J = 8.59 Hz, 1 H) 7.89 (s, 1H) 8.04
(d, J = 8.59 Hz, 1 H) 8.17 (d, J = 8.59 Hz, 1 H) 8.31 (s, 1 H) 8.87
(dd, J = 4.17, 1.64 Hz, 1 H) 26 204 ##STR00296## 2-(methyl{(3R)-
1-[1-(quinolin- 6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6-
yl]pyrrolidin- yl}amino)ethanol. TFA salt 1 H NMR (400 MHz, MeOD) d
ppm 2.43 (td, J = 8.21, 5.05 Hz, 1 H) 2.64-2.74 (m, 1 H) 3.04 (s, 3
H) 3.34-3.46 (m, 3 H) 3.70-3.79 (m, 1 H) 3.86- 3.97 (m, 3 H)
4.00-4.08 (m, 1 H) 4.20-4.32 (m, 2 H) 6.07 (s, 2 H) 7.90 (dd, J =
8.34, 5.05 8.27 (s, 1 H) 8.86 (d, J = 7.83 Hz, 1 H) 9.09 (dd, J =
4.80, 1.52 Hz, 1 H) 41 205 ##STR00297## 1-[1-(quinolin-
6-ylmethyl)-1H- [1,2,3]triazolo[4,5- b]pyrazin-6- yl]pyrrolidin-
3-ol. TFA salt 1H NMR (400 MHz, DMSO- d6) d ppm 1.96-2.04 (m, 2 H)
3.61-3.72 (m, 3 H) 4.39-4.49 (m, 1 H) 5.05-5.17 (m, 1 H) 5.91 (s, 2
H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.76 (dd, J = 8.59, 2.02 Hz, 1
H) 7.93 (s, 1 H) 8.01 (d, J = 8.84 Hz, 1 H) 8.22 (s, 1 H) 8.36 (d,
J = 7.58 Hz, 1 H) 8.89 (dd, J = 4.29, 1.77 Hz, 1 H) 41 206
##STR00298## 6-({6-[(3R)- 3-morpholin- 4-ylpyrrolidin- 1-yl]-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl}methyl)- quinoline. TFA salt
1H NMR (400 MHz, DMSO- d6) d ppm 1.76-1.88 (m, 1 H) 2.16-2.27 (m, 1
H) 2.36-2.46 (m, 3 H) 2.86-2.97 (m, 1 H) 3.40-3.41 (m, 3 H)
3.55-3.66 (m, 4 H) 3.79-3.94 (m, 2 H) 5.91 (s, 2 H) 7.53 (dd, J =
8.34, 4.29 Hz, 1 H) 7.75 (dd, J = 8.84, 2.02 Hz, 1 H) 7.94 (s, 1 H)
8.00 (d, J = 8.59 Hz, 1 H) 8.23 (s, 1 H) 8.36 (d, J = 7.58 Hz, 1 H)
8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 41 207 ##STR00299##
6-({6-[(3S)-3-(4,4- difluoropiperidin- 1-yl)pyrrolidin- 1-yl]-1H-
[1,2,3]triazolo[4,5- b]pyrazin-1- yl}methyl)- quinoline. TFA salt
1H NMR (400 MHz, DMSO- d6) d ppm 1.86-2.02 (m, 5 H) 2.18-2.28 (m, 1
H) 2.54-2.65 (m, 4 H) 3.04-3.16 (m, 1 H) 3.33-3.38 (m, 1 H)
3.45-3.57 (m, 1 H) 3.75-3.85 (m, 1 H) 3.85-3.97 (m, 1 H) 5.90 (s, 2
H) 7.53 (dd, J = 8.34, 4.29 Hz, 1 H) 7.75 (dd, J = 8.72, 1.89 Hz, 1
H) 7.94 (d, J = 1.26 Hz, 1 H) 8.00 (d, J = 8.84 Hz, 1 H) 8.23 (s, 1
H) 8.33-8.38 (m, 1 H) 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 41 208
##STR00300## 6-({6-[(3R)-3-(4,4- difluoropiperidin-
1-yl)pyrrolidin- 1-yl]-1H- [1,2,3]triazolo[4,5- b]pyrazin-1-
yl}methyl)- quinoline. TFA salt 1H NMR (400 MHz, DMSO- d6) d ppm
1.89-1.97 (m, 5 H) 2.18-2.25 (m, 1 H) 2.52-2.64 (m, 4 H) 3.03-3.14
(m, 1 H) 3.45-3.55 (m, 2 H) 3.70-3.82 (m, 1 H) 3.86-3.94 (m, 1 H)
5.90 (s, 2 H) 7.52 (dd, J = 8.34, 4.04 Hz, 1 H) 7.75 (dd, J = 8.72,
1.89 Hz, 1 H) 7.93 (s, 1 H) 8.00 (d, J = 8.59 Hz, 1 H) 8.22 (s, 1
H) 8.35 (d, J = 7.58 Hz, 1 H) 8.88 (dd, J = 4.29, 1.52 Hz, 1 H)
41
TABLE-US-00005 TABLE 5 Example Structure Name NMR Method 209
##STR00301## 2-[4-(3- Quinolin-6- ylmethyl-3H- [1,2,3]tri-
azolo[4,5- b]pyrazin- 5-yl)- pyrazol-1- yl]-ethanol mesylate salt
1H NMR (400 MHz, DMSO- d6) d ppm 9.06-9.30 (m, 1H H) 8.64 (s, 1H)
8.33-8.40 8.89 (dd, J = 4.17, 1.64 Hz, 1 H) 8.64 (s, 1H) 8.33-8.40
(m, 1H) 8.33 (s, 1H) 7.94- 8.09 (m, 2H) 7.82 (dd, J = 8.59, 2.02
Hz, 1H) 7.53 (dd, J = 8.34, 4.04 Hz, 1H) 6.15 (s, 2H) 5.01 (s, 1H)
4.24 (t, J = 5.31Hz, 2H) 3.78 (t, J = 5.31Hz, 2H) 42 210
##STR00302## [4-(3- Quinolin-6- ylmethyl- 3H- [1,2,3]tri-
azolo[4,5- b]pyrazin- 5-yl)- pyrazol-1- yl]-acetic acid 1H NMR (300
MHz, DMSO- d6) .delta. ppm 9.21 (s, 1H) 8.89 (dd, J = 4.14, 1.70
Hz, 1H) 8.56 (s, 1H) 8.38 (dd, J = 8.19, 1.60 Hz, 1H) 8.22 (s, 1H)
7.98-8.08 (m, 2H) 7.83 (dd, J = 8.67, 1.88 Hz, 1H) 7.53 (dd, J =
8.29, 4.33 Hz, 1H) 6.15 (s, 2H) 4.59 (s, 2H) 43 211 ##STR00303##
N,N- dimethyl-3- (4-(3- (quinolin-6- ylmethyl)- 3H- [1,2,3]tri-
azolo[4,5- b]pyrazin 5-yl)-1H- pyrazol-1- yl)propan- 1-amine 1H NMR
(400 MHz, DMSO- d6) .delta. ppm 9.47 (s, 1H), 9.24 (s, 1H), 8.94
(dd, J = 4.29, 1.77 Hz, 1H), 8.70 (s, 1H), 8.44 (d, J = 7.83 Hz,
1H), 8.38 (s, 1H), 8.06 (d, J = 8.59 Hz, 1 H), 8.00 (s, 1H), 7.85
(dd, J = 8.72, 1.89 Hz, 1H), 7.59 (dd, J = 8.34, 4.29 Hz, 1H), 6.17
(s, 2H), 4.30 (t, J = 6.69 Hz, 2H), 3.07 (dt, J = 10.55, 5.21Hz,
2H), 2.77 (d, J = 4.55 Hz, 6H), 2.16-2.25 (m, 2H). LC-MS 413. 44
212 ##STR00304## 6-[(S)-1-(6- Bromo- [1,2,3]tri- azolo[4,5-
b]pyrazin- 1-yl)-ethyl]- quinoline 1H NMR (300 MHz, DMSO- d6)
.delta. ppm 8.99 (s, 1H) 8.90 (dd, J = 4.14, 1.70 Hz, 1H) 8.28-8.46
(m, 1H) 7.94- 8.08 (m, 2 H) 7.82 (dd, J = 8.85, 2.07 Hz, 1H) 7.54
(dd, J = 8.29, 4.14 Hz, 1H) 6.50-6.66 (m, J = 7.16 Hz, 1H) 2.19 (d,
J = 6.97 Hz, 3H) 44 213 ##STR00305## 6-{1-[6-(1- Methyl-1H-
pyrazol-4- yl)- [1,2,3]tri- azolo[4,5- b]pyrazin- 1-yl]- ethyl}-
quinoline 1H NMR (300 MHz, DMSO- d6) .delta. ppm 9.18 (s, 1H) 8.89
(dd, J = 4.14, 1.51 Hz, 1H) 8.62 (s, 1H), 8.35-8.43 (m, 1H) 8.28
(s, 1H) 7.96- 8.11 (m, 2H) 7.81-7.94 (m, J = 1.88, 1H), 7.53 (dd, J
= 8.29, 4.14 Hz, 1H) 6.46-6.65 (m, J = 7.35 Hz, 1 H), 3.94 (s, 3H)
2.25 (d, J = 7.16 Hz, 3H) 42 214 ##STR00306## 6-{(S)-1-[6-
(1-Methyl- 1H-pyrazol- 4-yl)- [1,2,3]tri- azolo[4,5- b]pyrazin-
1-yl]-ethyl}- quinoline 1H NMR (300 MHz, DMSO- d6) .delta. ppm 9.20
(s, 1H) 8.87- 8.96 (m, 1H) 8.57-8.72 (m, 1H) 8.36-8.47 (m, 1H) 8.30
(s, 1H) 7.98-8.14 (m, J = 19.976 Hz, 2H) 7.81- 7.97 (m, 1H)
7.48-7.60 (m, J = 8.29 Hz, 1H) 6.50- 6.69 (m, J = 7.54 Hz, 1H) 3.96
(s, 3H) 2.27 (d, J = 6.97 Hz, 3H) 42 215 ##STR00307## 6-{(R)-1-[6-
(1-Methyl- 1H-pyrazol- 4-yl)- [1,2,3]tri- azolo[4,5- b]pyrazin-
1-yl]-ethyl}- quinoline 1H NMR (300 MHz, DMSO- d6) .delta. ppm 9.20
(s, 1H) 8.87- 8.96 (m, 1H) 8.57-8.72 (m, 1 H) 8.36-8.47 (m, 1H)
8.30 (s, 1H) 7.98-8.14 (m, J = 19.97 Hz, 2H) 7.81- 7.97 (m, 1H)
7.48-7.60 (m, J = 8.29 Hz, 1H) 6.50- 6.69 (m, J = 7.54 Hz, 1H) 3.96
(s, 3H) 2.27 (d, J = 6.97 Hz, 3 H) 42 216 ##STR00308## 2-{4-[3- (1-
Quinolin-6- yl-ethyl)- 3H- [1,2,3]tri- azolo[4,5- b]pyrazin- 5-yl]-
pyrazol-1- yl}-ethanol 1H NMR (300 MHz, DMSO- d6) .delta. ppm 9.20
(s, 1H) 8.82- 8.92 (m, 1H) 8.62 (s, 1H) 8.34-8.45 (m, 1H) 8.22-8.33
(m, 1H) 8.05- 8.11 (m, 1H) 7.96-8.04 (m, 1 H) 7.82-7.93 (m, 1H)
7.44- 7.59 (m, 1H) 6.47- 6.64 (m, 1H) 4.88-5.05 (m, 1 H) 4.17-4.28
(m, 2 H) 3.71- 3.86 (m, 1H) 2.24 (d, J = 7.16 Hz, 3H) 42 217
##STR00309## 2-{4-[3- ((S)-1- Quinolin-6- yl-ethyl)- 3H-
[1,2,3]tri- azolo[4,5- b]pyrazin- 5-yl]- pyrazol-1- yl}-ethanol 1H
NMR (300 MHz, DMSO- d6) .delta. ppm 9.20 (s, 1H) 8.89 (dd, J =
4.14, 1.70 Hz, 1H) 8.63 (s, 1H) 8.35-8.46 (m, 1H) 8.27-8.33 (m, 1H)
7.97-8.11 (m, 2 H) 7.84- 7.94 (m, 1H) 7.53 (dd, J = 8.19, 4.24 Hz,
1H) 6.49- 6.66 (m, 1H) 4.98 (t, J = 5.27 Hz, 1H) 4.24 (t, J = 5.27
Hz, 2 H) 3.72-3.84 (m, 2H) 2.24 (d, J = 7.16 Hz, 3H) 42 218
##STR00310## 2-{4-[3-((R)-1- Quinolin- 6-yl-ethyl)- 3H- [1,2,3]tri-
azolo[4,5- b]pyrazin- 5-yl]- pyrazol-1- yl}-ethanol 1H NMR (300
MHz, DMSO- d6) .delta. ppm 9.20 (s, 1H) 8.89 (dd, J = 4.14, 1.70
Hz, 1H) 8.63 (s, 1H) 8.35-8.46 (m, 1H) 8.27-8.33 (m, 1H) 7.97-8.11
(m, 2H) 7.84- J = 8.19, 4.24 Hz, 1H) 6.49- 7.94 (m, 1H) 7.53 (dd,
6.66 (m, 1H) 4.98 (t, J = 5.27 Hz, 1H) 4.24 (t, J = 5.27 Hz, 2 H)
3.72-3.84 (m, 2 H) 2.24 (d, J = 7.16 Hz, 3H) 42 219 ##STR00311##
2-[4-(3- Quinazolin- 6-ylmethyl- 3H-[1,2,3] triazolo[4,5-
b]pyrazin- pyrazol-1- yl]-ethanol 1H NMR (400 MHz, MeOD) d ppm 3.95
(t, J = 5.31 Hz, 2H) 4.33 (t, J = 5.31 Hz, 2H) 6.23 (s, 2H) 8.05
(d, J = 8.84 Hz, 1 H) 8.14-8.22 (m, 2H) 8.30 (s, 1H) 8.54 (s, 1H)
9.11 (s, 1H) 9.24 (s, 1H) 9.53 (s, 1H) 42 220 ##STR00312## 6-[6-(1-
Methyl-1H- pyrazol-4- yl)-[1,2,3] triazolo[4,5- b]pyrazin-
1-ylmethyl]- quinazoline 1H NMR (400 MHz, DMSO- D6) d ppm 3.93 (s,
3H) 4.09 (q, J = 5.14 Hz, 1H) 6.19 (s, 2 H) 8.00-8.06 (m, 1H) 8.08-
8.15 (m, 2H) 8.29 (s, 1H) 8.62 (s, 1H) 9.21 (s, 1H) 9.28 (s, 1H)
9.60 (s, 1H) 46
Biological Assays
General
[0382] In vitro assays may be used to determine the level of
activity and effect of the different compounds of the present
invention on one or more of the PKs. Similar assays can be designed
along the same lines for any PK using techniques well known in the
art. See for example, Technikova-Dobrova Z, Sardanelli A M, Papa S
FEBS Lett. 1991 Nov. 4; 292: 69-72.
[0383] A general procedure is as follows: compounds and kinase
assay reagents are introduced into test wells. The assay is
initiated by addition of the kinase enzyme. Enzyme inhibitors
reduce the measured activity of the enzyme.
[0384] Presently, the continuous-coupled spectrophotometric assay
was used to determine the level of activity and effect of the
different compounds of the present invention on the tyrosine kinase
activity of HGFR on the Met-2 substrate peptide. In the
continuous-coupled spectrophotometric assay the time-dependent
production of ADP by the kinase is determined by analysis of the
rate of consumption of NADH by measurement of the decrease in
absorbance at 340 nm. As the PK produces ADP it is re-converted to
ATP by reaction with phosphoenol pyruvate and pyruvate kinase.
Pyruvate is also produced in this reaction. Pyruvate is
subsequently converted to lactate by reaction with lactate
dehydrogenase, which simultaneously converts NADH to NAD. NADH has
a measurable absorbance at 340 nm whereas NAD does not.
[0385] The presently preferred protocol for conducting the
continuous-coupled spectrophotometric experiments for specific PKs
is provided below. However, adaptation of this protocol for
determining the activity of compounds against other RTKs, as well
as for CTKs and STKs, is well within the scope of knowledge of
those skilled in the art.
HGFR Continuous-Coupled Spectrophotometric Assay
[0386] This assay was used to analyze the tyrosine kinase activity
of HGFR on the Met-2 substrate peptide, a peptide derived from the
activation loop of the HGFR. Assay results in the form of Ki values
(.mu.M) are summarized in Table 6.
[0387] Materials and Reagents: [0388] 1. HGFR enzyme from Upstate
(Met, active) Cat. #14-526 [0389] 2. Met-2 Peptide (HGFR Activation
Loop) Ac-ARDMYDKEYYSVHNK (MW=1960). Dissolve up in 200 mM HEPES, pH
7.5 at 10 mM stock. [0390] 3. 1 M PEP (phospho-enol-pyruvate) in
200 mM HEPES, pH 7.5 [0391] 4. 100 mM NADH (B-Nicotinamide Adenine
Dinucleotide, Reduced Form) in 200 mM HEPES, pH 7.5 [0392] 5. 4 M
MgCl.sub.2 (Magnesium Chloride) in ddH.sub.2O [0393] 6. 1 M DTT
(Dithiothreitol) in 200 mM HEPES, pH 7.5 [0394] 7. 15 Units/mL LDH
(Lactic Dehydrogenase) [0395] 8. 15 Units/mL PK (Pyruvate Kinase)
[0396] 9. 5M NaCl dissolved in ddH.sub.2O [0397] 10. Tween-20
(Protein Grade) 10% Solution [0398] 11.1 M HEPES buffer:
(N-[2-Hydroxethyl]piperazine-N-[2-ethanesulfonic acid]) Sodium
Salt. Dissolve in ddH2O, adjust pH to 7.5, bring volume to 1 L.
Filter at 0.1 .mu.m. [0399] 12. HPLC Grade Water; Burdick and
Jackson #365-4, 1.times.4 liters (or equivalent) [0400] 13.100%
DMSO (SIGMA) [0401] 14. Costar #3880--black clear flat bottom half
area plates for K determination and % inhibition [0402] 15. Costar
#3359--96 well polypropylene plates, round bottom for serial
dilutions [0403] 16. Costar #3635--UV-plate clear flat bottom
plates for % inhibition [0404] 17. Beckman DU-650 w/micro cell
holders [0405] 18. Beckman 4-position micro cell cuvette
Procedure:
[0406] Prep Dilution Buffer (DB) for Enzyme (For 30 mL prep) [0407]
1. DB final concentration is 2 mM DTT, 25 mM NaCl.sub.2, 5 mM
MgCl.sub.2, 0.01% Tween-20, and 50 mM HEPES buffer, pH 7.5. [0408]
2. Make up 50 mM HEPES by adding 1.5 mL 1 M HEPES into 28.1 mL of
ddH2O. Add rest of the reagents. Into 50 mL conical vial, add 60
.mu.L of 1M DTT, 150 .mu.L 5M NaCl.sub.2, 150 .mu.L 1M MgCl.sub.2,
and 30 .mu.L of 10% Tween-20 to give total volume of 30 mL. [0409]
3. Vortex for 5-10 seconds. [0410] 4. Aliquot out DB at 1 mL/tube
and label tubes as "DB HGFR" [0411] 5. Note: This can be prepared
and stored ahead of time. [0412] 6. Freeze un-used aliquots in
microcentrifuge tubes at -20.degree. C. freezer. Prep Compounds
[0413] 1. For compound dilution plate, add 4 .mu.L of 10 mM stock
into column 1 of plate, and bring volume to 100 .mu.L with 100%
DMSO. [0414] 2. Set up the Precision 2000 dilution method. A final
concentration of 200 .mu.M compound in 50% DMSO, 100 mM HEPES (1:2
serial dilution).
Prep Coupled Enzymatic Buffer:
[0414] [0415] 1. Final concentration in assay:
TABLE-US-00006 [0415] Reagent (Stock Conc.) Final Conc. In Assay a.
PEP (1 M) 1 mM b. NADH (100 mM) 300 .mu.M c. MgCl.sub.2 (4 M) 20 mM
d. DTT (1 M) 2 mM e. ATP (500 mM) 300 .mu.M f. HEPES 200 mM (pH
7.5) 100 mM g. Pyruvate Kinase (PK) 15 units/mL h. Lactic
Dehydrogenase (LDH) 15 units/mL i. Met-2 peptide (10 mM) 0.500 mM
j. HGFR 50 nM
[0416] 2. For a 10 mL reaction buffer add 10 .mu.L of 1M PEP, 33
.mu.L of 100 mM NADH, 50 .mu.L of 4M MgCl.sub.2, 20 .mu.L of 1M
DTT, 6 .mu.L of 500 mM ATP, and 500 .mu.L of 10 mM Met-2 peptide
into 100 mM HEPES buffer pH 7.5 and vortex/mix. [0417] 3. Add
coupling enzymes, LDH and PK, into reaction mix. Mix by gentle
inversion. Running samples [0418] 1. Spectrophotometer
settings:
TABLE-US-00007 [0418] i. Absorbance wavelength (.lamda.): 340 nm
ii. Incubation time: 10 min iii. Run time: 10 min iv. Temperature:
37.degree. C.
[0419] 2. Add 85 .mu.L of CE reaction mix into each well of assay
plate. [0420] 3. Add 5 .mu.L of diluted compound into a well of the
assay plate. [0421] 4. Add 5 .mu.L of 50% DMSO for negative control
into last column of assay plate. [0422] 5. Mix with multi-channel
pipettor or orbital shaker. [0423] 6. Pre-incubate for 10 minutes
at 37.degree. C. [0424] 7. Add 10 .mu.L of 500 nM HGFR to each well
of assay plate; the final HGFR concentration is 50 nM in a total
final volume of 100 .mu.L. [0425] 8. Measure activity for 10
minutes at .lamda.=340 nm and 37.degree. C.
TABLE-US-00008 [0425] TABLE 6 Example Ki 1 0.008 2 0.011 3 0.064 4
0.069 5 0.02 6 0.011 7 0.002 8 0.006 9 0.009 10 0.004 11 0.004 12
0.038 13 0.003 14 0.04 15 0.016 16 0.003 17 0.046 18 0.005 19 0.003
20 0.003 21 0.004 22 0.012 23 0.006 24 0.001 25 0.005 26 0.019 27
0.045 28 0.015 29 0.024 30 0.008 31 0.059 32 0.069 33 0.01 34 0.033
35 0.004 36 0.002 37 0.004 38 0.003 39 0.021 40 0.012 41 0.036 42
0.08 43 0.045 44 0.046 45 0.019 46 0.043 47 0.046 48 0.062 49 0.033
50 0.024 51 0.015 52 0.088 53 0.068 54 0.042 55 0.005 56 0.037 57
0.011 58 0.005 59 0.011 60 0.03 61 0.01 62 0.013 63 0.022 64 0.004
65 0.047 66 0.018 67 0.041 68 0.027 69 0.003 70 0.021 71 0.023 72
0.031 73 0.037 74 0.033 75 0.023 76 0.065 77 0.019 78 0.037 79
0.011 80 0.021 81 0.043 82 0.015 83 0.034 84 0.026 85 0.012 86
0.021 87 0.054 88 0.05 89 0.041 90 0.039 91 0.025 92 0.016 93 0.029
94 0.036 95 0.02 96 0.017 97 0.02 98 0.013 99 0.021 100 0.037 101
0.023 102 0.024 103 0.039 104 0.049 105 0.029 106 0.009 107 0.047
108 0.026 109 0.022 110 0.023 111 0.027 112 0.029 113 0.008 114
0.04 115 0.012 116 0.01 117 0.011 118 0.041 119 0.030 120 0.041 121
0.022 122 0.025 123 0.008 124 0.035 125 0.015 126 0.016 127 0.040
128 0.028 129 0.013 130 0.007 131 0.054 132 0.008 133 0.051 134
0.007 135 0.035 136 0.03 137 0.027 138 0.009 139 0.021 140 0.047
141 0.006 142 0.049 143 0.009 144 0.003 145 0.005 146 0.007 147
0.034 148 0.030 149 0.015 150 0.001 151 0.02 152 0.001 153 0.015
154 0.039 155 0.043 156 0.032 157 0.018 158 0.031 159 0.013 160
0.013 161 0.014 162 0.017 163 0.025 164 0.014 165 0.026 166 0.004
167 0.013 168 0.004 169 0.026 170 0.021 171 0.01 172 0.004 173
0.004 174 0.007 175 0.008 176 0.023 177 0.029 178 0.333 179 0.148
180 0.412 181 0.177 182 0.857 183 0.837 184 0.231 185 0.098 186
0.564 187 0.106 188 0.103 189 0.187 190 0.647 191 0.142 192 0.140
193 0.108 194 0.811 195 0.117 196 0.174 197 0.004 198 0.031 199
0.138 200 0.162 201 0.182 202 0.620 203 0.570 204 0.037 205 0.022
206 0.022 207 0.023 208 0.156 209 0.005 210 0.006 211 0.006 212
0.042 213 0.003 214 0.001 215 0.027 216 0.004 217 0.003 218 0.035
219 0.061 220 0.044
* * * * *